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Abstract 
CD40 is a member of the tumour necrosis factor receptor (TNFR) superfamily and ligation by membrane- 
presented CD40 ligand (mCD40L), but not soluble agonists, causes extensive apoptosis in malignant 
epithelial cells, including colorectal carcinoma (CRC) cells. This thesis aimed to unravel the precise cell 
signalling pathways responsible for mCD40L-mediated apoptosis in CRC cells.  
This study has provided evidence that CRC cell death by mCD40L is rapid. mCD40L activated MOMP, 
cytochrome c release from mitochondria and induction of Bak/Bax within <6 hours post ligation. The pro-
apoptotic role of Bax was confirmed by shRNA-mediated Bax knockdown as this attenuated apoptosis and 
decreased caspase 3/7 activity. mCD40L triggered rapid TRAIL induction and a caspase-dependent 
pathway that involved caspase-10 (but not caspase-8) and caspase-9 to cause CRC cell death. Thus CD40 
cross-talks with the extrinsic pathway by inducing TRAIL-mediated, caspase-10 activation, mitochondrial 
disruption, tBid activation, Bak/Bax induction, and activation of caspase-9 and -3/7 to cause CRC cell death.  
When the signalling pathways triggered by CD40 were studied further, we found that CD40 induced both p-
JNK and p-p38 in CRC cells which is necessary for apoptosis, and that JNK might be acting downstream of 
p38. p38 and JNK directly regulated Bak/Bax and TRAIL induction at the transcriptional level. We also 
showed that TRAF1, -3, and 6 were induced in CRC cells as early as 1.5 hours post ligation. Our studies 
not only demonstrated a novel pattern of TRAF regulation in CRC cells but revealed for the first time that 
TRAF3 has an essential role in CD40-mediated CRC cells death. TRAF3 is central in the induction of 
apoptosis as its knockdown attenuates apoptosis, by abrogating p38 and JNK activation, induction of 
Bak/Bax and caspase-3/7 activation. Therefore, despite the existence to a dual apoptotic pathway being 
engaged in CRC cells, TRAF3 appears to be central in both signalling axes.  
ROS are rapidly induced in CRC cells by CD40 in a Nox-dependent fashion and this plays an important role 
in CD40-mediated killing. More specifically, CD40 activation appears to result in TRAF3-dependent 
p40phox activation. CD40 also regulates directly ROS scavenging mediators, as we detected reduction in 
Trx-1 expression. Moreover, CD40 triggered activation of the Trx-regulated pro-apoptotic kinase ASK-1, 
which provided direct molecular explanation for the importance of ROS in CD40 signalling and downstream 
activation of MKKs and p38/JNK. Thus, the mCD40L-CD40-TRAF3-NOX axis utilises ROS for the activation 
of ASK-1/MKK/p38/JNK pro-apoptotic pathways in CRC cells.  
Based on observations in this thesis and more recent findings following completion of this work, we 
hypothesise that at some point the MAPK/p38/JNK pathway diverges to drive on one hand transcriptional 
upregulation of TRAIL, activation of tBid and cross talk to the mitochondria, whilst the other p38/JNK 
pathway directly induces Bak/Bax to also induce MOMP and mitochondrial death, the latter being more 
reminiscent of CD40-mediated cell death in UCC cells. However, unlike UCC cells were the operation of 
only the latter pathway takes place means apoptosis requires a minimum of 24-36 hours to occur, in CRC 
cells there is rapid amplification of the apoptotic signal and quick induction of death. To our knowledge, this 
is the first demonstration of such extensive and rapid carcinoma cell apoptosis triggered by CD40 ligation.    
Overall, this study has identified the intracellular signalling cascade triggered by CD40 ligation and results in 
extensive apoptosis in CRC cells. It has identified a TRAF3-Nox-ROS-ASK1-MKK-p38/JNK pathway (that 
activates caspase-10 and caspase-9) as the driving force that triggers both a TRAIL-associated extrinsic as 
well as the intrinsic apoptotic pathways. Thus, in CRC cells CD40 induces apoptosis by pathway cross talk 
which permits strikingly rapid apoptosis. These findings not only provided novel observations on the 
mechanisms of apoptosis triggered by the TNSRF member CD40, and also reinforced the importance of the 
quality of CD40 signal in determining functional outcome, but they have also raised interesting hypotheses 
for further biological studies. Equally importantly, the findings have also assisted in the formulation of a 
novel combinatorial therapeutic approach that may exploit CD40 for anticancer therapy.  
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CHAPTER 1: INTRODUCTION 
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1.1 Apoptosis 
1.1.1 General 
Apoptosis or Programmed Cell Death (PCD) refers to a physiological type of cell 
death involving an active process. The two terms refer to distinct and well defines 
physiological processes, however often they are used interchangeably.  
PCD is a term originally used to describe cells that die at a specific time and place 
during development. Cell death is a genetically programmed natural phenomenon which 
eliminates unnecessary cells (Pereira and Amarante‐Mendes, 2011). Physiologically, there is 
a close balance between apoptosis and the production of new cells which prevents 
excessive cell proliferation and achieves homeostatic control of overall cell numbers in the 
body. When apoptosis is not working cells can multiply uncontrollably and thus dysregulation 
of apoptosis can be associated with cancer. Apoptosis is distinct from necrosis, which in 
general is a pathological cell death; however more recent research has provided evidence for 
the existence of controlled necrosis which will not be discussed here (Edinger and 
Thompson, 2004). 
In 1972, Kerr's team showed that, in several cell types, death is preceded by a 
condensation of the nucleus and cytoplasm, fragmentation of the cell contents in apoptotic 
bodies (membrane structures containing cytoplasmic and nuclear debris) and elimination of 
the last components by phagocytosis (see Figure 1.1) (Kerr et al., 1972). In addition, this 
type of cell death induced no inflammatory response and did not affect neighbouring cells. 
Necrosis, by contrast, is in general referred to as "accidental" cell death, which occurs while 
cells are exposed to extreme conditions that differ from physiological situations, such as 
hypothermia, hypoxia or tissue injury. In necrosis, the cell swells and bursts the cell 
membrane, discharging the cell contents into the surrounding tissue and causing a local 
inflammation. This inflammation is caused by the presence of inflammatory substances and 
enzymes present in the cytoplasm. Organelles (including the mitochondria and the nucleus) 
remain intact throughout the process (Weedon et al., 1979). Since the characteristics 
observed by Kerr contrasted with those of necrotic cells (see Figure 1.1), this group of 
researchers proposed the term apoptosis, which in Greek describes the fall of leaves in 
autumn, to identify this type of PCD (Kerr et al., 1972). 
Currently, it is recognised that cell apoptosis is mainly characterised by cell 
shrinkage, condensation of chromatin, fragmentation of the nucleus, degradation of nuclear 
DNA and the formation of vesicles containing the cell debris. From a biochemical point of 
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view, generation of DNA fragments corresponding to multiples of 160-200bp has long been a 
characteristic associated with apoptosis (Martin et al., 1994).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 1 Apoptosis versus necrosis 
This diagram shows the characteristics of different morphological changes in the process of cell death 
by apoptosis versus necrosis) is characterized by loss of plasma membrane integrity, flocculation of 
chromatin, cell lysis followe by swelling with leakage of intracellular content and disintegration of 
organelles. While the apoptotic process involves alteration of membrane permeability, chromatin 
condensation, cell shrinkage, formation of apoptotic bodies without disintegration of organelles 
(Weedon et al., 1979). 
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A 
B 
ϭ 
Ϯ 
ϯ 
1) Cell shrinking, chromatin condensation 
and membrane blebbing. 
2) Nuclear fragmentation and formation of 
apoptotic bodies 
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B) Disruption of the cell membrane 
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1.1.2 Physiological roles of apoptosis 
Apoptosis plays an important role in embryogenesis (and in this case it is correctly 
referred to as PCD, in the morphological changes in cellular homeostasis, in atrophy in tissue 
repair, in tumour regression, and in immunity. Apoptosis is critically important during various 
developmental processes. For instance, both the nervous and immune system arises during 
overproduction of cells. This early overproduction is then followed by the death of those cells 
that were unsuccessful in establishing functional synaptic connections in the nervous system 
or productive antigen specificities in the immune system. Apoptosis plays a critical role in T 
cell function, and for instance in the removal of T cells during the last phase of the immune 
response. In addition, during the development of the central nervous system in vertebrates, 
approximately 50% of neurons degenerate during the perinatal period by PCD. This 
phenomenon is controlled by specific trophic factors (Raff et al., 1993). 
1.1.3 Pathological aspects of apoptosis 
Dysregulation of apoptotic cell death is involved in the pathogenesis of many 
diseases. In healthy tissue, there is a regulated balance between cell division and cell death. 
This balance is disturbed in cancer cells, not only by unrestrained cell division but also by a 
dysregulation of programmed cell death.  In addition to cancer, dysfunction of apoptosis can 
also lead to diseases such as neurodegeneration or autoimmune diseases (Thompson, 
1995). Increased rates of apoptosis can lead to degenerative diseases such as stroke, 
atherosclerosis, diabetes, Parkinson‘s disease and Alzheimer‘s disease, while inhibition of 
apoptosis pathways may lead to proliferative diseases such as autoimmune diseases or 
cancer (MacFarlane and Williams, 2004). 
1.2. Molecular components of apoptosis 
1.2.1 Caspases 
Caspases are cysteine proteases that can be involved in the process of cell death 
upon stimulation of cells by chemical factors such as physicochemical signals (UV, gamma 
rays) or the deprivation of growth factors. Caspases can have a key role in the initiation and 
execution of apoptosis. In the term ‗caspase‘ (proposed by (Alnemri et al., 1996), the ‗C‘ is 
the active site cysteine while ‗aspase‘ defines the strict specificity of cleavage of the 
substrates of this family of proteases after an aspartic acid residue. These enzymes are 
initially synthesised as inactive pro-enzymes (zymogens) that upon both conformational 
changes and proteolytic cleavage becomes activated (as detailed in following sections). Of 
note, in addition to caspases, another known protease with the same specificity as caspases 
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(cleavage at aspartate residue) is Granzyme B, a serine protease contained in the granules 
of cytotoxic cells (e.g. cytotoxic T lymphocytes, CTL) that initiates the apoptotic death of 
target cells (Alnemri et al., 1996). 
1.2.1.1 Structure and activation of caspases 
The first caspase, caspase-1 or ICE, has been demonstrated in mammals by 
homology with the pro-apoptotic protein Ced-3 identified in Caenorhabditis elegans (C. 
elegans) (Miura et al., 1993). Fourteen different caspases have been identified so far 
(L;2ippens et al., 2003). All caspases have a conserved structure and are synthesised as 
inactive precursors or zymogens (Parrish et al., 2013). Caspases comprise a pro-domain of 
variable size and sequence located in the amino-terminal portion of the protein, a large 
subunit (20kDa) in the middle of the molecule and a small subunit (10kDa) localised in the 
carboxy terminal part. Some members of the caspase family have a binding domain between 
the large and small subunit. The N-terminal domain appears to play a role in protein-protein 
interactions and, thus, in regulating the activation of these enzymes (Thornberry, 1998) 
(Figure 1.2).  
Caspase activation involves the proteolytic cleavage of the zymogen form at two 
consensus sites for cutting the pro-domain and separating the two subunits. Caspases can 
activate other caspases or substrates to form an enzymatic cascade to amplify and integrate 
pro-apoptotic signals (Thornberry and Lazebnik, 1998, Thornberry, 1998). The two sites have 
different consensus cleavage caspases but they always occur after the Asp-X bond (Figure 
1.2). Although the large subunit contains the catalytic domain, its activity requires binding to 
the small subunit. Indeed, crystallography studies indicated that the active forms of caspase 
tetramers are formed by the association of two heterodimers containing two independent 
catalyticsites (Wilson et al., 1994).  
Caspase activation tends to be an early event occurring during apoptosis and inhibition of 
caspases by specific proteins (caspase-specific peptides) prevents the occurrence of the 
morphological characteristics of apoptosis; conversely, the administration of recombinant 
caspases induces apoptosis (Thornberry et al., 2000). 
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Figure 1. 2 Activation of caspases 
Caspases are produced as inactive precursors containing a pro-domain and two subunits of 
approximately 20 and 10 kDa (p20 and p10, p18 and p12, respectively, in the examples shown). The 
pro-domain of initiator caspases is longer and contains domains (such as Death Effector Domain, or 
DED) important for interaction with adapter proteins. The arrows show the order of cleavage of pro-
caspases. After cleavage, the subunits associate to form the active structure, having two active sites 
(Amarante-Mendes and Green, 1999). 
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1.2.1.2 The various classes of caspases 
Not all caspases act as direct, effector molecules of the dying process. Indeed, only 
caspase-3, -6, -7 and -14, which have a short pro-domain, are directly involved in the 
execution of apoptosis. In fact, caspase-2, -8, -9, and -10, which have a long pro-domain, are 
initiators or regulatory molecules of apoptosis (Figure 1.2). These function as signalling 
molecules; they are recruited to affect protein complexes via their pro-domain and are 
capable of self-activation by the transducing signal to activate effector caspases. It is now 
known that caspase-8 and -10 are activated by the death receptor pathway (see following 
sections), whereas caspase-9 is activated by the mitochondrial apoptotic pathway 
(Amarante-Mendes and Green, 1999, Gupta, 2003). This difference in the role of caspases 
relates to the presence of units of protein-protein interactions, such as areas of death effector 
domain (DED) (for caspase -8 and -10) or caspase recruitment domain (CARD) (for caspase 
-1, -2, -4 and -9) at the pro-domain. Indeed, caspase-8 and -10 contain DEDs capable of 
binding in a homophilic fashion to other DEDs present in adaptor signalling molecules. The 
CARD domain in pro-caspase -1, -2, -4 and -9 is allowed in the same way to join other 
caspases or other adaptor molecules. Some caspases such as caspase-1, -4, -5, -11, -12 
and -13 appear to be involved as inflammation caspases probably by inducing cleavage of 
the pro–inflammatory cytokines such as Interleukin-1 and Interleukin-18 (Oyadomari et al., 
2002). 
1.2.1.3 Main substrates of caspases and their cleavage 
Several substrates of caspases have been identified and one of the most studied 
mechanisms of activation is the nucleases leading to DNA fragmentation. These nucleases 
cleave genomic DNA between nucleosomes to generate fragments of ~180 base pairs. 
These nucleases are named DFF for DNA fragmentation factor in humans and CAD for 
caspase-activated DNase in mice. They exist in the cell as inactive complexes because they 
are associated with an inhibitory subunit. Nuclease DFF40 is complexed with the inhibitory 
protein DFF45 in humans and the mouse CAD is complexed with ICAD. Normally CAD exists 
as an inactive complex with ICAD (inhibitor of CAD). During apoptosis, ICAD is cleaved by 
caspases such as caspase 3 to release CAD then rapid fragmentation of DNA (Figure1.2). 
The endonuclease so released will generate DNA fragments of 180 base pairs (Samejima et 
al., 2001). 
However, it appears that, in some forms of apoptosis, this internucleosomal DNA 
fragmentation is replaced by a fragmentation of high molecular weight (Kaufmann et al., 
2000). Some members of the Bcl-2 family (see following sections) may also be cleaved to be 
activated; the best example of this is the Bid protein, which is cleaved by caspase -8 in 
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certain conditions (Li et al., 1998, Luo et al., 1998) (Figure1.2). The loss of cellular 
morphology is probably the consequence of cleavage of cytoskeletal proteins such as 
gelsolin and nuclear proteins such as nuclear laminins (Kothakota et al., 1997), and the 
occurrence of budding membranes appears to be caused by cleavage of the p21-activated 
kinase (PAK-21) at the regulatory subunit and at the catalytic subunit, allowing activation 
(Rudel and Bokoch, 1997) (Figure1.2). Nearly 100 caspase substrates have been reported 
previously, indicating the complexity of death by apoptosis (Hengartner, 2000). 
1.3 Members of the Bcl-2 family 
1.3.1 Structure 
Members of the Bcl-2 family (B-cell leukaemia/lymphoma 2-like proteins) are 
important regulators of apoptosis. This family, containing about 15 members, can be divided 
into two groups according to their activity: proteins with anti-apoptotic activity and proteins 
with pro-apoptotic activity. These two groups differ in their structure but they comprise four 
common and conserved regions; the BH domains for "Bcl-2 homology". The regions BH1, 2 
and 3 form the hydrophobic pocket capable of binding a BH3 domain from another protein; 
the BHγ domain is an amphipathic α helix (Gross et al., 1999). 
Members of the Bcl-2 family that are anti- apoptotic, such as Bcl-2, Bcl-xL, Bcl-w, Mcl-
1, A1/BFL-1 and BOO/DIVA, contain domains BH1, 2, 3 and 4 (Figure 1.3). The pro-
apoptotic members are divided into two subgroups; the first contains three domains (BH1, 2, 
and 3) such as Bax, Bak, Bok/MTD, while the second group contains those with only the 
BH3-domain such as Bid, Bad, Bik/NBK, BLK, HRK, and BIM (BOD), also called "BH3 
proteins". The BH3 region seems to be heavily involved in the pro-apoptotic activity (Figure 
1.3). The BH4 and the near region sequences present in only the anti-apoptotic proteins can 
be phosphorylated. By forming complexes with other proteins, such as calcineurin (CN), 
connections with other pathways of apoptosis can be initiated (Shibasaki et al., 1997). All the 
proteins of the Bcl-2 family contain a hydrophobic carboxy-terminal domain of 20 amino acids 
for their attachment in intracellular membranes, mostly in the mitochondria, but also in the 
endoplasmic reticulum (Krajewski et al., 1993). 
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Figure 1. 3 Members of the Bcl-2 family 
Classification of Bcl-2 family members, only some representative members are shown, and they are 
found in mammals, unless otherwise stated. The BH domains are indicated (Adapted from (Gross et 
al., 1999).  
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1.3.2 Regulation of the Bcl-2 members 
Members of the Bcl-2 are regulated transcriptionally and post-translationally by 
cytokines or survival factors and death. In addition to the dimerisation process allowing 
proteins to activate (homodimerisation) or to inhibit (heterodimerisation), other phenomena 
such as post-translational modifications (phosphorylation or proteolysis) can regulate the 
activity of certain members of this family. Hyper-phosphorylation of Bcl-2 appears to alter its 
anti-apoptotic activity in certain cells (Chang et al., 1997). Kinases may phosphorylate Bcl-2, 
an example being the c-Jun N-terminal kinase (JNK) which is activated by stress (Chang et 
al., 1997). 
Bad is a protein that can bind to Bcl-XL and inhibit its anti-apoptotic activity. This 
connection is only allowed if the binding site of Bad is dephosphorylated. Several kinases 
can phosphorylate the Bad protein. This is the case with the Akt/PKB/RAC protein, which is a 
serine threonine kinase acting upstream kinase of phosphatidyl inositol triphosphate (PIP-3) 
(Zha et al., 1996)  and cAMP dependent kinase (PKA) (Harada et al., 1999). 
The Bid protein (22 kDa) is a substrate of caspase-8 and as demonstrated more 
recently of caspase-10 and has to be cleaved to be active. The C-terminal 15 kDa fragment 
generated by proteolysis (truncated Bid, tBid) can thus be inserted at the level of the 
mitochondrial membrane, and it allows the activation of the mitochondrial pathway, thus 
amplifying the signal initiated by the death receptor pathway (Li et al., 1998, Luo et al., 1998, 
Milhas et al., 2005). 
Bim can interact with Bcl-2 and promote the induction of apoptosis after certain 
stimuli. The Bim is a protein localised at the microtubule complex in intact cells. After 
induction of death by certain death signals, it dissociates from the complex and translocates 
to the mitochondria without being cleaved (Puthalakath et al., 1999). 
1.3.3 Mechanism of action 
Most of these small Bcl-2 proteins can dimerise; therefore, this often occurs between 
pro-apoptotic proteins and anti-apoptotic proteins. The regulation of apoptosis by these 
proteins therefore results from the delicate balance in the expression level of pro- versus 
anti-apoptotic proteins; cells expressing more pro-apoptotic proteins are susceptible to death, 
while cells that do not are resistant (Hengartner, 2000).  
The main function of these regulators is to control the release of pro-apoptotic factors, 
such as cytochrome c, from the mitochondrial intermembrane space to the cytosol. Indeed, 
the addition of pro-apoptotic proteins is sufficient to induce the release of cytochrome c; in 
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contrast, the anti-apoptotic proteins prevent release of the cytochrome c (Antonsson and 
Martinou, 2000, Gross et al., 1999). In addition, caspase inhibitors do not alter the release of 
cytochrome c, which implies that caspases are not involved in these events. Bcl-2 appears to 
be very often linked to mitochondrial membrane proteins, while others such as Bax, Bid, Bad 
and Bim translocate from the cytosolic areas to the mitochondria during apoptosis. These 
proteins play an important role in transducing the signal from the cytosol to the mitochondria. 
The translocation of these proteins is controlled by post-translational modifications, such as 
Bad de-phosphorylation or cleavage of Bid (Gross et al., 1999).  
Bax is first translocated from cytosol to mitochondria. Its conformation is then 
modified and the outsourcing of its amino-terminal domain allows its oligomerisation and its 
insertion in the outer mitochondrial membrane (Jurgensmeier et al., 1998). This insertion 
capacity appears to be related to the structural homology of family members Bcl-2 with 
certain bacterial toxins, allowing them to form pores at the mitochondrion. This insertion is 
indeed quickly followed by the release of cytochrome c. Other studies suggest that the 
capacity for insertion is facilitated by the interaction with the voltage-dependent anion 
channel (VDAC). These changes in the conformation of Bax appeared to be favoured by Bid 
interaction (Eskes et al., 2000). These changes can also be reduced or prevented by Bcl-2 or 
Bcl-xL, as these anti-apoptotic proteins can act by interactions with Bax (Desagher et al., 
1999). Unexpectedly, Bcl-2 also fails to inhibit Bax-induced cytochrome c release, although it 
co-localises with Bax to mitochondria. Rosse and colleagues reported that cells 
overexpressing both Bcl-2 and Bax show no signs of caspase activation and survive with 
important amounts of cytochrome c in the cytoplasm.  Also, reported that Bcl-2 can interfere 
with Bax killing downstream of and independently of cytochrome c release (Rosse et al., 
1998). 
Interestingly, members of the Bcl-2 family can modulate the cell cycle; indeed, Bcl-2 
can promote the entry of cells in the G0 phase, and block and delay their entry into the cell 
cycle (Linette et al., 1996, Mazel et al., 1996). This effect is probably separate from its anti-
apoptotic activity as an alteration of its structure at the non-conserved domain allows cells to 
continue the cell cycle but does not change its anti-apoptotic activity; (Uhlmann et al., 1996).  
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1.4 Role of mitochondria in apoptosis 
1.4.1 General 
The mitochondrion plays a fundamental role in the cell, producing a large part of the 
energy required by the cell, participating in calcium homeostasis, maintaining the redox 
potential and intracellular pH, and playing a key role in the modulation of calsium 
homeostasis and oxidative stress (Adams, 2003). This means that a major mitochondrial 
dysfunction can result in programmed cell death. A change in the electron transport may be 
sufficient to increase the production of oxygen free radicals and acidify the cytoplasm. Under 
these conditions, electrons are no longer produced in sufficient quantity and reduction of the 
synthesis of ATP results in the accumulation of lactate by stimulating glycolysis. Moreover, 
the electrons released from the mitochondria can reduce oxygen superoxide ions, which are 
highly reactive oxygen free radicals (Adams, 2003). 
1.3.4 Role of Bcl-2 family members in the regulation of the cell cycle 
1.4.2 Channel opener mechanisms 
During apoptosis, water and various solutes enter the mitochondria, causing its 
swelling and the release of the various constituents of the inter-membrane space into the 
cytosol, while the matrix components are retained in the mitochondria through the inner 
membrane and remain intact. Several models have been proposed to explain the underlying 
mechanism of substance release from the mitochondria to the cytoplasm during the effector 
phase of apoptosis (illustrated in Figure 1.4) and these will be discussed below.  
1.4.3 The rupture of the outer mitochondrial membrane 
The first model involves hyperpolarisation of the internal membrane prior to the 
release of cytochrome c in some systems. This hyperpolarisation results from the failure of 
the exchange between cytoplasmic ADP and mitochondrial ATP (Heiden et al., 1999). This 
exchange is normally carried out by the voltage-dependent anion channels (VDAC) localised 
in the outer membrane of the mitochondria and the carrier of adenylic nucleotide (ANT), 
which is located in the inner membrane. This lack of exchange appears to inhibit the activity 
of the F1F0–ATPase, which prevents the return of H+ ions to the matrix and therefore 
contributes to the hyperpolarisation. Such an increase in mitochondrial membrane potential 
may cause the osmotic swelling of the matrix, resulting in the rupture of the outer 
mitochondrial membrane (Heiden et al., 1999) (Figure 1.4a). 
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1.4.4 The mitochondrial permeability transition pore 
This model involves a second mega-channel, the mitochondrial permeability transition 
pore (or MPTP). The MPTP is a non-selective channel with "high conductance", which may 
be formed by affixing transmembrane proteins residing in the inner membrane and the outer 
membrane of the mitochondrion (Crompton, 1999). Different studies show that the pore is 
mainly formed by the association of the ANT of VDAC and cyclophilin D (Figure1.4b). The 
opening of the pore can be induced by various physiological effectors such as calcium, a 
decrease in the concentration of adenine nucleotide or inorganic phosphate, the production 
of oxygen free radicals or a change in pH (Crompton, 1999), and by the presence of Bax 
protein. 
The opening of the pore increases the permeability of the inner membrane of the 
mitochondria. This leads to dissipation of the mitochondrial membrane potential (proton-
dependent), a chemical imbalance between the cytoplasm and the mitochondrial matrix and 
an uncoupling of oxidative phosphorylation, thus causing an osmotic swelling which can lead 
to rupture of the outer membrane. Importantly, it has been suggested that the amount of ATP 
available after the opening of the pore is a key factor in the induction of death by necrosis or 
apoptosis. In addition, members of the Bcl-2 family can regulate the opening of the pore. Bcl-
2 can prevent this opening (Kroemer et al., 1997, Shimizu et al., 1998); Bax, on the other 
hand, causes a drop in membrane potential mitochondrial and promotes the opening (Marzo 
et al., 1998) (Figure 1.4d). 
1.4.5 Pore formation by members of the Bcl-2 family 
It remains unclear, however, what the chronology of events is, i.e. whether the pore 
opening is the cause or the consequence of the release of cytochrome c. Indeed, several 
studies have shown that the release of cytochrome c can occur in the absence or before the 
collapse of mitochondrial membrane potential (Bossy-Wetzel et al., 1998, Goldstein et al., 
2000). One explanation of this phenomenon is that the reversible (transient) MPTP opening 
may affect the permeability of the mitochondrial outer membrane, while allowing restoration 
of the mitochondrial membrane potential. In addition, the opening of the pore may be a 
consequence of the inhibition of electron transport due to the release of cytochrome c, 
resulting in a fall of the mitochondrial membrane potential and the level of ATP, or the 
consequence of the activation of caspases (Marzo et al., 1998). Indeed, caspase inhibitors 
can prevent the collapse of mitochondrial membrane potential without blocking the release of 
cytochrome c (Bossy-Wetzel et al., 1998). Opening caspase-dependent MPTP could amplify 
the loop through which the early release of cytochrome c induces changes at the 
mitochondrial level. This model would seem to reinforce the observations made, i.e. the 
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release of cytochrome c followed by a drop in mitochondrial membrane potential.  Rupture of 
the outer mitochondrial membrane explains the massive release of pro-apoptotic factors or 
soluble inner mitochondrial membrane proteins (SIMP) contained in the mitochondria (AIF, 
caspases...) (Bossy-Wetzel et al., 1998). 
Nevertheless, many studies indicate that these changes would be a consequence 
rather than a cause of the release of cytochrome c. Therefore, another mechanism must 
allow the release of cytochrome c. The assumption of a channel capable of passing the 
protein has been studied. It could be formed by some members of the Bcl-2 in view of the 
strong homology of Bcl-xL with the subunit of diphtheria toxin capable of forming a 
membrane pore. It has been suggested that of the Bcl-2 family such as Bax can insert 
themselves, following appropriate conformational change (see previous sections), in the 
outer mitochondrial membrane (Figure1.4c). Whether these proteins, consisting of a 
hydrophobic region and a helix alpha (α) surrounded by five amphipathic helices (Schendel 
et al., 1998), can be inserted into the lipid bilayer and oligomerised to form a channel that is 
large enough to pass small proteins remains to be demonstrated. It has been shown that 
these proteins could form a functional ion channel in synthetic lipid vesicles. These channels 
are pH-dependent, have voltage and show low ionic selectivity. The properties of the 
channels formed by proteins, pro-or anti-apoptotic, differ significantly (Schlesinger et al., 
1997). 
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Figure 1. 4 Mechanisms of channel opening explaining the release of cytochrome c  
Mechanisms of mitochondrial membrane permeabilization are regulated by the pro-apoptotic Bcl-2 
family and other proteins. (a) Increase in mitochondrial membrane potential may cause the osmotic 
swelling of the matrix, resulting in the rupture of the outer mitochondrial membrane. (b) Opening of the 
MPTP (which includes among others VDAC, ANT and cyclophilin D) causes the ingress of water which 
leads to the bursting of the outer membrane. (c) Formation of channels by Bax or Bak. (d) Formation 
of chimeric channels, such as Bax / VDAC (from (Desagher and Martinou, 2000)). 
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1.5 Pathways for the induction of apoptosis 
The initiation stage of apoptosis is a reversible phenomenon in which the apoptotic 
signal (-intra or -extra-cellular) is transmitted by the initiator caspases following recruitment of 
adaptor molecules (Reed, 2000). 
There are two main caspase-dependent signalling pathways of apoptosis: the death 
receptor pathway (also known as the Extrinsic pathway) and the mitochondrial pathway (or 
Intrinsic pathway) (Reed, 2000). These pathways appear to be distinct, but the Death 
Receptor pathways can cross-talk with and cause apoptosis by the mitochondrial pathway 
through cleavage and activation of Bid as described above (Figure 1.5). In addition to these 
two classical pathways, more recently the apoptotic pathway that involves the endoplasmic 
reticulum-dependent caspase-12 has been demonstrated (Oyadomari et al., 2002), and 
another caspase-independent apoptotic pathway is can be initiated by the mitochondria 
through the release of an apoptosis-inducing factor (AIF) (Elmore, 2007). 
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 Figure 1. 5 The extrinsic and intrinsic pathways of apoptosis  
The receptor-mediated (extrinsic) pathway is triggered by members of the TNFR subfamily known as 
the Death Receptors (such as CD95/Fas/Apo-1). Receptor-specific ligands mediate receptor 
aggregation and formation of a death-inducing complex, which recruits pro-caspases via death domain 
proteins associated with the receptor. The mitochondrial pathway is often activated in response to 
DNA damage, involving the activation of a pro-apoptotic member of the Bcl-2 family (Bax, Bid). Pro- 
and anti-apoptotic Bcl-2 family members regulate the release of cytochrome c from the inner 
mitochondrial membrane. Released cytochrome c associates with Apaf-1, dATP and procaspase-9 
forming the apoptosome. Subsequently effector caspases are activated, resulting in the cleavage of 
specific substrates and cell death (Adapted from (Reed, 2000)). 
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1.5.1 The death receptor pathway (the extrinsic apoptotic pathway) 
The ligands, which are members of the family of tumour necrosis factor (TNF) and are 
responsible for the activation of their cognate receptors, play an important role in cell 
proliferation, differentiation, apoptosis, modulation of the immune response and the induction 
of inflammation (Pitti et al., 1996). More than sixteen members of the TNF ligand family have 
been identified, including TNFα, FasL, TRAIL (APO- βL), lymphotoxin α, lymphotoxin ȕ, 
CD27L, CD30L, CD40L, CD137L, OX40L, RANKL, LIGHT, TWEAK, APRIL, and TL1 BAFF. 
Most ligands are synthesised as transmembrane precursors before their extracellular 
domains are cleaved by the action of metalloproteinases to form soluble forms. The ligands 
are produced in the form of trimers and bind to receptors of the TNF receptor family (the 
TNFRs), which are transmembrane proteins characterised by a cysteine-rich extracellular 
pattern (on the extracellular region) and a death domain (DD) in their cytoplasmic tail. 
Therefore, cell death initiated by these ligands requires receptor trimerisation (Pitti et al., 
1996). 
Not all of these ligands induce cell death. Indeed, CD27L, CD30L and CD40L can be 
involved in cell survival, unlike ligands TNFα, FasL or TRAIL. Death induced by the members 
of the TNF family of receptors leads to the activation of caspases and is dependent 
(Longthorne and Williams, 1997). 
1.5.1.1 Fas (CD95, Apo -1) and Fas ligand (CD178, FasL) 
Glycoprotein Fas (CD95, Apo-1) is a transmembrane receptor constitutively 
expressed in the lymphocytes, while the transmembrane ligand FasL (CD95L, CD178, Apo-
1L) is induced after activation. The Fas receptor is also expressed on the surface of many 
cell types. The ligand can be released from the cell surface as soluble protein, and it also has 
the ability to bind with the receptor. The steps in the apoptotic pathway mediated by Fas are 
shown in Figure 1.6. Binding of the ligand to its receptor results in receptor trimerisation (and 
multimerisation) and activation. The cytoplasmic domain of Fas has no intrinsic enzymatic 
activity but contains a death domain (DD) of 80 amino acids, enabling binding of an adaptor 
protein, Fas-associated death domain (FADD). FADD also has, in addition to its DD, a death 
effector domain (DED), allowing it to bind with pro-caspase-8 (FLICE or "FADD - like ICE") or 
pro-caspase-10. The formation of this complex, called Death-Inducing Signalling Complex 
(DISC), initiates the enzymatic activation of apoptosis. Active caspases are released from the 
complex and will activate other pro-caspases such as pro-caspase -3, -6, and -7. These 
effector caspases induce activation of different substrates, causing cellular changes 
characteristic of apoptosis (Gupta, 2003). 
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1.5.1.2 The TNF/TNF-R pathway 
TNF-α is secreted primarily by activated macrophages and lymphocytes in response 
to infection. This factor acts by binding to receptors of type 1 and 2 (TNF-R1 and TNF-R2) 
and activates several signalling pathways. Both receptors are transmembrane receptors 
which differ in their cytoplasmic domain. These two receptors can induce a cell survival 
signal, but TNF-R1 can also cause a death signal by DD domain. The binding of TNF-α to its 
receptor can lead to activation of the transcription factors NF-kB and (anti-apoptotic) (Figure 
1.6)  and  AP-1 (apoptotic) (Hsu et al., 1995). 
The binding of TNFα causes trimerisation of TNF-R1 and allows binding of the 
adaptor protein TRADD (TNF-R Associated death domain); this adaptor will in turn recruit 
FADD through its DD domain. Similarly, as in the apoptosis induced by the Fas receptor, 
caspase -8 or -10 will be activated by the DISC TNF-R1 / TRADD / FADD to act on effector 
caspases -3, -6 -7 (Figure 1.7) (Boldin et al., 1996). 
However, TNF-R1 can also activate an independent pathway of FADD via the 
receptor interacting protein (RIP), although this route is less common than the FADD-
dependent pathway. TRADD has a field that can be associated with the RIP protein. The 
latter is associated with the protein RAIDD (RIPK1 domain containing adapter with DD) 
which has a CARD domain (Recruiting caspase domain); this domain also has caspases-3, -
9 and -2. Although the activation of caspase-8 and -10 is FADD dependent, activation of 
caspase-2 is independent of FADD and is done through the DISC TNF-
R1/TRADD/RIP/RAIDD, as shown in Figure 1.6 (Karin and Lin, 2002). 
TNFα can also induce a cell survival signal through two types of adaptor proteins, 
TNFR-associated factor-2 (TRAF-2) and RIP. TRAF-2 and RIP can induce cell survival by 
activation of the MAP kinase pathway and the NF-kB, respectively. TNF-R2 receptor does 
not have a cytoplasmic domain (DD), but TNFα binding to TNF-R2 leads to the interaction of 
TRAF-1 and -2 in the cytoplasmic tail of TNF-R2. It has been reported that TNF-R2 has an 
important role that induces anti-apoptotic and inflammatory responses  by TNF-R1 (Declercq 
et al., 1998). 
The DR3 receptor resembles TNF-R1, and it induces apoptosis in the same way 
through the proteins TRADD, FADD and caspase-8. The ligand of this receptor, Apo3L, is 
close to the TNF but is synthesised constitutively in all tissues, unlike TNF which is 
synthesised after activation of macrophages and lymphocytes (Choi et al., 2008, Janeway et 
al., 2001). 
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Figure 1. 6 The death receptor pathway (extrinsic pathway) 
Regulation of apoptosis by death receptors, Fas signalling induces apoptosis, while TNF-R1 can 
induce or represses death. The case of Fas provides the simplest model of triggering apoptosis by 
death receptors. In the presence of ligand (FasL), Fas trimerises and recruits, via its cytoplasmic 
domain DD (death domain), the FADD (Fas Associated Death Domain) adapter with a DD-DD 
interaction. FADD also contains a DED and in turn recruits pro-caspases-8 interaction domains 
between homologous DED. This activates pro-caspase-8 by means of induced proximity and leads to 
the release of active caspase-8. But TNF-α binding to TNF-R1 can also result in survival signals when 
TRADD binds other mediators. The RIP (Receptor Interactive Protein) is essential for the activation of 
the anti-apoptotic NF-kB by TNF-R1 and interferes with the binding between TRADD and FADD 
(which leads to the activation of pro-caspase -8) by associating transiently TRADD. Blocking or 
inhibition of the activation of NF-kappa B plays an important role in regulating signal (survival or death) 
induced by TNF-R1. (Adapted from (Gupta, 2003). 
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1.5.1.3 The TRAIL (Apo-2L) receptor pathway 
Similar to TNF ligands, tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL or Apo2L) is a transmembrane protein of approximately 34 kDa, which can form 
trimers as with other members of the TNF family. The interaction between the TRAIL and 
TRAIL-R1 receptors (DR4) and/or TRAIL/R2 (DR5, Apo-2, TRICK2) quickly induces cell 
death in target cells and particularly in tumour cells (Pitti et al., 1996, Mariani et al., 1997). 
TRAIL ligands and their receptors are constitutively expressed in many tissues (Pitti et al., 
1996, Mariani et al., 1997), which implies the existence of a control mechanism of apoptosis 
induced by TRAIL. Ligand-binding to the receptor allows the interaction of this complex with 
adaptor proteins such as FADD or TRADD (previously described in section 1.5.1). 
The progress-induced signalling by the receptors TRAIL-R1 and TRAIL-R2 is similar 
to that induced through FasL/Fas (Figure 1.7). Indeed, procaspase-8 is activated by 
interaction of DED present in the adapter proteins as well as procaspase-8. Three other 
receptors belonging to the family of TRAIL receptors have been identified: TRAIL-R3 (DcR1, 
TRID, LIT), TRAIL-R4 (DcR2, TRUNDD) and osteoprotegerin (OPG). Their function as 
modulators interferes with the activity of death receptors because they do not have their own 
cytoplasmic domain. For this reason they are considered to be non-apoptotic and represent a 
control mechanism of TRAIL-induced apoptosis (Figure 1.7). Osteoprotegerin has been 
described as a soluble receptor capable of binding to TRAIL and inhibiting its action (Emery 
et al., 1998). 
1.5.1.4 Regulation of the Extrinsic apoptotic pathway 
Apoptosis mediated by the extrinsic pathway is regulated in particular at the DISC 
complex assembly or its activation. The FLIP protein (FLICE- inhibitory protein) is an isoform 
of the caspase-8 containing two DED but no areas of the catalytic site. It acts by competing 
with caspase-8 and -10 and preventing their recruitment at the DISC (Figure 1.6). Two FLIP 
isoforms have been identified, the long (FLIPL) and the short (FLIPS) cellular form. They were 
presented to bind to the CD95 DISC and thus inhibit activation of caspase 8. Both are 
capable of inhibiting the induction of apoptosis induced several death receptors (CD95, TNF-
R1, DR3, and DR4), suggesting that these receptors use similar signalling pathway (Krueger 
et al., 2001). FLIP over-expression induces resistance to receptor-mediated apoptosis. 
Furthermore, it has been shown that FLIP could induce the activation of the transcription 
factor NF-kB and the Extracellular signal-Regulated protein Kinase (ERK) signalling pathway 
(Kataoka et al., 2000). Therefore, these proteins act as anti-apoptotic mediators (Krueger et 
al., 2001). 
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Another mode of regulation relates to the receptor itself. Most of the TNFRs also exist 
in a soluble form following alternative splicing or by proteolysis. These soluble forms, 
therefore, compete vis-a-vis the transmembrane form of the receptor with the ligand, thus 
blocking the recruitment of adaptor proteins and, therefore, activation of pro-caspases 
initiators. In addition, these soluble forms have the PLAD domain (pre-ligand assembly 
domain) necessary for the trimerisation of these receptors, but distinct from the ligand-
binding domain. Two studies have shown that a Fas trimer could be assembled 
independently of ligand binding (Papoff et al., 1999, Siegel et al., 2000). 
1.5.1.5 Amplification of the death receptor pathway 
The classical death receptor pathway occurs in cells expressing caspase-8, but in 
other cell types this route can be amplified via cross-talk with the mitochondrial pathway 
through the activation of Bid by caspase-8 (Figure 1.6). Indeed, caspase-8 cleaves Bid, a 
member of the Bcl-2, N-terminal to the exposure of its BH3 domain level. The rapid 
translocation of the truncated form of Bid from the cytosol to the mitochondrial membrane 
suggests a similar association of the ligand to a specific receptor mechanism (Wang et al., 
1996). The exposure of the BH3 domain allows Bid to fit into the mitochondrial membrane 
and bind Bax or other pro-apoptotic proteins. Bid causes the release of cytochrome c and 
induces the activation of caspase-9 before activating caspase-3 (Wang et al., 1996). 
Another protein forming the junction between the two channels has been identified. 
This is the BAR protein (Bifunctional Apoptosis Regulator), a regulatory protein capable of 
associating with anti-apoptotic molecules Bcl-2/Bcl-xL by a SAM domain (Sterile Alpha Motif) 
and caspase-8 by the DED domain (Zhang et al., 2000). Another signalling pathway of Fas 
independent of caspase-8 has been proposed showing the involvement of serine-threonine 
kinase RIP (receptor-interacting protein) (Pitti et al., 1996). 
1.5.2 The mitochondrial pathway (the intrinsic apoptotic pathway) 
1.5.2.1 The caspase-dependent mitochondrial pathway 
Many stimuli, such as chemotherapeutic agents, UV radiation, cellular stress (e.g. 
lack of attachment to substrate or ‗anoikis‘) and lack of growth factors (‗death by neglect‘), 
appear to induce apoptosis via the mitochondrial pathway independent of a death receptor 
pathway. The mitochondrion is an organelle comprising an outer membrane, a 
transmembrane area, an inner membrane and a matrix. The inner membrane has several 
proteins such as ATP synthase, the electron transport chain and the Adenylic Nucleotide 
Transporter (ANT) (Zoratti and Szabò, 1995). Under normal physiological conditions, these 
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three proteins allow the formation of an electrochemical gradient (membrane potential) by the 
respiratory chain. The inner membrane space contains cytochrome c, some pro-caspases (-
2, -3, and -9), the Smac /Diablo protein, Apoptosis-Inducing Factor protein (AIF) and 
endonuclease G. The outer membrane has a voltage-dependent anion channel (VDAC), 
which creates a major pathway for ATP/ADP, cytochrome c and other mitochondrial 
metabolites through the mitochondrial outer membrane (MOM) (Shoshan-Barmatz and 
Gincel, 2003). Then causes the release of these proteins into the cytoplasm, and the 
permeabilisation of the inner membrane causes a change of the mitochondrial membrane 
potential as well as the release of cytochrome c, which is one of the major steps in the 
induction of apoptosis by the mitochondria (Figure 1.7) (Ravagnan et al., 2001).   
1.5.2.2 Cytochrome c 
Cytochrome c is encoded by a nuclear gene and is synthesised as a precursor that is 
unable to participate in the induction of apoptosis.  The precursor is imported into the 
mitochondria where it is processed. The protein becomes globular due to cytochrome c 
heme lyase (CCHL). Apo-cytochrome c, the precursor of cytochrome c, has relatively little 
detectable secondary structure and lacks covalently attached heme compared to its mature 
counterpart holocytochrome c (Fisher et al., 1973). It is a nuclear gene product which is 
synthesized on free cytoplasmic ribosomes and then released into a cytoplasmic pool. Its 
import into mitochondria is mediated by specific binding sites (Zimmermann et al., 1981). 
During import, heme is covalently attached via thioether linkages to cysteine residues, near 
the amino terminus of the apo-cytochrome c precursor, in a reaction which is catalysed by 
the enzyme cytochrome c heme lyase (CCHL) (Taniuchi et al., 1983). The process requires 
heme in the reduced state (19) and is coupled to the transport of cytochrome c across the 
outer mitochondrial membrane. Cytochrome c is sequestered in the mitochondrial 
intermembrane space where it exerts its physiological function of electron transport between 
complexes III and IV of the respiratory chain (Ravagnan et al., 2002). In 1996, Liu and 
colleagues showed that cytochrome c was required for activation of caspase-3 (Liu et al., 
1996a). Other studies have confirmed this by showing that the release of cytochrome c and 
caspase activation was blocked by the anti-apoptotic protein Bcl-2 (Kluck et al., 1997, Yang 
et al., 1997).
  
It is now well-established that cytochrome c released into the cytosol is the origin of 
the formation of the apoptosome. Most recently, the knockout of the gene-encoding 
cytochrome c a confirmed the crucial importance of this protein in apoptosis (Vempati et al., 
2007). These studies show that no other cellular protein can replace cytochrome c for the 
oligomerisation of Apaf-1 (Apoptotic protease activating factor-1) and activation of caspase-
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3 induced by cellular stress agents or agents targeting the mitochondria cellular stress or a 
mitochondrial targeting agent. (Li et al., 2000).  In most cases, the release of cytochrome c 
is dependent on caspase activity (Bossy-Wetzel et al., 1998). 
The mechanism by which cytochrome c is released, as well as its release kinetics, 
has been the subject of much controversy. The release of cytochrome c seems to be 
dependent on the presence of Bax or Bak in the outer mitochondrial membrane. Regarding 
the kinetics of the release of cytochrome c, work by Douglas Green‘s team has 
demonstrated that it occurs rapidly and at once (Goldstein et al., 2000). It appears that the 
mitochondrion integrates different signals, and once the threshold is reached, the entire 
cytochrome c is released in one step. However, this observation cannot be generalised. 
According to the apoptotic stimulus, depending on the cell type used and the level of 
polarisation of the mitochondrial membrane, in certain cases only a proportion of 
cytochrome c from a few mitochondria is released in an amount sufficient to induce caspase 
activation. This observation suggests that there is a link between the release of cytochrome 
c and the collapse of mitochondrial membrane potential (MMP). Goldstein et al. (2000) 
showed that the release of cytochrome c was done before the fall of MMP, while Heiskanen 
et al. (1999) showed that these two events occur simultaneously (Goldstein et al., 2000, 
Heiskanen et al., 1999). However, if the release of cytochrome c occurs before the fall of 
MMP, this implies that the mitochondrion maintains its MMP with a group of cytochrome c 
which remained associated with the respiratory chain. There are therefore two groups in 
mitochondrial cytochrome c; a large quantity of cytochrome c would be in free form in the 
intermembrane space and would allow a small amount to ensure the release of 
mitochondrial respiration in the first group so as to maintain production of ATP required for 
the formation of the apoptosome (Martinou et al., 2000). 
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Figure 1. 7 The mitochondrial pathway of apoptosis 
Many pro-apoptotic signals converge on mitochondria leading to the release of many of the 
intermembrane space proteins under the control of proteins of the Bcl2 family. Cytochrome c (cyt c) 
induces caspase activation execution (caspases-3 and -7) via the apoptosome. Smac/Diablo and 
Omi/HtrA2 neutralise caspase inhibition induced by the IAP (inhibitor of apoptosis protein) execution. 
AIF (apoptosis inducing factor) and endoG (endonuclease G) are involved in the degradation of DNA 
execution independent of caspase activity (adapted from (Ravagnan et al., 2002). 
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1.5.2.3 The protein Apaf-1 
Apaf-1 (Apoptotic protease for activating factor-1) is a protein of approximately 
130kDa comprising a caspase recruitment domain (CARD domain) in the amino terminal 
part, a region having high homology to Ced-4 and C-terminal domain containing several 
WD40 repeats (WD40 domains) that are involved in protein-interactions proteins (Cain et al., 
2002). The WD40 repeats are necessary for binding to cytochrome c, but they are not 
sufficient. The WD domain also plays an important role in the recruitment of pro-caspase-3. 
The CARD domain of Apaf-1 is not exposed in normal conditions and therefore cannot 
interact with caspase-9; however, in the presence of ATP and cytochrome c, Apaf-1 changes 
conformation and can interact with caspase-9 through the exposure CARD domain as shown 
in Figure 1.8 (Li et al., 1997). In 2000, previous years, several Apaf-1 isoforms have been 
identified in tumor cell lines, but their expression in tissues and ability to activate procaspase-
9 remain poorly characterized. Several studies have reported that Apaf-1 has at least six 
splice isoforms in human cells (Li et al., 1997). Also, some studies have been reported to 
have at least six splice isoforms in human cells. Apaf-1XL and Apaf-1L have the ability to 
cleave procaspase-9, binding with cytochrome C.  Apaf-1 cDNAs cloned from Hela cells, 
Apaf-1M, and Apaf-1S, and Apaf-1 mRNA in normal tissues including prostate also has been 
reported (Walke and Morgan, 2000, Fu et al., 2001, Perkins et al., 2000). 
1.5.2.4 The formation of the apoptosome 
The apoptosome involved in apoptosis induced by mitochondria consists of Apaf-1, 
cytochrome c, and procaspase-9, which is a protein complex of ~700kDa in size (Figure 1.8). 
In the cytosol, cytochrome c interacts with the carboxy terminal domain of Apaf1 (Hu et al., 
1998b) and allows the presence of nucleotides to unmask the key areas of Apaf1, the WD40 
domains and CARD domain. The WD40 domains allow multimerization of Apaf-1 and the 
CARD domain can recruit the initiator caspase pro-caspase-9 via its own CARD domain 
(Cain et al., 2001). The three-dimensional structure of the apoptosome has been solved by 
cryo-electron microscopy (Acehan et al., 2002). The apoptosome is formed by seven Apaf1 
molecules that interact with each other at their N-terminus to form a wheel-like structure (the 
―wheel of death‖). The CARD domains of Apaf1 monomers are at the center of the 
apoptosome that is, as the DISC, an inducer of proximity used to locally concentrate pro-
caspase-9. Association between Apaf-1 and pro-caspase-9 forms a holoenzyme complex 
resulting in active caspase-9 by self-dimerization and proteolytic cleavage and also increases 
its enzymatic activity (Rodriguez and Lazebnik, 1999). Caspase-9 was has been described 
as capable of cleaving in both the cytoplasm and in the apoptosome, but the active caspase-
9 is actually the one related to the apoptosome (Rodriguez and Lazebnik, 1999).The 
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autoproteolytic cleavage of caspase-9 is at its residue D315, although it should be noted that 
this cleavage is not required for its activity but it is a reflection of its activation (Rodriguez and 
Lazebnik, 1999). Once activated, caspase-9 can then cleave executionercaspases like 
caspase-3 and -7 (Acehan et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 8 The formation of the apoptosome and its inactivation 
In the cytoplasm, cytochrome c intreacts with the WD40 domain of the protein Apaf1, causing a 
conformational change that allows the oligomerization of Apaf1 as heptamer. The CARD domain of 
Apaf1 molecules are at the center of the apoptosome and will be able to recruit procaspases 9. This 
arrangement of Apaf1 CARD domains can concentrate procaspases 9, which promotes their activation 
by dimerization. The various stages of training apoptosome are inhibited by several antiapoptotic 
proteins. HSP27 inhibits binding cytochrome c to Apaf1. HSP70 and 90 inhibit multimerization of 
Apaf1. HSP70 and inhibits the recruitment of procaspase 9. Adapted from (Acehan et al., 2002). 
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1.5.2.5 Role of ATP in apoptosis 
The integrity of the mitochondrial membrane is often altered during apoptosis induced 
by the mitochondrion, which causes a reduction in ATP production accompanied by the 
release of apoptotic factors in the cytosol. Furthermore, apoptosis is a process requiring 
energy, including the apoptosome formation (Figure 1.8) for the condensation of the 
chromatin, for the fragmentation of DNA but also to transport molecules to the  nucleus (Kass 
et al., 1996, Richter et al., 1996).  
1.5.3 Regulation of caspase-dependent pathways 
1.5.3.1 The inhibitors of apoptosis proteins (IAPs) 
The IAPs are proteins that inhibit cell death by preventing cleavage of caspases and 
therefore their activity (Fesik and Shi, 2001) (Figure1.8). They were originally described as 
inhibitors of viral, but unlike the other two viral proteins, which are CrmA bovine smallpox 
virus and baculovirus p35 protein, the IAPs are the only ones with homologous proteins in 
mammals. The IAPs comprise one or more BIR (baculoviral IAP repeat) domains that are 
essential for their anti-apoptotic activity and allow binding to caspases. Each BIR domain has 
distinct functions and a binding specificity to caspases (Verhagen et al., 2001). The BIR2 
domain inhibits caspase -3 and -7, while the BIR3 domain inhibits the activity of caspase -9 
(Ekert et al., 2001). 
XIAP (X-linked inhibitor-of-apoptosis protein) is one of the best known of this family of 
molecules and it can inhibit the activation of the initiator caspase-9 as well as the effector 
caspases -3 and -7. Indeed, it can bind to active caspase -9 and has the ability to act on 
caspase-3 or caspase-7, thus blocking the apoptotic pathway (Deveraux et al., 1999, Wei et 
al., 2008). 
1.5.3.2. Inhibitors of IAPs 
Smac (Second Mitochondria-derived Activator of Caspase) and its counterpart 
DIABLO (Direct IAP Binding protein with Low pI) and have similarities with the Grim Reaper 
and HID Drosophila proteins. These block the anti-apoptotic activity of the IAP, as does 
Smac/DIABLO in mammals (Du et al., 2000, Verhagen et al., 2000) (Figure 1.8). 
Smac/DIABLO is highly expressed in the heart, liver, kidneys, spleen and in several cancer 
cell lines. It is synthesised in the cytoplasm as a precursor of 239 amino acids and is 
exported into the mitochondrion by means of its 55 amino acid N-terminal mitochondrial 
localisation signal (MLS). Once in the new compartment, the localisation signal is cleaved 
and the protein acquires its pro-apoptotic activity by homo-dimerising (Chai et al., 2000). Its 
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release from the mitochondria is induced by many apoptotic stimuli and controlled by 
members of the Bcl-2 family (Adrain et al., 2001). Smac/DIABLO was the first identified 
protein to directly inhibit the functions of IAPs; it is also linked to the death receptor pathway 
(Srinivasula et al., 2001). Smac/DIABLO interacts by binding IAPs with the third BIR domain 
(BIR3) of XIAP; in this way it prevents the binding of IAPs to caspase -3, -7 and -9. XAF-1 
(XIAP associated factor 1) is a protein capable of activating other caspases by inhibiting IAPs 
(Figure 1.8). Unlike Smac/DIABLO, XAF-1 is a continuously active nuclear protein which has 
a zinc finger domain allowing it to interact directly with XIAP. Its expression seems to be 
reduced in some cancer cell lines (Liston et al., 2001). 
Smac and XAF-1 are not the only inhibitory proteins known to target IAPs. More 
recently Omi/HtrA2 (high temperature requirement protein A2) was identified as a new 
inhibitory protein (Martins et al., 2002, Verhagen et al., 2001) (Figure 1.8). The precursor 
HtrA2 is 50kDa protein in which the N-terminal part contains the MLS. This is cleaved after 
being imported into the mitochondria and then generates a protein of 36 kDa. HtrA2 belongs 
to the family of serine proteases that are conserved during evolution. In normal human cells, 
HtrA2 is contained in the mitochondrial intermembrane space, but following apoptosis 
induction with various agents such as staurosporine, TRAIL, or UV irradiation, it is released 
into the cytosol. In the cytosol, HtrA2 binds to XIAP and IAPs in the same manner as Smac 
/DIABLO and facilitates caspase activation. HtrA2 induces apoptosis by two different 
mechanisms, the first by inhibition of IAPs to caspase activation, and the second by the 
serine protease activity independent of caspase (Hegde et al., 2002, Suzuki et al., 2001). 
1.5.3.3 Other regulatory proteins 
Other complex proteins involved in the regulation of the apoptotic signal exist in other 
"strategic sites" of the cell, such as the endoplasmic reticulum, the Golgi apparatus, the 
lysosomes or the nucleus (Ferri and Kroemer, 2001). Like the activity of the XAF-1 protein 
recently described, the nucleus also has a role in the regulation of apoptosis and it does not 
suffer the events used to remove the cell. Another nuclear protein DESD (DED-containing 
DNA-binding protein) exerts its anti-apoptotic activity by inhibiting the activation of caspase-6 
or by blocking transcription. This protein seems to be modulated by another protein called 
DEDAF (DED- associated factor), which is also able to bind to FADD and caspase -8 or -10 
and promote the formation of the DISC (Zheng et al., 2001). 
Members of the Bcl-2 family (Bcl-2, Bax, Bid, Bak) can also regulate the mitochondrial 
pathway by acting on the release of cytochrome c (Hu et al., 1998a). Hu and his colleagues 
have demonstrated that Bcl-xL interacts with caspase-9 and Apaf-1, and also in that study 
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showed that Bcl-xL inhibits the maturation of caspase-9 that was mediated by Apaf-1, a 
process that was conserved from nematodes to humans (Hu et al., 1998a). 
In addition to that, the heat shock proteins or Hsp are also both inducers and 
inhibiting factors of apoptosis (Figure 1.9). Various studies show that the Hsp-70 and Hsp-90 
can bind to the CARD domain of Apaf-1, thus preventing the oligomerisation and activation of 
pro-caspase-9 (Pandey et al., 2000, Saleh et al., 2000). Hsp-27 blocks the oligomerisation of 
Apaf-1 by binding to cytochrome c (Bruey et al., 2000). 
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Figure 1. 9 Events regulated by Heat shock proteins (HSPs) in the mitochondrial pathway  
Extracellular signals (Survival signals) or stresses (Death signals) congregate to control the 
mitochondria mediated pathway to caspase activation and apoptosis. HSPs intervene at multiple 
points within this pathway; upstream of the associated mitochondrial changes to regulate the 
engagement and/or progression of apoptotic events. HSP-mediated potentiation of a signalling 
pathway is depicted as a direct interaction between the HSP and its target (+) Adapted from (Beere, 
2004). 
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1.5.4 The caspase-independent mitochondrial pathway 
Several proteins in the intermembrane space can induce apoptosis directly without 
activation of caspases. This is the case in the induction of apoptotic factor (AIF) and 
Endonuclease G (Endo G) which, when released from mitochondria, translocate to the 
nucleus causing chromatin condensation and cleavage of DNA thus generating large 
fragments of DNA (Figure 1.7) Lorenzo et al., 1999). 
1.5.4.1 The AIF 
The AIF factor was identified several years ago by Guido Kroemer‘s team (Susin et 
al., 1999, Cande et al., 2002). The AIF gene is located on chromosome X and encodes a 
protein of 57kDa. AIF is a flavoprotein consisting of three domains: the MLS sequence at the 
amino-terminal side, a sequence of 27 amino acids and a domain with oxidoreductase 
activity of carboxy-terminal 485 amino acids (Lorenzo et al., 1999). The precursor of the AIF 
(67 kDa) is synthesised in the cytoplasm and then imported into the mitochondria (Susin et 
al., 1999). Once in the intermembrane space, the MLS sequence is cleaved and the protein 
changes its conformation while incorporating the prosthetic group FAD (Flavin adenine 
dinucleotide). This is probably a bifunctional protein with an oxidoreductase activity and pro-
apoptotic role (Ye et al., 2002). 
After cell exposure to pro-apoptotic stimuli, AIF translocates from the intermembrane 
space into the cytosol and to the nucleus (Susin et al., 2000). This usually precedes the 
release of cytochrome c. The mechanism by which the AIF translocates to the cytosol is still 
unknown. Transport to the nucleus could be due to a nuclear localisation sequence. The 
effect of the AIF as an apoptogenic molecule has been studied both in vitro and in vivo. In 
vitro it has been shown that the AIF translocates through the cytoplasm to the nucleus, the 
place where it leads to chromatin condensation and DNA degradation into large fragments of 
50 kbp condensations; this is a direct interaction with DNA without sequence specificity (Ye 
et al., 2002). This interaction is mainly by its carboxy-terminal domain, and it may be 
modulated by the level of translocation to the nucleus and is greater during the phase of 
condensation during the late phase of formation of apoptotic bodies (Ye et al., 2002). 
In addition, the effects of AIF are negated by over-expression of Bcl-2 and are the 
same in cells with or without caspase activities: the action of AIF is thus independent of 
caspases. AIF can also be inhibited by an endogenous protein, Hsp70 (Ravagnan et al., 
2001). This has been shown in vitro by chromatin condensation and in vivo by the nuclear 
and mitochondrial level overexpression of Hsp70. The action of Hsp70 is due to apoptosis by 
firstly inhibiting the formation of the apoptosome as Hsp70 binds to Apaf-1. But 
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overexpression of Hsp70 in cells not expressing caspase also prevents cell death; this 
suggests that Hsp70 can bind to other proteins such as AIF. The binding of Hsp70 to Apaf-1 
and AIF appears to be by the binding domain of Hsp70 ATP present, without intervention of 
Hsp70 chaperone activity (Ravagnan et al., 2001). 
Many aspects of the function of AIF are still unknown, including its mode of action on 
DNA, its oxidoreductase activity and its signal transduction. The DNA condensation observed 
during apoptosis may be explained by the direct interaction of the DNA- AIF (Ye et al., 2002). 
Indeed, this interaction could alter the structure of chromatin and promote nucleases such as 
topoisomerase II or cyclophilin, which also generate fragments of 50kb similar to those 
obtained after induction of AIF. These fragments correspond to the loop-like structures at the 
level of chromatin (Widlak and Garrard, 2009, Samejima et al., 2001). 
1.5.4.2 Endonuclease G 
Endonuclease G is a highly conserved non-specific nuclease (Li et al., 2001). It is 
encoded by a nuclear gene and probably involved in the replication of the mitochondrial 
genome. During apoptosis, endonuclease G passes through the outer membrane of the 
mitochondria and translocated into the nucleus (van Loo et al., 2001). Endonuclease G can 
act with exo-nuclease and the DNase I in the nucleus to generate DNA fragments of higher 
molecular weight (Widlak et al., 2001), but it can also generate oligonucleosomal fragments 
(Samejima et al., 2001). 
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1.6 Reactive oxygen species (ROS) 
ROS represent an intensive area of current research due to their role as signalling 
molecules in pathways controlling an array of aspects of cellular physiology. This concept 
has been there ever since it was essentially brought out in the 1990s when it was found that 
hydrogen peroxide was mandatory in cytokine, hormone (such as insulin), growth factor, as 
well as AP-1 and NF-κB signalling (Finkel, 1998). 
Not before long, many reports pointed out that H2O2 may endorse phosphatase 
inactivation using cysteine oxidation and gave reasonable biochemical mechanisms in which 
ROS could be capable of imposing on signalling routes (Rhee et al., 2000). Simultaneous 
with these preliminary findings on ROS signaling, the common concept of the mitochondrion 
being the ―powerhouse of the cell‖ was contested with the unearthing that letting loose of 
cytochrome c
 regulates apoptosis (Liu et al., 1996b). The notion that a mitochondrial 
protein that is involved in oxidative phosphorylation similarly takes a major part in 
signalling pathway, unlocked the likelihood that metabolism-related signaling is a 
rather common but not unique system. Even though it was evident that metabolism 
was controlled by cellular signalling pathways, it was however not greatly valued that 
metabolism could react to control signalling. Cytochrome c‘s two-fold role implied a 
cross-talk between mitochondrial metabolism and signaling pathways. It could possibly 
be that the release of mitochondrial ROS was a different way of this cross-talk (Liu et al., 
1996b). 
The first studies to check this likelihood brought out that mitochondria emit H2O2 
under physiological hypoxia to initiate the transcription factor hypoxia inducible 
factor1 (HIF-1), which is essential for metabolic adaptation in low oxygen (Chandel 
et al., 1998). After that, mitochondrial release of H2O2 appeared to initiate c-Jun N-
terminal kinase1 (JNK1), p53, and NF-κB (Chandel et al., 2000, Nemoto et al., 2000). There 
have been a lot of reports that brought out the significance of ROS-dependent signaling in 
numerous systems (Collins et al., 2012). When brought together, this information proposed 
that the release of ROS represents an important mode of communication (amid mitochondrial 
role) and other cellular processes to sustain homeostasis and encourage adaptation to 
constant stress (Collins et al., 2012).
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1.6.1 Mitochondria-generated ROS 
ROS are superoxide molecules that are formed from oxygen (O2) and can easily 
oxidize other molecules. The majority of the intracellular ROS originate from superoxide (O2•-
), which is made by the one electron reduction of O2. Superoxide is changed into hydrogen 
peroxide (H2O2) by superoxide dismutases (SODs) (Collins et al., 2012). 
There are several location that have been identified to generate O2•- in mitochondria 
(Brand, 2010); although exactly how ROS levels are regulated in vivo is still unclear. What is 
interesting to note is that whereas these ROS generating locations can deposit O2•- into the 
mitochondrial matrix, merely place IIIQo (on complex III) and glycerol-3-
phosphatedehydrogenase can emit O2•- in to the inter membrane space. The inter 
membrane space has higher chances of accessing the cytosol because all ROS 
have to do is traverse the external mitochondrial membrane but the matrix ROS has 
to traverse the internal and the external mitochondrial membranes (Muller et al., 
2004). This then means that O2•- which is generated from site IIIQo and glycerol-3-
phosphate dehydrogenase could have an advantage when it comes to signalling 
ability in the cytosol. Despite all this knowledge, more research is required to 
determine which places/sites of ROS production are physiologically significant 
(Muller et al., 2004). 
1.6.2 Mitochondrial ROS are tightly regulated           
            Very tight regulation of ROS levels is essential especially because the quantities of 
ROS can deduce specificity and role when it comes to their capability to engage in 
physiological cell signaling (Figure 1.10). This then means that signaling ability of ROS is 
maintained on numerous levels (Muller et al., 2004). 
            To begin with, antioxidant enzymes are able to remove ROS. As mentioned 
earlier, SODs transform O2•- to H2O2. While SOD1 is found in the mitochondrial inter 
membrane space and cytoplasm, SOD2 is found in the mitochondrial matrix, whereas 
SOD3 is tied to the extracellular matrix. Peroxiredoxin enzymes (PRXs), glutathione 
peroxidases enzyme (GPXs) together with catalase enzymes, have the ability to 
remove H2O2. Mammalian cells express six PRX isoforms together with PRX3 and 
PRX5 in the mitochondria. PRXs perform this by going through oxidation by H2O2 at a 
functional site cysteine and thereafter reduction by thioredoxin, thioredoxin 
reductase, and NADPH. The available eight GPXs are oxidized by H2O2 and then 
subsequently reduced by glutathione (GSH). Catalases are located in peroxisomes. 
How quick these antioxidant enzymes react with H2O2 (rateconstant, k) and the 
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concentration of H2O2 and enzyme, concentrations of H2O2 remain poorly 
characterised. On the other hand, peroxiredoxins have elevated rate constant and 
this is the reason they are believed to be behind scavenging nanomolar levels of 
H2O2 linked with signalling. GPXs too have the same rate constants however, they are 
only vital when there is higher intracellular concentration of H2O2, and this is when 
GPXs is able to start to compete with PRXs for substrate (Winterbourn and Hampton, 
2008). This shows that PRXs are important for switching ROS signaling off as GPXs are 
important for cushioning elevated levels of ROS to a level which the cell cannot be destroyed 
and also stimulate signaling stress responses. Catalases have very low affinity for hydrogen 
peroxide and are limited to peroxisomes. The control of actions and expression levels 
of these antioxidants take place in many ways and in different operation so as to 
deal with ROS levels (Winterbourn and Hampton, 2008).
 
Besides control of ROS scavenging, controlling ROS generation could modify the 
signaling ability of ROS. The factors that control electron transport chain ETC 
production of ROS in vivo are not completely comprehended. Most of what is 
currently understood is ;as a result of research that involved mitochondria and cel ls  
(Murphy, 2009). It has been discovered that what largely regulates ROS generation is the 
redox state of the ETC. For instance, hindering ETC electron carriers results in them being 
decreased, as a result more of superoxide is produced. An additional significant cause 
of ROS generation is the proton motive force (pmf) which is made up of an electrical 
gradient (ѱ mitochondrial membrane potential) and chemical gradient (pH) through the 
internal mitochondrial membrane. The pmf is produced when protons are removed out 
of the matrix into the inter membrane space by complexes I, III, and IV as electrons 
are shifted across the ETC. When there is pmf is increased it results in more ROS 
being generated (Echtay et al., 2002). 
Finally, the signalling ability of ROS could be modified by mitochondrial localization. 
ROS are molecules that have a short life span and thus one way to improve their 
competence is by co-localisation of their site of  generation and their site of signalling role. 
In theory, the quantity of mitochondria in the cell has the ability to modify the quantity of ROS 
generated and as a result, also modify their intracellular function. Nevertheless, the 
mitochondrial biogenesis factor increases expression of antioxidant enzymes to upfold 
redox (St-Pierre et al., 2006). 
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Figure 1. 10 Mitochondria Produce ROS for signalling  
Superoxide (O2.-) is generated at the mitochondrial respiratory chain and emitted into both the matrix 
and intermembrane space. Matrix superoxide is converted to hydrogen peroxide (H2O2) by superoxide 
dismutase 2 (SOD2); this hydrogen peroxide can diffuse through both inner and outer mitochondrial 
membranes to access the cytosol or be converted to water (H2O) by glutathione peroxidases (GPX) or 
peroxiredoxins (PRX). Inter-m;embrane space superoxide can exit the mitochondria through voltage-
dependent anion channels (VDAC) and be converted to hydrogen peroxide in the cytosol by 
superoxide dismutase 1 (SOD1). The cytosol also possesses glutathione peroxidases and 
peroxiredoxins that can reduce hydrogen peroxide to water. Cytosolic hydrogen peroxide is believed 
to be the primary form of signalling ROS in the cell, where it can oxidize protein thiol residues 
(Winterbourn and Hampton, 2008). 
1.6.3 Physiological targets of ROS 
There is a lot of evidence that ROS can result in reversible post translational 
protein modifications to precisely control signaling pathways. H2O2 can oxidise thiol 
groups (-SH) on cysteine residues to develop sulphenic acid ( -SOH), which is able to 
bond with GSH to turn it into a glutathionylated form (-SSG), with neighboring thiols to 
create a disulphide bond ( -SS-), it could also with amides to create amide (-SN-) (Finkel, 
2012). All these alterations could have an effect on the actions of the target protein thus 
changing its operation in a signaling pathway. Phosphatases seem to be vulnerable to 
control by ROS because they have a reactive cysteine which is their active site. It prevents 
their de-phosphorylation activity (Rhee et al., 2000). PTP1b, PTEN, and MAPK 
phosphatases are a good example of phosphatases that can be controlled in such 
a way (Rhee et al., 2000). 
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1.6.4 Mechanisms of ROS generation and their role as signalling molecules 
        The NADPH oxidase (Nox) protein family contains several isoforms, namely 
NOX1, NOX2, NOX3, NOX4, and NOX5 also, in parallel, two members appointed 
DUOX1 and DUOX2 (dual oxidase) (De Deken et al., 2000, Dupuy et al., 1999). 
These enzymes share the ability to transport electrons through the plasma membrane to 
produce superoxide and other reactive oxygen species (ROS) (Genestra, 2007). 
The NOX produce ROS by electron transfer from NADPH to O2 through an FAD heme 
group which then results into O2•-. The reactive oxygen species or ROS (Reactive Oxygen 
Species) are small molecules including oxygen-derived oxygen radicals: superoxide anions 
(O2•-), hydroxyl radicals (OH•), hydroperoxyl (HOO•) peroxyl (RO2•) and alkoxyl (RO•) but also 
non-radical as hypochlorous acid (HOCl) compounds, ozone (O3), singlet oxygen (1O2) and 
hydrogen peroxide (H2O2) (Genestra, 2007). O2•- is changed to H202 by superoxide dismutase 
(SOD) and when H2O2 reacts with metal ions it creates water or OH•- or otherwise could be 
altered to H2O via glutathione peroxidase catalase, as shown in Figure1.11 (Winterbourn and 
Hampton, 2008, Paletta-Silva et al., 2013, Terada, 2006). 
 
Figure 1. 11 The formation and elimination of ROS 
The oxygen approves an electron; it generates superoxide anion which is very reactive. Superoxide 
anion is changed to hydrogen peroxide via superoxide dismutase (SOD). Hydroxyl radicals are 
created when hydrogen peroxide receives electrons. The hydroxyl radicals are converted to water by 
means of Glutathione peroxidase catalase. Figure adopted from (Terada, 2006). 
 
           ROS intracellular concentration seems to control stress survival or apoptotic 
responses. There is evidence to suggest that low levels of ROS means that they are being 
utilised inside the cell as signaling mediators for natural homeostasis (frequently 
proliferation); moderate levels (even though linked to proliferation) could trigger a stress 
response, making cells to adapt through the expression of anti-oxidants, while high levels of 
ROS at a pro-apoptotic limit, primarily harm cellular structural elements and dynamically 
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prompt pathways of apoptosis - see Figure 1.12 (Jiang et al., 2011, Sena and Chandel, 
2012, Terada, 2006). 
 
 
Figure 1. 12 Balance shifts in ROS levels alter cellular homeostasis 
The generation of low ROS in ordinary throughout cell homeostasis while the elevated volume 
resulted into cellular adaptation like growth in anti-oxidant expression through NF-κB and Ref-1 
pathways. Elevated levels of ROS / oxidative stress trigger pathways of apoptosis or cell senescence 
found in p38 or JNK pathways (Adopted from Terada, 2006). 
 
1.6.5 ROS and malignant transformation 
The ability of tumor cells to utilise oncogene activation and tumor suppressor 
mutation to positively control tumour development appears to be associated with ROS-linked 
signalling (Dang, 2012). Recent evidence has indicated that de novo activation of the 
oncogenes epidermal growth factor receptor (EGFR) HER-1 and -2 receptors (Trachootham 
et al., 2006) and H-Ras elevates the in vitro division rate of tumour cells which coincides with 
an abundance of high ROS concentrations (Choudhary et al., 2010, Choudhary et al., 2011, 
Choudhary and Wang, 2009). Additionally, the over-expression of the leukotriene B4 
receptor 2 (LTB4R2) gene amplifies NOX-1 and -4 expression, and produces elevated  levels 
of oxidative stress in vitro and in vivo (Kim et al., 2009, Shimada et al., 2009). In agreement 
with these results, the in vivo attenuation of ROS stimulating genes NOX-1 and alkylated 
DNA healing protein alkB homolog 8 (ALKBH8) lessen oxidative stress (Shimada et al., 
2009). Mitochondrial cytochrome B gene (MT-CYB) increases oxidative stress, NF-κB 
activation, Cyclin-D1 and type IV collagenase, which enhaces the exceedingly malignant 
properties of tumour cells in vivo (Dasgupta et al., 2008). This shows that there is a very 
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strong connection between oncogene activation and the generation of oxidative stress in 
epithelial cells (Shimada et al., 2009). 
The elevated energy requirements that is vital for extreme cell division after oncogene 
activation makes the mitochondria generate ROS as a natural secondary product which 
results in oxidative stress (Chung et al., 2009, Trachootham et al., 2009, Trachootham et al., 
2006). The extra ROS triggers additional DNA damage (mutations) as well as  triggering cell 
survival and proliferation pathways via NF-κB and Ref-1, which repeatedly endorse 
carcinogenesis (Angkeow et al., 2002, Li et al., 2009, Weinberg et al., 2010). To add on to 
that, it has been proposed that oxidative stress could leaves the cells in the state of H202 and 
on the positive side, alter the tumor micro-environment for sustained growth (Schmielau and 
Finn, 2001). Thus, uncontrolled ROS generation could encourage numerous elements that 
are hallmarks of cancer development (Schmielau and Finn, 2001). 
However, in spite of the advantages provided by ROS-mediated signalling, the 
sustained oxidative stress in response to hyper proliferative signaling simultaneously results 
in the cell‘s disadvantage because it can be ‗pushed‘ toward ROS-related pro-apoptosis. In 
fact, it has been revealed that de novo oncogene expression stimulates normal cells 
following cisplatin or H2O2 treatment and that this is due to increased JNK signaling mediated 
by a ROS level rise (Benhar et al., 2001, Trachootham et al., 2006). 
While they get used to the increased metabolic requirements, cancer cells have to 
control their basal ROS concentrations by over-expression of antioxidants so as to inhibit or 
prevent cell death. Evidence for this has been provided by experiments that demonstrated a 
significant effect for the compound ȕ-phenyl ethyl isothiocyanate (PITC). This is a chemical 
which interrupts the cell‘s key antioxidant protein Glutathione (GSH). The pharmacological 
inhibitor PITC, when used in combination with cisplatin, has been shown to be highly 
effective in more aggressive tumors over cisplatin treatment alone, because more aggressive 
tumour cells are highly reliant on the elimination of metabolic ROS via the essential GSH 
antioxidant defense (Trachootham et al., 2006). The disparity in ROS between normal cells 
and malignant cells throughout carcinogenesis provides a novel therapeutic target as the 
biochemical modification of ROS, the high levels of which are necessary for tumor cell 
growth, might represent a tumour-specific therapeutic opportunity (Wang and Choudhary, 
2011). 
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1.6.6 Cancer cell antioxidant defence against ROS 
1.6.6.1 General 
Tumour cells acquire resistance to chemotherapeutic drugs because they alter their 
intracellular environment (Shannon et al., 2003). Given that ROS-regulated oxidative stress 
is vital to cancer development, tumour cells adapt by increasing the expression of the 
antioxidant protein families Glutathione (GSH) and Thioredoxin (Trx), thus upholding 
intracellular ROS concentrations that are lower than the critical pro-apoptotic limit that 
pushes them in the direction of cell death (Raffel et al., 2003, Godwin et al., 1992). This 
increased expression protects cancer cells from the activation of oxidative stress receptive 
ASK1 kinase, the continued activation of JNK (Liu and Min, 2002), and the opening of PTPs 
in the mitochondria, as every single one of these could potentially activate apoptotic death 
(Damdimopoulos et al., 2002). To add on to that, Trx and GSH are located in the 
mitochondria, in which they stabilize mitochondrial levels of oxidative stress and inhibit cell 
apoptosis beside the antioxidant enzymes like cytochrome c (Aon et al., 2012). The 
important roles of Trx and GSH in regulating oxidative stress and ROS-induced cell 
apoptosis, and thus their impact on cancer development, are becoming increasingly 
appreciated (Damdimopoulos et al., 2002). 
1.6.6.2 Glutathione (GSH) 
GSH is stimulated by the combinations of Glutathione S-transferases (GSTps), 
together which are described as excessively expressed in numerous malignancies (Pljesa-
Ercegovac et al., 2011). The elevated GSH and GSTp proteins function so as to shield 
cancer cells from ROS releasing agents that include chemotherapy, radiotherapy and 
oxidative stress-inducing cancer drugs (Kato et al., 2000). This renders the GSH system a 
target for pharmacological intervention which may permit the differential targeting of tumour 
cells by ROS-mediated cell death, as they are operating at conditions of high oxidative stress 
in comparison to their normal counterparts (Estrela et al., 2006, Trachootham et al., 2006). In 
view of the fact that GSTp is a biological inhibitor of JNK and ASK1 (Simic et al., 2009) it has 
been proposed that GSH reduction may also alter the responses of tumour cells to TNFR 
mediated apoptosis (Estrela et al., 2006); nevertheless, there have not been any clinical 
experiments that have employed this method. Overall, however, GSH inhibition in 
combination with tumour apoptosis-stimulating molecules represents a new possibility of 
cancer therapies (Ortega et al., 2011). 
JNK activation is based on its release from its biological inhibitor protein GSTp as 
ROS results in disulphide bond creation and dimerization (Adler et al., 1999) as described in 
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Figure 1.13. In vivo research has confirmed that genetic knockout of GSTp weakens JNK 
initiation and in accordance with this, mice deficient in GSTp show constitutive initiation of 
JNK (and thereafter AP-1), which is what is behind the elevated expression of antioxidant 
enzymes, so as to protect the cell from oxidative stress (Elsby et al., 2003). The elevated 
expression of GSTp has been seen in carcinomas, such as that of the bladder (UCC); it has 
been suggested that increased GSTp expression could inhibit the initiation of apoptotic 
pathways and thus result in tumours that are unaffected by ROS-inducing chemotherapeutic 
drugs (Simic et al., 2009). To add on to that, bladder cancer cells also exceedingly express 
superoxide dismutase (SOD), which as descrived above is an enzyme which enables the 
conversion of superoxide anion to hydrogen (Hempel et al., 2009). 
 
 
Figure 1. 13 The regulation of JNK by GSTp 
Monomeric GSTp prevents JNK actions and therefore the activation of c-Jun. Elevated oxidative 
stress which also means increased ROS results in GSTp to detach from JNK giving way for it to 
initiate c-Jun activation and provoke cellular apoptosis (for more explanation see 5.3.2). The figure 
was redrawn from (Simic et al., 2009).  
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1.6.6.3 Thioredoxin (Trx) 
The human Thioredoxin (Trx) system includes Trx and Trx reductase which function 
as antioxidants to regulate cellular redox reactions. It has been shown that Trx can 
translocate from the cytoplasm to the nucleus when oxidative stress occurs to enable 
initiation/activation of transcription factors NF-κB, AP-1 and p53 (Hirota et al., 1999, Ueno et 
al., 1999). Oxidative stress just as it is similar to other outer stresses, results in activation of 
ROS sensitive MAPK signalling pathways which coordinate the apoptotic response (Apel and 
Hirt, 2004) and the most noticeable target associated with is mitogen activated protein 
kinase-kinase-kinase (MAPKKK) apoptosis signaling kinase-1 (ASK1). Under normal 
conditions, reduced Trx binds to and inhibits ASK-1. When ROS levels increase, Trx is 
oxidized by ROS (oxidative stress), it is released from the N-terminus of ASK1 and after this 
ASK1 homo-oligomerises and auto-phosphorylates at residue Thr845 (Liu and Min, 2002) as 
shown in Figure 1.14 . 
Clinically, excessive expression of Trx has been found for instance in colon tumours 
and this has been associated with more aggressive tumours, diminishing sensitivity to 
chemotherapy and general diminished survival rates (Raffel et al., 2003). This reduces 
patient‘s prognosis since it triggers the generation of VEGF and Ref-1 which are associated 
with angiogenesis and cell survival (Noike et al., 2008). It has been shown that cancer 
patients have Trx blood plasma levels and this is also linked with more generation of VEGF. 
Therefore, preventing Trx by employing novel pharmacological Trx inhibitors like, such as 
PX-12, has been suggested as a cancer therapeutic agent that aims at reducing Trx and 
VEGF in cancer patients (Baker et al., 2006). Clinical testing has revealed some success 
following intravenous infusions of PX-12 (Ramanathan et al., 2009) although this required 
significant lengths of infusion time (Ramanathan et al., 2011). It has been recommended that 
new research should aim at new generation Trx inhibitors if these are ever to be utilized as 
mono-therapies (Ramanathan et al., 2011). 
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Figure 1. 14 The regulation of ASK1 by thioredoxin (Trx) 
Upon oxidative stress ROS oxidizes thioredoxin that ensures release from ASK1. ASK1 is then auto 
phosphorylated and drives apoptosis or cell stress responses.  The figure is redrawn from (Biswas et 
al., 2006). 
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1.7 CD40 and its ligand CD154 (CD40L) 
In 1984, the CD40 antigen was first identified by an antibody raised against a urinary 
bladder carcinoma that was also found to bind B cells (Karmann et al., 1995, Koho et al., 
1984, Paulie et al., 1984). In 1985 and 1986, it was detected by a monoclonal antibody 
(mAb) interacting with carcinomas and B cells (mAb S2C6, antigen p50 (Paulie et al., 1985)), 
and an antibody showing co-stimulatory effects for B lymphocyte proliferation (mAb G28-5, 
antigen Bp50 (Clark and Ledbetter, 1986, Paulie et al., 1985). This antigen was labelled 
CDw40 in 1986 at the Third International Workshop on Leukocyte Antigens in Oxford, and in 
1989 at the Fourth Workshop in Vienna it was documented as CD40. Stamenkovic and 
colleagues isolated a cDNA clone encoding CDw40 from a mammalian cell expression 
library (Stamenkovic et al., 1989). The cDNA encodes a polypeptide with structural 
similarities to several growth factor receptors and an extensive similarity to nerve growth 
factor (NGF) receptor (Johnson et al., 1986, Radeke et al., 1987). 
CD40 is known to be expressed on different cells in the immune system, such as B 
cells, dendritic cells, basophils, eosinophils and monocytes. CD40 can, furthermore, be 
detected on endothelial cells, keratinocytes, smooth muscle cells, epithelial cells and 
fibroblasts (Kooten and Banchereau, 1997, Schönbeck and Libby, 2001, van Kooten and 
Banchereau, 2000). Its cognate ligand, CD40 ligand (CD40L), also common known as 
CD154, is mainly transiently expressed on activated T-cells, but it can also be found on 
basophils, eosinophils, monocytes, macrophages, dendritic cells, NK cells, B lymphocytes, 
platelets, mast cells, endothelial cells, smooth muscle cells and epithelial cells (Schönbeck 
and Libby, 2001). A common feature of all these cells is that the CD154 expression is non-
constitutive but can be rapidly induced upon activation. CD40 ligand (also known as gp39, T-
BAM, or TRAP) was first described as a membrane protein on activated T cells (Armitage et 
al., 1992, Hollenbaugh et al., 1992).  
1.7.1 Structure of CD40 
CD40, the high-affinity receptor of CD40L, is a 48kDa Type I transmembrane protein 
belonging to the family of TNF receptors (Andre et al., 2002a). The CD40 gene is found in 
the region of chromosome 20, q12.13.2 and consists of 9 exons with a total length of 16.3 kb 
(Grimaldi et al., 1992). Exon I encodes the promoter sequence of the protein exons II-VI for 
the extracellular domain, exon VII for the transmembrane domain and exons VIII and IX 
encode the intracellular domain of CD40. The final total protein contains 255 amino acids; 
the majority (171 amino acids) forms the extracellular region of the molecule (Naismith and 
Sprang, 1998), with the C-terminal domain being located in the intracellular region and the N-
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terminal domain found in the extracellular side. The extracellular region of CD40 is mainly 
composed of a repetitive sequence rich in cysteine residues (20 in total), which are divided 
into four areas, each comprising an arrangement of two subdomains of a total of four (A1, 
A2, B1 and B2) (Figure 1.15). This arrangement is typical of proteins belonging to the family 
of TNF receptors (van Kooten and Banchereau, 2000). 
 
 
Figure 1. 15 Structure of the gene and the human CD40 protein 
 A) The CD40 gene contains 9 exons encoding the extracellular, transmembrane and 
intracellular domains of the protein (leader sequence= promoter; EC = Extracellular; TM= 
transmembrane; IC= intracellular). B) The CD40 protein is composed mainly of a long 
extracellular domain containing a sequence of 20 cysteine residues (horizontal lines) divided 
into four areas each comprising two sub-areas. Adapted from (van Kooten and Banchereau, 
2000). 
Some confusion as to the exact arrangement of multimeric CD40 present on the membrane 
surface still exists. Some investigators have reported the presence of CD40 as dimers, while 
others reported an assembly of three CD40 molecules (trimer) constitutively in trimeric form 
on the cell surface via PLAD, a pre-ligand-binding assembly domain. (Chan et al., 2000). 
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1.7.2 Structure of CD40L 
CD40L (CD154) is a Type II transmembrane protein of 39kDa in size belonging to the 
TNF superfamily (Abou-Saleh et al., 2009). The gene of CD40L is located in the q26.3-27.1 
region of chromosome X, a fragment with a length 13 kb (Chakrabarti et al., 2005). It consists 
mainly of five exons; exon I encodes the transmembrane and intracellular region of CD40L, 
whereas exons II -V encode the extracellular region of the molecule (Figure 1.16). 
 
 
 
Figure 1. 16 Structure of the gene and protein of human CD40L 
The gene encoding CD40L contains 5 exons coding for different regions of the protein (IC=intracellular 
TM= transmembrane, extracellular=EC). Schematic structure (left), and crystallographic representation 
(right). Protein CD40L (monomer). The extracellular region of the molecule comprises the C-terminal 
domain, whereas the N-terminal domain is found in the intracellular region. This organisation is typical 
of proteins belonging to the TNF family. Adapted from (van Kooten and Banchereau, 2000). 
CD40L protein consists of 261 amino acids and comprises a C-terminal domain 
located in the extracellular region and a N- terminal domain in the intracellular region of the 
CD40L molecule (Chakrabarti et al., 2007). Although CD40L is a type II transmembrane 
protein, it appears to form a multimeric complex composed of three monomers (trimer) 
associated with the cell membrane (Xia et al., 2010). This structure would facilitate its 
interaction with CD40, most probably as a trimer, to allow induction of intracellular signals. 
Besides the membrane form, there is also a form of soluble CD40L (sCD40L) circulating in 
the blood. This form is almost exclusively an enzymatic cleavage at the membrane following 
platelet activation and remains a functional trimer of 18kDa (Li et al., 2008). 
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1.8 Interaction of CD40 with CD40L 
The structure of the extracellular part of CD154 has been resolved by X-ray 
crystallography (Karpusas et al., 1995). It consists of two beta sheets with jellyroll topology 
that forms a symmetric homotrimer. The crystal structure of CD154 and the CD40 model has 
been used together with site-directed mutagenesis to identify five CD40 residues, Y82, D84, 
N86, E74 and E117, and five CD154 residues, K143, Y145, Y146, R203 and Q220, which 
are important for the CD40-CD154 interaction (Bajorath, 1998, Bajorath et al., 1995, Bajorath 
and Aruffo, 1997). Thus, the CD154 binding site has been shown to be located in the second 
and third domains of CD40. It has been suggested that polar interaction between the basic 
residues on the CD154 and the acidic residues on CD40 plays an important role in this 
interaction (Singh et al., 1998). Currently, there are two models of possible interaction 
between CD40L and CD40 receptor. CD40 is a complex formed of either three molecules 
(trimer) constitutively associated with the membrane, or simply an assembly of three 
individual molecules (monomers) not associated with the ability to trimerise the following 
binding of CD40L. Thus, the first interaction model suggested that CD40L (always trimeric) 
promotes the formation of a homotrimeric complex of CD40 following its interaction with it 
(Figure 1.17A) (Anand et al., 2003). This would eventually troop the association of 
cytoplasmic adapter proteins and induction of intracellular signals. Furthermore, in the 
second model of interaction, CD40 is already found in the form of a trimer level of the 
membrane, thereby increasing its affinity for the stoichiometric CD40L, also a trime (Figure 
1.17B) (Anand et al., 2003). This last interaction hypothesis is currently the most commonly 
accepted in the literature, since it appears to be supported by a large amount of experimental 
data. Certainly the most compelling evidence in favour of the latter statistic is based on an 
elegant study demonstrating that all receptors associated with the TNF family, including 
CD40, are found as trimers pre-assembled at the plasma membrane via the PLAD domain 
(Chan et al., 2000), contrary to the original view of oligomerisation receptor upon binding of 
CD40L (Anand et al., 2003). 
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Figure 1. 17 The two models of interaction between CD40L and CD40  
A) The first interaction model of CD40L (always trimeric) promotes the formation of a homotrimeric 
complex. B) CD40 is found already in the form of a trimer level of the membrane, thereby increasing 
its affinity for the stoichiometric CD40L. Adapted from (Anand et al., 2003). 
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1.8.1 Other receptors of CD40L 
CD40 was long considered to be the only receptor for CD40L. However, three other 
receptors have been identified, in particular integrins αIIbȕγ, Mac-1 and α5ȕ1. Although 
CD40 remains the main high-affinity receptor of CD40L, these other partners seem to 
perform a very special function in various pathophysiological conditions. αIIbȕγ integrin was 
identified as a receptor for CD40L on the platelet surface, and the interaction between these 
two seems to promote platelet activation and stabilisation of the platelet thrombus in vivo 
(Andre et al., 2002b, Prasad et al., 2003). The interaction is possible between CD40L and 
αIIbȕγ through the KGD domain (Lysine-Aspartic acid-Glycine) of CD40L. Most integrin 
receptors αIIbȕ, have at least one KGD and αIIbȕ contains a recognition domain for this 
pattern, allowing their interaction domain. Mac-1 is the major integrin involved in the 
adhesion of monocytes and neutrophils to the activated endothelium during inflammation and 
is also a receptor for CD40L. This interaction promotes the adhesion and transmigration of 
leukocytes at the atherosclerotic plaque, and it is involved in neointimal formation, a key 
component of atherosclerosis (Li et al., 2008). The exact residues involved in this interaction 
are still unknown, but it seems that CD40L interacts with Mac-1 in its active conformation. 
Finally, integrin α5ȕ1 is the main fibronectin receptor and was more recently identified as one 
of the other receptors of CD40L (Leveille et al., 2007). 
1.9 Role of CD40/CD40L in immune system 
In previous sections of this chapter, the function of CD40-CD40L in different cell types 
was introduced. In this section, a comprehensive discussion of the main physiological 
functions of the CD40/CD40L system will be undertaken, which will include details on its 
involvement in humoral immunity (antibody production), cellular immunity and regulation of 
inflammatory mediators, and more specifically its involvement in the induction of apoptosis  
(Ma and Clark, 2009). 
1.9.1 Humoral immunity 
Humoral immunity is associated with B cells and antibody production, which requires 
close involvement of T lymphocytes and APCs, such as dendritic cells. Together, these 
factors ultimately lead to the differentiation of B cells into plasma cells and the production of 
immunoglobulins (for example; IgA, IgE, IgG and IgM) (Ma and Clark, 2009). The importance 
of the CD40/CD40L axis in humoral immunity was demonstrated mainly by three 
approaches: first, by clinical manifestations and symptoms observed in patients with hyper 
IgM (HIM) syndrome, (Aruffo et al., 1993, Allen et al., 1993, Korthäuer et al., 1993); secondly, 
by the genetic approach (deletion of the genes for CD40 and CD40L) (Renshaw et al., 1994, 
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Castigli et al., 1994, Xu et al., 1994); and, finally, by the use of blocking peptides or 
antibodies directed against the complex CD40/CD40L (Foy et al., 1994, Van den Eertwegh et 
al., 1993). Each of these approaches, as highlighted by several studies, points to the same 
conclusion, i.e. the absence of the CD40/CD40L interaction leads to a severe defect in the 
production of the immunoglobulins IgG, IgA and IgE (that is to say, thymus-dependent T cells 
response) in response to a pathogenic infection, without affecting the T cell- independent 
immune response (Ma and Clark, 2009) 
The CD40/CD40L complex occupies a critical role in humoral immunity through its 
involvement in the interactions between dendritic cells (or APC), T cells and B lymphocytes 
in the immune response cells (Figure 1.18). These cell interactions are characterised 
primarily by two important steps, namely activation of T cells via the APCs (dendritic cells in 
particular) and the activation and differentiation of B lymphocytes into plasma cells via their 
interaction with activated T cells and dendritic cells (Ma and Clark, 2009). Figure1.18 
illustrates the cellular interactions in humoral immunity and highlighting the importance of the 
CD40/CD40L complex in this process (Ma and Clark, 2009). 
 
 
Figure 1. 18 Role of CD40/CD40L interactions in humoral immunity 
The CD40/CD40L complex occupies a critical role in humoral immunity through its association in the 
interactions between dendritic cells (or APC), T-lymphocyte and B- lymphocytes in the immune 
response cells. Adapted from (Ma and Clark, 2009) 
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The exposure to a pathogenic agent (eg. bacterial infection) leads to activation of CD40 on 
the dendritic cells (Liang et al., 2009, Hellman and Eriksson, 2007). The dendritic cells were 
subsequently able to interact with CD40L-activated T cells, increasing the expression of co-
stimulatory molecules CD80/CD86 and B7-1/B7-2, and promoting the release of IL-12 and 
IL-10 by dendritic cells (Cella et al., 1996, Caux et al., 1994, Ma and Clark, 2009). The 
cellular responses are intimately involved in the differentiation of T cells into Th1 effector 
cells, regulatory T and Th17 (Th1 IL-12 and IL-10, and regulatory T Th17) (Iezzi et al., 2009, 
Bettelli et al., 2006, Veldhoen et al., 2006). Subsequently, the interaction of CD40L on T cell 
effector CD40 B cells induces the release of IL-2 and IL-4 by T effector cells (Natural killer 
cells) effectives. Meanwhile, the CD40/CD40L complex is also involved in the interaction of 
dendritic cells with B lymphocytes. This interaction facilitates the secretion of Stimulator 
Protein of B lymphocytes ("B lymphocyte Stimulator protein", BLyS or BAFF) and a 
proliferation-inducing ligand (APRIL) by dendritic cells which, in conjunction with IL- 2 and IL-
4 released by T lymphocytes, promotes differentiation of B lymphocytes into immunoglobulin-
producing plasma cells (DeKruyff et al., 1993, Craxton et al., 2003). 
It is important to note that it is difficult to put a precise chronological order to these 
events since, in reality; these interactions are bidirectional and may take place in concurrent 
ways. To conclude, the dendritic cells, T lymphocytes and B lymphocytes are able to interact 
simultaneously, indicating the need to consider these cellular responses as a whole and not 
as separate elements. In short, the CD40/CD40L axis is an integral element in the 
cooperation between the different elements in the humoral response and antibody 
production. 
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1.9.2 CD40/CD40L in cell mediated immunity 
As mentioned above, the CD40/CD40L axis was originally discovered on cells 
involved in immunity, such as T and B lymphocytes. The CD40 receptor is expressed 
constitutively on professional antigen-presenting cells such as B cells (B-lymphocyte) (Valle 
et al., 1989, Clark, 1990, Stamenkovic et al., 1989), and it also expressed early and 
throughout development (Uckun et al., 1990). Thus, it activates T cells (both CD4+ or CD8+) 
(Ware et al., 1991, Indzhiia et al., 1992), monocytes (van Kooten and Banchereau, 2000), 
macrophages/microglia (Gerritse et al., 1996), dendritic cells (van Kooten and Banchereau, 
2000), platelets (Inwald et al., 2003) and is expressed on epithelial cells (Ruggiero et al., 
1996), fibroblasts (See figure 1.19) (Yellin et al., 1995), endothelial cells and carcinomas 
(Schönbeck and Libby, 2001). 
The CD40 receptor is frequently expressed in the form of a doublet consisting of 
protein 43 to 47kDa (Clark and Ledbetter, 1986, Braesch-Andersen et al., 1989). Although 
the form in which the receptor is expressed may depend on the cell type (BERG et al., 1996), 
it is certain that its expression is constitutive in most cell types. CD40 is found in lipid rafts 
(Kaykas et al., 2001, Pham et al., 2002). In addition, cytokines such as IFN-Ȗ, IL-1, IL-3, IL-4, 
TNF-α and GM-CSF (granulocyte macrophage colony-stimulating factor) may increase its 
expression (reviewed in (Schönbeck and Libby, 2001), while transforming growth factor-ȕ 
(TGF-ȕ) inhibits the increase in the degradation of the mRNA of CD40 (Nguyen et al., 1998). 
As mentioned above, the CD40 receptor and CD40 ligand were originally discovered 
in the cells involved in immunity, such as B lymphocytes and T lymphocytes (Armitage et al., 
1992, Lederman et al., 1992). Indeed, this receptor and its ligand are present in most of cells 
of the immune system and they have an important role in inflammation in addition to a pivotal 
role in immune reactions. Table 1.1 summarises the expression of CD40 and CD40L in the 
various cells of the vascular cells (Yellin et al., 1995). 
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Figure 1. 19 Expression of CD40 and CD40 ligand on different cells types 
Different cells have abilty to express CD40 and its ligand. The interaction of CD40 with CD40L causes 
to express of different proteins and triggers the activation of different signalling patwys in different cells 
in the body (Gormand et al., 1999). 
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1.9.2.1 B Lymphocytes 
The role of CD40/CD40L complex in B cells is crucial to the humoral immune 
response. B cells constitutively express CD40 interacting with the CD40L on T cells activated 
in the presence of antigens in any infection. This interaction, in the presence of cytokine 
released by T cells (IL-4, IL-2 and IL-10), induces the proliferation and differentiation of B 
lymphocytes into plasma cells and antibody production, as shown in Figure 1.20 (Aruffo et 
al., 1993). CD40/CD40L interaction seems sufficient by itself to induce the production of IgG 
and IgA antibodies, while a co-stimulation in the presence of IL-4 is necessary particularly for 
the production of antibody IgE (Armitage et al., 1993, Spriggs et al., 1992). 
In the absence of the CD40/CD40L interaction, B cells produce only IgM, as observed 
in patients suffering from syndrome HIGM (Hyper IgM syndrome) (Hill and Chapel, 1993). 
Furthermore, in the activated B cell, the CD40/CD40L interaction induces the release of 
cytokines IL-6, IL-10 and TNF-α (Boussiotis et al., 1994), an increase in the intercellular 
adhesion molecule-1 (ICAM-1) associated with lymphocyte function- antigen-1 (LFA-1), 
vascular cell adhesion molecule-1 (VCAM-1) (Barrett et al., 1991, Rousset et al., 1991) and 
increased major histocompatibility protein complex-1 and-2 (MHC-I and MHC-II), (Khanna et 
al., 1997, Klaus et al., 1994), all of which facilitate the proliferation and differentiation of these 
cells into plasma cells. Interestingly, B lymphocyte‘ expression of CD40L also appears to be 
involved in a positive feedback loop, since CD40L expressed on one B cells can in turn 
interact with CD40 of another B cell, thereby facilitating activation and differentiation of B 
lymphocytes (Clodi et al., 1998, Grammer et al., 1995). CD40 activation would then be more 
involved in the differentiation of these cells into memory B cells (Gray et al., 1997, Pound and 
Gordon, 1997). 
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Figure 1. 20 Role of CD40/CD40L complex in the B lymphocytes and antibody production 
CD40/CD40L interaction appears necessary by itself to induce the production of IgA, IgE and 
IgG antibodies. B)  In the non-appearance of the CD40/CD40L interaction, B cells produce 
only IgM Adapted from (Lievens et al., 2009). 
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1.9.2.2 T Lymphocytes 
T cells require the presence of two main signals in order to induce their full activation. 
The first signal (Signal 1) comes from the interaction of the T cell receptor (TCR) with peptide 
MHC molecules on antigen-presenting cells (APC). The second (Signal 2) is called co-
stimulatory and is mainly via the CD28/B7 complex and CD40/CD40L – in fact the 
CD40/CD40L signal is sometimes referred to as Signal 3 (Lievens et al., 2009). This co-
stimulatory signal is essential to the proliferation, differentiation and survival of T cells (van 
Essen et al., 1995, Grewal et al., 1995). The first signal induces the expression of CD40L in 
the T cell membrane, and it subsequently interacts with CD40 on APCs cells, such as B 
cells, macrophages or dendritic cells. This bidirectional interaction enhances the activation of 
T cells and promotes their proliferation and differentiation into effector (mature) T cells (van 
Essen et al., 1995). Activated T lymphocyte also expresses CD40, but its exact involvement 
in the function of these cells remains poorly characterised. On the other hand, it appears that 
CD40 is involved in the interaction of T lymphocytes with CD4+ and CD8+ cells. The 
interaction of CD40 with CD40L on the CD8+ and CD4+ allows differentiation of CD8+ 
lymphocytes into memory cells, as with B lymphocytes (Bourgeois et al., 2002). 
1.9.2.3 Monocytes / Macrophages 
The role of CD40/CD40L complex in the function of monocytes is well documented. 
Monocytes constitutively express CD40 and, as APC, they are able to interact with the 
CD40L of T cells (Cella et al., 1996, Schönbeck and Libby, 2001). This interaction is 
bidirectional, so that the monocyte promotes activation of T cells which, in turn, induce the 
activation and differentiation of monocytes into macrophages. Binding of CD40L on the T 
lymphocytes to CD40 on monocytes and macrophages leads to the release of several 
cytokines (IL-12, IL-1ȕ, IL-6, IL-8 and TNF-α (Alderson et al., 1993, Wagner et al., 1994) and 
Metalloproteinase Matrix (MMPs), (MMP-1 MMP-2, MMP-3 and MMP-9) (Mach et al., 1997, 
Malik et al., 1996), an increase of co-stimulatory molecules ICAM-1, LFA-3, B7-1 and B7-2 
(Kiener et al., 1995) and secretion of tissue factor and nitric oxide (NO) (Mach et al., 1997). 
These biological effects are essential to the immunity-related, inflammatory and angiogenic 
function of these cells. Most biological effects of CD40L on monocytes are due to its 
interaction with CD40, although other receptors on the surface of these cells are able to 
induce various cellular responses, especially Mac-1. Indeed, it was recently demonstrated 
that the interaction of CD40L/Mac-1 promotes the adhesion and migration of monocytes to 
the endothelium, and the release of myelo-peroxidases during the inflammatory response 
(Zirlik et al., 2007). Activation of monocytes increases membrane expression of CD40, as 
well as CD40L. The precise function of CD40L in these cells is still unknown, but it may be 
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involved in monocyte/monocyte interactions via CD40. This interaction would amplify the 
activation and differentiation of monocytes, increasing their secretory function (Suttles and 
Stout, 2009). 
1.9.2.4 Dendritic cells 
The dendritic cell (DC) occupies a central place in the immune system. The CD40-
CD40L interaction on DC, mainly as a co-stimulatory factor, promotes the activation of T 
lymphocytes.  Activation of DC, such as that observed in the presence of pathogens, causes 
a significant increase in DC cell surface CD40. This receptor is able to interact with the 
CD40L on activated T cells, increasing the expression of co-stimulatory molecules 
CD80/CD86 and B7-1/B7-2, and it promotes the release of the IL-12 by DC (Cella et al., 
1996, Caux et al., 1994). These cellular responses are intimately involved in the 
differentiation of T lymphocytes for Th1 immune responses (Shepherd and Kerkvliet, 1999, 
Iezzi et al., 2009). In addition, CD40L is functionally expressed by in response DC-CD40 
ligation  (Pinchuk et al., 1996). DC CD40 ligation by T-cell-CD40L, primes DC cells to 
become effective antigen presenting cells (APC) via upregulation of MHC class II molecules 
and CD80/CD86 (Ma and Clark, 2009) and CD40-CD40L co-simulation is essential for the 
activation of DC in response to pathogen associated molecular patterns (PAMPs) (Sacks and 
Noben-Trauth, 2002). Additionally, CD40L is functionally expressed by DC in response CD40 
ligation (Pinchuk et al., 1996). In such manner, DC have been shown in vitro to utilise 
membrane CD40L (mCD40L) in order to mediate their cytotoxic effect effects towards 
urothelial cell carcinomas (UCC) and colorectal carcinomas (CRC), therefore, CD40 is not 
only essential for DC activation, but for their ability to induce CD40-mediated cell cytotoxicity 
(Hill et al., 2008b). DC also express CD40L, but in small quantities compared to CD40. 
Although the exact function of CD40L dendritic cells remains to be fully verified, it appears to 
be involved in bidirectional interaction between dendritic cells and B lymphocytes (Bergtold et 
al., 2005, Wykes and MacPherson, 2000). 
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1.9.2.5 Neutrophils 
Neutrophils are among the first vascular cells recruited to inflammatory sites and are actively 
involved in the immune mechanisms of the body. Vanichakarn et al. have demonstrated that 
activated neutrophils express CD40 and this appears to play an important role in 
platelet/neutrophil interactions (Vanichakarn et al., 2008). In addition, platelets are able to 
activate neutrophils through the release of soluble CD40L that follows their stimulation. 
sCD40L induces secretion of ROS in neutrophils, which in turn promotes the activation of 
platelets reciprocally. Furthermore, the results of the study by Li et al indicated that the 
interaction of platelets with neutrophils increases expression of Mac-1 and high levels of 
sCD40L, and that neutrophils promote platelet aggregate formation and neointimal formation 
following vascular injury (Li et al., 2008). 
1.9.2.4 Platelets 
Platelets play a fundamental role in haemostasis but also actively participate in 
inflammatory reactions by inflammatory cytokines, growth factors and MMPs. The resting 
platelets constitutively express CD40, whereas CD40L is present in the membrane upon cell 
activation (Henn et al., 1998). The study by Henn et al. first demonstrated the importance of 
the CD40/CD40L complex function in platelets (Henn et al., 1998). They showed that CD40L 
on activated platelets is able to interact with the CD40 on endothelial cells and monocytes to 
induce a significant inflammatory reaction. In particular, this interaction increases the 
expression of some proteins such as Intercellular Adhesion Molecule-1 ICAM-1 (CD54), 
Vascular Cell Adhesion Molecule-1 VCAM-1 (CD106), and E-selectin protein (CD62E); it also 
promotes the release of the Monocyte chemo-attractant protein-1 (MCP-1/CCL2), IL-6, IL-8, 
and induces the production of MMP-9. Moreover, it was also demonstrated that platelet 
sCD40L is involved in stabilising the thrombus through its interaction with integrin αIIbȕγ 
(Andre et al., 2002b). Little information exists about the role of platelet CD40, but it seems 
that the stimulation of platelets by sCD40L induces the release of Regulated on Activation, 
Normal T Cell Expressed and Secreted (RANTES) and the production of reactive oxygen 
species (ROS) (Chakrabarti et al., 2005, Danese et al., 2004). 
1.9.2.6 Endothelial cells  
CD40/CD40L occupies a prominent position in the activation of endothelial cells and 
smooth muscle cells. Endothelial cells express CD40 and CD40L. Activation of CD40 on 
endothelial cells contributes significantly to their inflammatory role (Karmann et al., 1995). In 
particular, this binding induces expression of adhesion molecules ICAM-1, VCAM-1 and E-
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selectin, and it causes the release of cytokines such as IL-1, IL-6, IL-8, MCP-1, the 
macrophages inflammatory protein-1α (MIP-1α) and RANTES (Rizvi et al., 2008, Bavendiek 
et al., 2002). Endothelial cells are actively involved in the mechanisms of angiogenesis, and 
the CD40/CD40L axis seems to occupy a more important place in this phenomenon 
(Karmann et al., 1995). 
First, the activation of endothelial cells by CD40L promotes the synthesis and 
secretion of MMP-1, MMP-2 and MMP-9 which are involved in the digestion of the 
extracellular matrix, a key step in angiogenesis (Mach et al., 1999). In addition, CD40 
activation triggers the secretion of vascular endothelial growth factor (VEGF) by endothelial 
cells, which is essential to the initiation and progression of angiogenesis mechanisms (Melter 
et al., 2000). Additionally, the binding of CD40 on endothelial cells promotes the expression 
of cyclooxygenase-2 (COX-2), which has a pro-angiogenic activity via the induction of the 
basic fibroblast growth factor (bFGF) (Schonbeck et al., 1999). The CD40/CD40L complex is 
involved in the pro-coagulant function of endothelial cells. Consequently, it was 
demonstrated that ligation of CD40 via CD40L induces the synthesis and release of tissue 
factor from endothelial cells, (Bavendiek et al., 2002), which triggers the activation of the 
coagulation cascade and platelet activation (Schonbeck et al., 1999). 
1.9.2.7 Smooth muscle cells 
The role of the CD40/CD40L dyad in smooth muscle cells is less well documented, 
but it appears that CD40L is able to trigger the activation of signalling pathways involved in 
the mitogenic activity of these cells. It also particularly activates the Src tyrosine kinase 
pathway, which leads to the secretion of cytokines such as MCP-1 and IL-8 (Hermann et al., 
2002, Mukundan et al., 2004). In addition, the activation of the CD40 receptor of this cell 
leads to the degradation of collagen through the interstitial matrix and also via MMPs, which 
have the ability to promote proliferation and migration of these cells (Horton et al., 2001, 
Newby, 2007). 
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1.9.2.8 Epithelial cells 
Young and colleagues first discovered CD40 expression on epithelial cells of human 
nasopharynx, tonsil and ectocervical tissue by using immunohistochemical analysis, as well 
as cultured epithelial cells and several epithelial cell lines (Young et al., 1989), while CD40 
ligand (CD154) expression has been observed on epithelial cells of the glomerulus as well as 
the proximal tubule. Yellin and colleagues reported initially that CD40 also expressed in 
normal kidney, and expressed on parietal epithelial cells (Yellin et al., 1995). Cruickshank 
and co-workers reported that intestinal epithelial cells, which encounter enteric antigens, 
express CD40 together with other co-stimulatory molecules; however, these cells were 
unable to promote mitogen- or antigen-driven activation of CD4+ T cells (Yellin et al., 1995). 
The presence of CD40 on diseased cells and its absence on unaffected epithelium as 
well as its inducibility by pro-inflammatory cytokines, e.g., IFN-α, indicated a role for epithelial 
CD40 in the development of carcinomas/epithelial neoplastic at sites of chronic inflammation 
(Stamenkovic et al., 1989), a hypothesis also supported by the later finding that a large 
majority of nasopharyngeal carcinoma cells expressed CD40 (Zong et al., 1991). More 
studies of CD40 distribution in the human thymus revealed that cortical and medullary thymic 
epithelial cells express this receptor in situ and, inducible through pro-inflammatory cytokines 
such as IL-1, TNF-α, or IFN-y, also in vitro (Galy and Spits, 1992, Patel et al., 1995). Further 
studies established that CD40 expressed on these thymic epithelial cells offers co-stimulation 
for clonal expansion of CD4+ thymocytes (Briscoe et al., 1998). In addition to neoplastic and 
thymic epithelial cells, normal human bronchial epithelial cells constitutively express CD40 in 
situ (Gormand et al., 1999). 
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Table 1. 1 Expression of CD40/CD40L axis in the cells of the immune vascular system 
Cell Type 
CD40 CD40L 
Form of CD40L 
Active   Inactive Active Inactive 
B lymphocytes +++ +++ ++ +++ Membrane 
T lymphocytes - +++ - +++ Membrane, soluble 
Monocytes / Macrophages + +++ + +++ Membrane 
Platelets ++ +++ - +++ Membrane, soluble 
Endothelial cells + +++ + + Membrane 
Smooth Muscle Cells +++ ND + ND Membrane 
Dendritic cells - +++ + + Membrane 
Neutrophils + +++ + + Membrane 
- Non expressed; +, weakly expressed; ++, moderately expressed, +++, strongly expressed, ND, 
undocumented.  
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1.10 Intracellular signalling pathways induced by CD40 
Since CD40 lacks intrinsic signalling activity, adapter molecules and TNF receptor 
associated factors (so-called TRAFs) are required for signal transduction by a CD40-CD154 
interaction (Schönbeck and Libby, 2001). The TRAF- family consists of six members, five of 
which (TRAF 1, 2, 3, 5, 6) depend on cell type and function to bind CD40 (Zapata, 2003). In 
endothelial cells, the association of TRAF2 and CD40 causes activation of pro-inflammatory 
signalling pathways (Mukundan et al., 2004). 
 
The specificity of the CD40 signal transduction is influenced not simply by the 
interaction with the different TRAFs. Rather, in this case, the localisation of the receptor 
plays an important role. CD40 is located in and on special membrane micro domains called 
―lipid rafts―. After CD40 CD154 interaction, the majority of CD40 in the lipid rafts are 
translocated, where the receptor is then associated with the various TRAFs (Arron et al., 
2002). The lipid raft-dependent association of TRAF2 with CD40 leads to the formation of 
pro-inflammatory cytokines (such as MCP-1) that the arteriosclerosis (Arron et al., 2002, 
Chen et al., 2006). 
The various cellular responses mediated by CD40/CD40L interaction are related to 
the activation of specific intracellular signalling pathways. CD40 is the main receptor 
promoting signalling, and there is still relatively little information about the precise signalling 
pathways triggered following activation by CD40L especially in epithelial cells (Georgopoulos 
et al., 2006). The binding of CD40 with CD40L causes the recruitment of adapter proteins, 
called TRAFs, in the cytoplasmic tail of the CD40 molecule (Bishop et al., 2007). Cellular 
relocation of TRAFs and their interaction with CD40 triggers the activation of several 
signalling pathways, which include the main pathway of NF-KB, the MAPK pathway (p38, 
JNK and Akt), the PI3 kinase pathway, and others (Davies et al., 2005, Elgueta et al., 2009). 
Any intracellular signalling induced by CD40 depends almost exclusively on TRAFs, but can 
be independent of TRAFs signalling pathways, such as the pathway of STAT5 resulting from 
the direct association of Janus kinase 3 (JAK3) with CD40 (Säemann et al., 2003, Säemann 
et al., 2002). Figure 1.21 summarises the main signalling pathways that result from the 
activation of CD40 as well as the function of the different members of the family of TRAFs in 
the activation of different signalling pathways triggered (Elgueta et al., 2009). 
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Figure 1. 21 The different signalling pathways induced by CD40  
Each member of the family of TRAFs has a separate function, but they sometimes overlap. The 
majority of signalling pathways of interaction between CD40 and CD40L depends on the activation of 
TRAFs, but there are also TRAF independent channels, such as the STAT5 pathway (Elgueta et al., 
2009). 
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1.10.1 Structure of TRAFs 
The TRAFs family consists of six members, named TRAF1 to TRAF6. The TRAFs 
consist of a C-terminal carboxyl named TRAF-C, a rich domain leucine zipper, TRAF-N, and 
two areas rich in zinc motifs, named zinc fingers and zinc ring, with the exception of TRAF-1 
which is devoid of both zinc areas (Figure 1.22) (Arch et al., 1998). The TRAF-C domain is 
involved in binding to TRAFs of CD40, whereas the N-TRAF domain is responsible for the 
homo- and hetero-dimerisation interactions of TRAFs (for example TRAF2/TRAF3 
interaction). The zinc-rich domains are involved in the recruitment and identifying additional 
proteins, such as kinases and transcriptional factors (Arch et al., 1998). 
Following the binding of CD40L to CD40, the TRAFs are, directly or indirectly via 
other TRAF members, recruited to the cytoplasmic tail of the CD40 molecule. The protein 
sequence involved in the interaction of TRAFs with CD40 differs from one member to 
another; thus, there is no consensus on the sequence responsible for this interaction, 
although some sequences have been found to overlap between some members, such as 
TRAF2 and TRAF3 (McWhirter et al., 1999, Ni et al., 2000). 
 
  
 
Figure 1. 22 Structures of TRAFs    
The schematic represents the structural organisation of the TRAFs. Currently six different TRAFs are 
known. All TRAFs are characterized by a C-terminally-located TRAF domain. TRAF proteins have a 
highly conserved C-terminus, through which they bind to the receptors and can interact with other 
TRAFs. The TRAFs family consists of six members: A) TRAF1, which is devoid of both zinc areas   
(Zinc fingers and Zinc ring) B) TRAF2 to TRAF6 which contain those domains. 
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1.10.2 TRAF1 
Following the activation of CD40, TRAF1 protein expression is significantly increased 
(Zapata et al., 2000, Schwenzer et al., 1999). Since TRAF1 has no motif of a zinc-rich 
domain, it seems to be involved in regulating the signalling of other members of TRAFs 
(Bishop et al., 2007). The binding site of TRAF1 on CD40 overlaps with that of TRAF2 and 
TRAF3, and it appears that TRAF1 is only able to interact weakly with CD40, in the absence 
of the involvement of TRAF2 (Pullen et al., 1998). At the level of B lymphocytes and APCs, 
TRAF1 deficiency causes a decrease in the recruitment of TRAF2 to the CD40 and an 
increase in the enzymatic degradation of the receptor (Xie et al., 2006, Arron et al., 2002). In 
addition, it appears that the recruitment of TRAF1 and TRAF2 is required for complete 
activation of the NF-kB pathway, since the dual genetic deletion of both members generates 
a stronger attenuation of the activation of NF-kB, compared to the individual gene deletion of 
one or any of these members (Xie et al., 2006). 
1.10.3 TRAF2 
TRAF2 is one of the most studied members and its main role is the activation of p38 
(MAPK), Akt, JNK and ERK1/2. Hostager et al. (2003) and Yeh et al. (1997) demonstrated 
that, in fibroblasts and B cells of the embryo in TRAF2-deficient mice, the activation of these 
signalling pathways was significantly inhibited after the binding of CD40L to CD40 (Hostager 
et al., 2003, Yeh et al., 1997). In addition, the recruitment of TRAF2 induces recruitment of 
protein kinase mitogen-activated kinase-1 (MEKK1) to the cytoplasmic tail of CD40 after 
CD40 ligation, which is an essential step in the activation of ERK1/2 proteins and activation 
of kinases JNK and p38 (Gallagher et al., 2007). At the level of B lymphocytes, TRAF2 also 
seems to participate in the activation of NF-kB, in collaboration with TRAF6. On the other 
hand, the interaction of one or the other with CD40 seems sufficient to induce activation of 
NF-kB. This was confirmed by results showing that the deficiency of TRAF2 or TRAF6 does 
not cause abnormality in the activation of NF-kB, but the double deletion of these two 
members induced severe inhibition of this pathway at the level of B lymphocytes. TRAF2 
also seems to participate in the activation of NF-kB, in collaboration with TRAF6. However, 
the interaction of one or the other with the CD40 seems sufficient to induce the activation of 
NF-kB This was confirmed by studies showing that the deficiency of TRAF2 or TRAF6 does 
not cause abnormality in activation of NF-kB, but the double deletion of these two members 
causes severe inhibition of this pathway (Hsing et al., 1997, Rothe et al., 1995, Yeh et al., 
1997). 
Despite its important role in the activation of signalling pathways induced by CD40, 
TRAF2 also appears to have a negative regulatory function (Gardam et al., 2008). Its 
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involvement as a negative regulator of signalling via CD40 comes from its constitutive 
interaction with TRAF3 (Figure 1.23). The interaction of TRAF2/TRAF3 allows proteins cIAP1 
and cIAP2 to degrade NIK protein, which inhibits activation of the NF-kB and promotes 
apoptosis (Vallabhapurapu et al., 2008, Zarnegar et al., 2008). Moreover, the removal of an 
accumulation of TRAF2 generates NIK in B cells (Vince et al., 2007). Following stimulation 
with CD40L, this protein complex is destabilized and TRAF2/TRAF3 is recruited to the CD40, 
which allows TRAF2 to activate NF-kB.  Degradation of TRAF2 (Self degradation) and 
TRAF3 (via cIAP1 / 2), has a role in the releasing and allow NIK to activate NF-kB. In short, 
cIAP1/2 occupy a dual function, that of degradation of NIK in the basal condition and the 
degradation of TRAF3 upon binding of CD40L. Meanwhile, TRAF2 also performs a dual 
function, i.e. that of its inhibitory role of NF-kB activation via its interaction with TRAF3, and 
its activator role of the NF-kB following its interaction with CD40 and its subsequent 
degradation (Bishop et al., 2007, Brown et al., 2002, Zarnegar et al., 2008). 
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Figure 1. 23 Illustration of the dual function of TRAF2 in the regulation of NF-kB  
TRAF2  functions A) Inhibitory role of NF-kB activation via its interaction with TRAF3, B) Activator role 
of the NF-kB following its interaction with CD40 and its subsequent degradation (Adapted from 
(Elgueta et al., 2009). 
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1.10.4 TRAF3  
TRAF3 was first known as an adaptor molecule that interacts with the cytoplasmic tail 
of CD40 and the EBV oncoprotein LMP-1 (latent membrane protein-1) (Cheng et al., 1995, 
Mosialos et al., 1995). Nevertheless, Inoue et al. reported that TRAF3 associates with other 
TNF-Receptor superfamily proteins such as CD27, CD30, 4-1BB, OX40, LT-ȕR, ATAR, 
AITR, and RANK (Inoue et al., 2000); it has also been demonstrated that TRAF3 plays 
different roles for various receptor functions in in vitro culture systems (Hostager and Bishop, 
1999). 
 
TRAF3 blocks the activation of NF-κB induced by CD40 and TNFRβ overexpression 
(Rothe et al., 1995). TRAF3 negatively regulates CD40-stimulated antibody secretion, 
however, whether the inhibition of NF-κB mediates this response is not clear (Hostager and 
Bishop, 1999). This implication is supported by experiments showing that removal of the 
protein in B cells increases the activation of NF-kB and JNK following stimulation by CD40L 
(He et al., 2007, Xie et al., 2004).  In addition, mice deficient in TRAF3 demonstrate an 
intracellular accumulation of the protein NIK (Xie et al., 2004, Vallabhapurapu et al., 2008, 
Zarnegar et al., 2008). However, it was demonstrated that overexpression of TRAF3 in 
epithelial cells promotes activation of the NF-kB pathway, contrary to B cells (Propst et al., 
2002), while Urbich et al. suggest that TRAF3 has dichotomous  functions depending on the 
cell type (Urbich et al., 2001). 
1.10.5 TRAF4 
TRAF4 was initially known as a protein localised in the nuclei of breast cancer cells, 
and it has also been detected in the cytoplasm of the cells (Régnier et al., 1995, Glauner et 
al., 2002). TRAF4 is barely expressed by vascular cells. It is more important in neuronal cell 
physiology and during embryogenesis (Masson et al., 1998, Regnier et al., 1997). Moreover, 
TRAF4 seems unable to interact with CD40 (Krajewska et al., 1998). Paradoxically, TRAF4 
has been implicated in promoting apoptotic pathways mediated by p53, yet has been 
observed to inhibit Fas-mediated cell death (Sax and El-Deiry, 2003, Fleckenstein et al., 
2003). Expression of TRAF4 in T cells is dependent on stimulators of the NF-kB pathway 
(Glauner et al., 2002). 
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1.10.6 TRAF5 
Very little information exists regarding the role of TRAF5 in CD40-mediated signalling. 
TRAF5 is unable to interact directly with CD40, but it appears to form a heterodimer with 
TRAF3 to facilitate activation of the NF-kB (Bishop et al., 2007). This was demonstrated in B 
cells where TRAF5 deficiency by the use of small interfering RNA (siRNA) significantly 
reduces the activation of the NF-kB, resulting in the reduction of expression of co-stimulatory 
molecules and antibody production by these cells (Hauer et al., 2005, Nakano et al., 1999). 
1.10.7 TRAF6  
TRAF6 plays an important role in the signalling pathways triggered by CD40 and also 
has a specific binding site for this function (Bishop et al., 2007) and can have several (often 
opposing) functions. Recently, TRAF6 has been shown to induce apoptosis via interaction 
with caspases and its activation by a RING domain-dependent mechanism (He et al., 2006). 
Interestingly, however, Benson and colleagues have shown that CD40 can defend B cells 
from CD95-mediated apoptosis by inhibition of caspase activation via TRAF6 and the 
PI3K/Akt pathway (Benson et al., 2006). 
In human epithelial cells treated with small specific interfering RNA for TRAF6, 
activation of NF-kB pathways, p38, JNK and Akt is significantly reduced or even completely 
inhibited following stimulation with CD40L, demonstrating the fundamental importance of this 
TRAF member (Davies et al., 2005). TRAF6 interacts directly with TRAF2 to regulate the 
activation of NF-kB. This close collaboration between TRAF2 and TRAF6 does not seem to 
depend on the interaction with the CD40 receptor since, even in the presence of the deletion 
of the binding domain of TRAF6 to CD40, TRAF6 is still able to interact indirectly with CD40 
through its direct interaction with TRAF2 and activate several important signalling pathways 
(Rowland et al., 2007). Under these conditions (where the binding domain is removed from 
CD40), activation of CD40 leads to expression of CD80 receptor and activation of the JNK 
pathway, in contrast to the total deficiency of TRAF6 protein in B cells (Rowland et al., 2007). 
This suggests that an important function of TRAF6 is connected to its indirect interaction with 
CD40, via its binding to TRAF2. One of the other important functions of TRAF6 lies in the 
PI3K pathway activation and subsequent activation of Akt, which protects against apoptosis 
(Arron et al., 2001, Davies et al., 2004). 
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1.11. The mitogen activated protein kinases (MAPKs) 
MAPKs are serine threonine kinase activated by phosphorylation at threonine and 
tyrosine residues. These proteins are part of phosphorylation cascades that have been 
described in many species including mammals (L'Allemain, 1994). Many stimuli activate the 
MAPK cascades including hormones, growth factors and stressors. MAPK cascades are 
involved in signaling pathways leading to mitosis, proliferation, differentiation, cell growth, 
gene expression and cell death in response to extracellular signals (Johnson and Lapadat, 
2002a, Zhang and Liu, 2002). 
1.11.1 General structure 
The MAPK family comprises 5 groups of kinases. Three groups have been widely 
studied, which include: Extracellular signal regulated kinases 1 and 2 (ERK), c- Jun N-
terminal kinases (JNK) 1, 2 and 3 (or stress-activated protein kinase, SAPK)) and the 
pγ8MAPK α, ȕ, ƴ and δ. Two other groups are less well known and their roles in cell 
signaling remains unclear; these are Extracellular signal regulated kinases the 3 and 4 and 
Extracellular signal regulated kinase 5 (Coulombe and Meloche, 2007). Downstream, the 
phosphorylated MAPK activate transcription factors such as c-myc, c-Jun or ATF2 but can 
also activate other kinases upstream and downstream of the MAPK cascade, thus refining 
the regulation of signaling pathways (Whitmarsh, 2007). 
Upstream signaling pathways activating the MAPK are numerous. To a large extent, 
they are activated by small G proteins of the Ras superfamily that activate MAPK kinase 
kinases such as Raf proteins (Chong et al., 2003). The MAPKKKs phosphorylate serine and 
threonine residues at the patterns Ser-xxx-Ser/Thr MAPK kinases such as MEK. Finally, 
MAPKK MAPKs phosphorylate at xxx -Tyr-Thr residues which in turn phosphorylate Pro-xxx-
Ser/Thr pattern transcription factors or other proteins of the signaling pathways (Biondi and 
Nebreda, 2003). 
1.11.2 ERK 1/2 
Extracellular signal regulated kinase (ERK) 1 and 2, which are 42 and 44kDa in size, 
respectively, were the first MAPK characterised and are the most studied. They are activated 
by growth factors, hormones, osmotic shock, cytokines, GPCR (G-protein coupled receptors 
heterotrimeric) and phorbol esters. They play a major role in cell proliferation and 
differentiation (Kang and Sucov, 2005, Kim et al., 2007). Activation of the ERK pathway 
leads to induction of genes leading to cellular hypertrophy, increased protein synthesis and 
the formation of sarcomeres (Aokl et al., 2000, Kim et al., 2007). 
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1.11.3 JNK 1/2 (SAPK) 
Three isoforms of c-Jun N-teminal kinase (JNK) or stress-activated MAP kinase 
(SAPK) have been characterised and are activated in response to many stimuli such as 
physical stress (heat, UV, osmotic shock), chemical factors (pH, ROS), metabolic factors 
(ischemia), biological factors (bacterial proteins, cytokines). The JNK cascade follows the 
traditional pattern of MAPK activation with MAPKKK (MEKK1-4) that activate MAPKK 
(MKK4, MKK7) activating the MAPK (Figure 1.24). As with ERK, JNK activation leading to 
gene expression by phosphorylation of transcription factors including c-Jun, ATF-2, Elk-1, 
MEF-2. JNK pathways predominate in cellular responses initiated by adrenergic G-protein 
coupled receptors and tyrosine kinase receptors such as the receptors for growth factors. 
The JNKs are involved in the activation of apoptosis, but apart from their pro-apoptotic role, 
they can also also have anti-apoptotic functions depending on the cell type and the nature of 
the stimulation. Their roles in cell physiology are numerous and depend on the area studied. 
They are involved in the development of the nervous system as in the regulation of insulin 
and obesity but also in hypertrophy and heart failure  (Brancho et al., 2003, Derijard et al., 
1995). 
1.11.4 The p38/MAPK 
Four isoforms of the p38 serine threonine kinases are activated by the MAPK 
signalling pathways, namely p38α/Mpkβ/CSBP, pγ8ȕ, pγ8δ/SAPK4 and pγ8Ȗ/SAPKγ. 
Stimulation of p38 shows similarities to JNK. At first, these two MAPKs were grouped under 
the term SAPK. Stimuli such as osmotic shock, or UV irradiation, oxidative stress  and 
anticancer agents can activate the cascade of p38 phosphorylation. Different stimuli can 
activate MAPKKK (ASK, TAK, PTKs), which activate MAPKK (MEK3, MEK6 MAPKK) but 
also other cascades (such as MEK4, MEKK1, 2 and 5, ASK), allowing them to phosphorylate 
p38. As with other MAPKs,. p38 kinases are activated by phosphorylation of threonine and 
tyrosine residues of their activation loop TGY by MAPKK kinases MKK3, 4 and 6 (Brancho et 
al., 2003, Derijard et al., 1995). The MAPKKs involved in the p38 pathway are TAK1 
ASK1/MAPKKK5, MUK/DLK/ZPK, MEKK4 and MLK3 (Zarubin and Jiahuai, 2005). The p38 
pathway plays an important role in the induction of genes involved in the inflammatory 
response (Kontoyiannis et al., 2001) and in the neuronal differentiation of myoblasts (Puri et 
al., 2000). The p38 pathway is also involved in apoptosis induced by Fas (Juo et al., 1997), 
by the loss of cell anchorage (Cardone et al., 1997) and may play a synergistic role with the 
JNK pathway in the induction of apoptosis (Xia et al., 1995). 
The pathway of MAPK1/3 is composed of a multi-module complex where the protein 
kinases Raf, MEK and MAPK1/3 are activated in a cascade by sequential phosphorylation. 
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The stimulation of Ras coupled membrane receptors, such as growth factor receptors, 
activates the MAPK1/3 pathway, by a complex mechanism involving both phosphorylation 
and dephosphorylation. MAPK1/3 kinases transmit the signal generated by the receptor by 
phosphorylating a variety of substrates in different subcellular compartments, which leads to 
the execution of various biological functions such as cell proliferation, cell differentiation and 
cell migration (Katz et al., 2007). 
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Figure 1. 24 The stress kinase pathway JNK/p38 MAPK  
Signalling pathways triggered by the JNK and p38 kinases which belong to the family of SAPK (for 
stress-activated protein kinase). JNK and p38 pathways are activated by various extracellular stress 
and inflammatory cytokines. JNK/p38MAPK kinase pathways are composed of a multi-module 
complex having various protein kinases activated by phosphorylation in a hierarchical order: MKKK 
activate MKK MAPK which ultimately activate JNK and/or p38  (Brancho et al., 2003). 
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1.13 Induction of apoptosis by the CD40 
A plethora of studies have demonstrated the importance of the CD40/CD40L system 
in apoptosis induction. However, the effect of CD40 ligation appears to be cell type and 
context-specific, as it induces either a pro-apoptotic or an anti-apoptotic effect (cell survival), 
depending on the cell type and/or its state. In general, activation of CD40 in B cells and T 
cells induces an anti-apoptotic signal and cell survival (Banchereau et al., 1991, Lomo et al., 
1997). Meanwhile, activation of several tumour cell lines, including B lymphoblastic, causes 
cellular apoptosis (Henriquez et al., 1999, Baker et al., 1998). 
As discussed above, the binding of CD40 in B cells generates the proliferation, 
differentiation and survival of these cells. Indeed, the blocking of CD40/CD40L interaction, by 
genetic or pharmacological approaches, prevents differentiation of B lymphocytes into 
plasma cells and causes cell death (apoptosis) (Clark and Ledbetter, 1986, Klaus et al., 
1997). The anti-apoptotic effects observed following activation of CD40 in B cells are 
primarily via an increase in anti-apoptotic proteins Bcl-xL, A20, Bfl-1, Mcl-1, and cFLIP 
(Figure 1.25). These factors protect against cell apoptosis in response to certain extrinsic 
apoptotic agents such as IgMs, FasL (Fas ligand) and TNF, and intrinsic agents, such as 
mitochondrial damage (Zhang et al., 1996). 
Unlike normal B cells, activation of CD40 on B lymphoblastoid and some tumour cells 
cause significant anti-proliferative and apoptotic effects. In response to CD40L, Bax, Bak and 
Bik apoptotic proteins are found to increase, thereby promoting the activation of caspase-3 
(Figure 1.25) (Szocinski et al., 2002, Tong et al., 2001). Furthermore, the activation of CD40 
on tumour cells also promotes the binding of FasL and TNF to their respective receptors, 
resulting in the increase of caspase 8 and cell apoptosis (Garrone et al., 1995, Wingett et al., 
1998). 
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Figure 1. 25 Mechanisms involved in apoptotic and anti-apoptotic effects mediated by the 
activation of CD40.  
Binding of CD40 in B cells prevents apoptosis through the extrinsic and intrinsic pathways. The 
intrinsic pathway comprises an increase in Bcl-xL anti- apoptotic factors, Mcl-1 and Bfl-1, which 
inhibits the activation of cytochrome c/Apaf-1/caspase-9 complex and the activation of caspase-3. 
Activation of CD40 also increases the apoptosis inhibitor protein survivin and also inhibits caspase-3. 
The extrinsic pathway of activation is from protein FLIP and their inhibitory effects on the activation of 
the TNF receptors and FasL, respectively. Unlike B cells, activation of CD40 on tumour cells causes 
the activation of the apoptotic proteins Bax, Bak and Bik, and promotes the binding of FasL and TNF 
to their receptors, while promoting cell death. Adapted from (Dallman et al., 2003). 
CD40L 
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1.13.1 Role of CD40/CD40 in apoptosis of the tumour 
As discussed in Section 1.5.3 of this chapter, the activation of CD40 on several 
tumour cell lines induces pro-apoptotic signals, causing cell death. For example, stimulation 
of B lymphoma cells, multiple myeloma cells and Burkitt's lymphoma cells with CD40L 
significantly reduces cell survival and proliferation, both in vitro and in vivo (in mice) 
(Henriquez et al., 1999, Baker et al., 1998). These anti-proliferative effects were also 
demonstrated in solid tumours, such as carcinomas of the bladder, ovary and skin. 
Georgopoulos  and colleagues demonstrated that membrane CD40 ligand (mCD40L) can 
induce apoptosis via a direct mechanism, while soluble CD40L did not induce apoptosis 
(Georgopoulos et al., 2006). Moreover, Georgopoulos and colleagues demonstrated that 
activation of the CD40 receptor on colorectal cancer cells in vitro via mCD40L causes high 
levels of death (Georgopoulos et al., 2007). Indeed, the treatment of carcinomas by a 
recombinant form of CD40L inhibits malignant cell proliferation and significantly increases the 
lifespan in mice (Tong et al., 2001, Eliopoulos et al., 1996, Ghamande et al., 2001, von 
Leoprechting et al., 1999) according to these observations we endeavour to understand the 
mechanism of CD40 ligation in colorectal cancer in order to develop effective cancer therapy.   
1.13.2 Cancer 
At first glance, the CD40/CD40L complex appears to facilitate the development and 
progression of cancer, as noted by the high levels of expression of these proteins on the 
surface of many tumour cells (Tong et al., 2001, Baxendale et al., 2005, Van den Oord et al., 
1996). For example, it was demonstrated that tumour cell non-Hodgkin's lymphoma, chronic 
lymphocytic leukaemia and burkitt lymphoma exploit the CD40/CD40L system as a tool of 
survival and cell growth, primarily through signage of NF-kB (Challa et al., 2002). In addition, 
there is a positive correlation between the expression of CD40L levels on certain tumour 
cells and the degree of aggressiveness and evolution of these cells (Van den Oord et al., 
1996). However, after a review of the function of this complex in the pathophysiology of 
cancer, one arrives at the conclusion that the CD40/CD40L axis occupies a negative role in 
the pathogenesis of cancer. Admittedly, the most definitive finding supporting this 
observation comes from the symptoms observed in patients with XHIM syndrome (a genetic 
mutation causing a severe abnormality of the interaction of CD40L with CD40), in which 
there is a high frequency of several lymphomas and carcinomas (Hayward et al., 1997). 
Indeed, many tumour cells seek to deregulate the CD40/CD40L system in order to maintain 
their growth and survival, such as CD4+ T lymphocytes of patients with chronic lymphocytic 
leukaemia trying to suppress their expression membrane CD40L, or by enzymatic cleavage 
or by a defect in membrane mobilisation following the activation (Cantwell et al., 1997). 
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These compensatory mechanisms serve to avoid the anti-tumour effects of cytotoxic T 
lymphocytes and natural killer cells (NK) in the immune response. In addition, Hock et al. 
reported that patients with acute myelogenous (or myeloid) leukaemia (AML) and multiple 
myeloma have high levels of soluble receptor CD40 (sCD40) in their circulation, thus 
reducing the cellular response to CD40L and correlating with a poor prognosis in these 
patients (Cantwell et al., 1997).  
The mechanisms by which the CD40/CD40L axis contributes negatively to tumour 
progression appear to be well characterised, and they include indirect and direct effects on 
the tumour cell. First, the CD40/CD40L complex is intimately linked to the production of 
cytotoxic T lymphocytes and NK cells that act directly on tumour cells to induce their cell 
death (indirect effects) (Loskog and Eliopoulos, 2009). Moreover, the binding of CD40 on 
tumour cells triggers a pro-apoptotic signal, which promotes cell death and leads to 
increased adhesion molecules and membrane proteins, such as the transporter antigen 
peptide-1 (TAP-1) (Cromme et al., 1994). This connection thus facilitates the recognition and 
interaction of anti-tumour immune cells (direct effects) (Loskog and Eliopoulos, 2009). 
79 
 
1.13 Colorectal Cancer   
1.13.1 General  
The colon is the name given to the last part of the intestine, which has a length of 
about 1.80 meters (6 feet) and is located between the small intestine and the rectum. The 
colon, also called the large intestine, ends in the rectum (Figure 1.26). Colon cancer and 
rectal cancer, commonly called colorectal cancer, is the third form of cancer most common 
cancers worldwide (Pisani et al., 1999, Fodde, 2002, Midgley and Kerr, 1999). In 2012, the 
World health Organisation (WHO) reported that ―Colorectal cancer is the third most common 
cancer in men (746,000 cases, 10.0% of the total) and the second in women (614,000 cases, 
9.2% of the total) worldwide. Almost 55% of the cases occur in more developed regions 
http://www.cssanz.org/index.php/news. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 26 shows structure of the large intestine.  
http://www.nlm.nih.gov/medlineplus/ency/imagepages/19220.htm 
1.13.2 Causes 
The causes of cancer are still not well established. In some cases, genes that 
determine the activity of a cell mutate and begin to give instructions that cause the 
uncontrolled growth of tissue. The main risk factor, which is the most obvious warning signal, 
is the presence of colorectal polyps. These benign growths that are occur within the colon. 
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Polyps in the shape of a small ball placed on a rod which forms a protrusion in the inner wall 
of the colon (Levin et al., 2008). They may cause rectal bleeding, but the blood is generally 
masked in the stool. Each new polyp has a 2.5% risk of becoming cancerous in the first 5 
years and 24% after 20 years. Larger polyps are more likely to become malignant as well as 
some people exhibit more than one polyp (Ham et al., 2010) (Figure 1.27). There are 
different stages of development of colorectal cancer; these stages are distinguished, 
depending on the degree of spread of cancer; Stage 0: at this stage The tumour is in situ, 
which means it is very superficial and does not invade the sub-mucosa, lymph nodes are not 
achieved and that there is no metastasis remotely. Stage I: the tumour invades the second 
layer (sub-mucosa) or the muscle layer (muscular) in the wall of the colon or rectum, lymph 
nodes are not affected and there is no distant metastasis. Stage II: The cancer cells through 
several layers of the wall of the colon or rectum, but no node is reached and there is no 
metastasis. Stage III: Cancer cells have spread to the lymph nodes near the tumour, and 
spread beyond the colon or rectum or spread to neighbouring organs such as the liver and 
lung (Shelton, 2002).  
 
 
Figure 1. 27 Colonoscopy of CRC with multiple polyps  
This figure shows images from a colonoscopy demonstrating colon and rectal cancer with multiple 
polyps: (A) Rectum (B) Multiple polyps in sigmoid colon – adopted from (Ham et al., 2010)). 
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1.13.3 Treatment and Prevention  
There are three forms of treatment possible in case of colon cancer: surgery, 
radiation and chemotherapy. Surgery is usually recommended treatment to cure colon 
cancer, but it is only suitable for people suffering from these disease stages 1-3. If the 
disease is diagnosed at stage 3, radiotherapy or chemotherapy is then associated with 
surgery. 
Immunogenic therapy may be a new therapeutic option for colon cancer and distant organ 
metastasis. Immunogenic therapy using immuno-stimulatory molecules to enhance anti-
tumoral immunity may be effective at treating cancer. 
The CD40 ligand (CD40L) is a type II membrane protein that belongs to the tumour 
necrosis factor (TNF) family, is predominantly expressed on CD4+ T cells, and binds the 
CD40 receptor on the membrane of antigen-presenting cells (APCs) (Roy et al., 1993, 
Grewal and Flavell, 1998). The interaction between CD40L and CD40 plays a crucial role in 
the activation of APC and in the initiation of both humoral and cellular immune responses 
(Bennett et al., 1998, Schoenberger et al., 1998). Therefore, gene transfer of CD40L has 
been proposed as an effective means of treating malignancies. Moreover, CD40 ligation 
triggers TNF, TRAIL and FasL induction in tumour cells which result in tumour cell death. It 
has also been reported that tumour specific T cells can be activated by CD40 ligation. 
Furthermore, CD40 ligation stimulates antigen presenting cells and natural killer cells to 
mediate cytotoxicity in tumour cells. In addition, cytokine secretion such as TNFα, cytokines, 
T helper cell activation, major histocompatibility induction and antigen presentation are other 
outcomes of CD40 ligation (Eliopoulos and Young, 2004). Collectively, because of its ability 
and both enhance immune responses and at the same time because of its capacity to induce 
direct cytotoxic effects on tumour cells Cd40 represents as very promising therapeutic target, 
for a variety of cancers involving CRC (Georgopoulos et al., 2007).      
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1.14 Aims   
The main aim of this project was to for the first time provide a comprehensive 
understanding of the mechanisms of CD40 killing in CRC cells by unravelling the signaling 
events that underpin the capability of membrane CD40 ligand to stimulate CD40-mediated 
apoptosis in CRC cells.  
More specifically: 
 Chapter 3: Utilize a co-culture system to induce mCD40L-mediated CD40 ligation 
in CRC cells and optimise a number of assays for the detection of CD40 mediated 
apoptosis.    Chapter 4: Using apoptosis detection assays, immunoblotting, pharmacological 
inhibitors and retrovirus-mediated shRNA-based RNA interference (RNAi) to 
study for the first time the regulation of key intracellular signalling components 
involved in pro-apoptotic mCD40L-induced CD40 signalling in CRC cells and 
provide functional evidence for a role of these components in apoptosis.   Chapter 5:  Provide a detailed understanding of the involvement of the ROS 
pathway in CD40 apoptosis by examining the extent of ROS generation, 
activation of NADPH oxidases as mediators of ROS generation and CD40-
mediated apoptosis and potential CD40-mediated modulation of antioxidant 
pathways to influence the activation of downstream apoptotic signaling pathways.  
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CHAPTER 2: MATERIALS AND METHODS 
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2. Material and Methods 
2.1 General 
All practical work was carried out in the School of Applied Sciences, at the University 
of Huddersfield in the X1/17 and XB/07 laboratories.  
2.2 Suppliers  
Commercial suppliers and manufacturers are indicated at the first mention of the reagent or 
equipment in the text. A comprehensive list of all suppliers is provided in Appendix I.  
2.3 Disposable plasticware 
Sterile and non-sterile plasticware was obtained from different suppliers (Sarstedt, 
Fisher Scientific, Greiner Bio-One or Alpha Laboratories). Non-sterile, disposable plasticware 
was sterilised by autoclaving in a Prior Clave/London Autoclave at 121°C under presser (2 
Bar) for 15 minutes and then left to dry at room temperature. 
2.4 Stock solutions 
All chemical reagents were either of analytical or tissue culture grade as appropriate 
for the experiment and were supplied by Sigma Aldrich unless otherwise stated. General 
laboratory stock solutions were prepared in the laboratories with deionised water (dH2O). All 
solutions which were used in tissue culture were prepared with ultra-pure water from a 
LabStar Ultra Violet purification unit. Heat stable solutions were sterilised by autoclaving at 
121°C (1 bar) for 15 minutes. Otherwise to ensure lack of contamination, solutions were also 
filter sterilised using Acrodisc (VWR) low-protein binding Tuffryn® HT syringe filters with a 
pore size of 0.2µm. 
2.5 Reagents 
2.5.1 Primary antibodies  
Primary antibodies used in this study are illustrated in the following Table 2.1. These 
antibodies were aliquoted in eppendorf tubes (10µl) and stored as recommended by the 
manufacturer until required. Working stock antibody solutions were prepared by diluting stock 
antibodies with TBS-Tween buffer (Tween20; Sigma Aldrich). This was dependent on the 
type of antibody. 
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Table2. 1 Primary antibodies 
Antigen Catalogue no/ Clone Host Supplier (product of) Dilution Application 
Molecular weight 
(kDa) 
Human CD40L AF617 Rabbit R&D systems 1:500 in TBS Tween20 0.1% FC, WB 37 
TRAF3 sc-949 / c20 Rabbit Insight Bio (Santa Cruz) 1:250 in TBS Tween20 0.1% 
WB, IP, IF, FCM 
and ELISA 65 
TRAF1 sc-7186 / h-186 Rabbit Insight Bio (Santa Cruz) 1:500 in TBS Tween20 0.1% 
WB, IP, IF and 
ELISA 52 
TRAF6 sc-8409 Mouse Insight Bio (Santa Cruz) 1:500 in TBS Tween20 0.1% 
WB, IP, IF, IHC(P) 
and ELISA 60 
Phospho-
SEK1/MKK4 
(Ser457) 
#4514 (C36C11) Rabbit New England Biolabs (NEB)/Cell Signalling Technology (CST) 
1:1000 in TBS, 5% w/v 
BSA, 0.1% Tween20 WB, FC 44 
Phospho-MKK7 
(Ser271/Thr275) #4171 Rabbit NEB (CST) 
1:1000 in TBS, 5% w/v 
BSA, 0.1% Tween20 WB 48 
JNK/SAPK #9258 Rabbit NEB (CST) 1:1000 in TBS, 5% w/v BSA, 0.1% Tween20 WB 46, 54 
Phospho-ASK1 
(Ser967) #3794 Rabbit NEB (CST) 
1:1000 in TBS, 5% w/v 
BSA, 0.1% Tween20 WB 155 
Phospho-JNK/SAPK 
(Thr183/Tyr185) 255 (G9) Mouse NEB (CST) 
1:500 in TBS, 5% w/v 
non-fat dry milk, 0.1% 
Tween20 
WB, IP IF, FC 
46 (phospho-
JNK1) 54 
(Phospho-JNK2/3) 
Cytochrome C (H-
104) sc-7159 Mouse Insight Bio (Santa Cruz) 
1:500 in TBS Tween20 
0.1% 
WB, IP, IF and 
ELISA 15 
ASK1 #3762 Rabbit NEB (CST) 1:1000 in TBS, 5% w/v BSA, 0.1% Tween20 WB 155 
BAX 2282-MC-100 (YTH-2D2) Mouse R&D systems (Trevigen) 
1:500 in TBS 0.1% 
Tween20 WB, IP 23 
Bcl-2 2291-MC-100 (YTH-8C8 Mouse R&D systems (Trevigen) 
1:500 in TBS 0.1% 
Tween20 WB, IP 25 
BAK AF816 Rabbit R&D systems 1:500 in TBS 0.1% Tween20 WB 28 
Phospho-p40phox 
(Thr154) #4311 Rabbit NEB (CST) 
1:500 5% w/v BSA, 
0.1% Tween20 WB 40 
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Human Thioredoxin #2285S Rabbit NEB (CST) 1:500 5% w/v BSA, 0.1% Tween20 WB 12 
ȕ-actin 
Clone AC15 A5441 - 2ML Mouse Sigma 
1:20,000 in0.1% 
Tween20 WB 42 
CD40 Sc-13128/ (H Mouse NEB(CST) 1:500 in0.1% Tween20 WB 43 
CK18 C8541 Mouse Sigma-Aldrich 1:2000 in0.1% Tween20 WB 45 
CK18 081213 Mouse Invitrogen 1:1000 in 0.1% Tween20 WB 45 
TRAIL 3219 Rabbit NEB (CST) 1:500 in 0.1% Tween 20 WB 28 
FasL 4273 Rabbit NEB (CST) 1:500 in 0.1% Tween 20 WB 26, 40 
CK8/18 889257A Mouse Invitrogen 1.1000 in 0.1% Tween 20 WB 52/48 
Phospho-P38 4511 Mouse NEB (CST) 1.500 in 0.1% Tween 20 WB 40 
DR5 8074 Rabbit NEB (CST) 1.500 in 0.1% Tween 20 WB 40, 48 
Bid (Human specific) 2002 Rabbit NEB (CST 1:250 0.1% tween 20 WB 15-22 
A table listing all primary antibodies used in this study, their catalogue number, host origin, supplier or manufacturer, optimal dilution, type of blocking buffer and 
the range of their applications is shown here. (Abbreviations - WB: Western blotting, IP: Immunoprecipitation, IF:Immunofluorescence, FC: Flow cytometry). 
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2.5.2 Secondary antibodies  
For detection of all monoclonal antibodies the Molecular probes Alexa Fluor® 680 Goat anti-
mouse IgG (H+L) antibody was used (Invitrogen Cat # A21057). Detection of all polyclonal 
antibodies was achieved using the Goat anti-Rabbit IgG IRDYE800 antibody (Tebu-bio Cat # 
039611-132-122). Fluorochrome conjugated secondary antibodies were titrated prior to use 
and are listed in Table 2.2. 
 
Table 2. 2 Secondary antibodies 
Antigen Catalogue no/ Clone Host 
Supplier 
(product of) Dilution Application 
Mouse 
IgG A21057 Rabbit Invitrogen 
1:10,000 in TBS 
0.1% Tween20 WB 
Rabbit IgG 039611-132-122 Goat Tebu-bio 1:10,000 in TBS 0.1% Tween20 WB 
Goat IgG 
Alexa 680 
A-21084 Donkey Invitrogen 1.10,1000 in TBS 0.1% Tween20 WB 
All secondary antibodies, which used in the current study, their catalogue number, host origin, 
supplier or manufacturer, optimal dilution, type of blocking buffer and the range of their 
applications. (Symbols - WB: Western blotting). Fluorescence detection of antibodies at 
wavelengths 680nm and 800nm was performed using the Licor Odyssey Infra-red imaging 
system. When not in use antibodies were stored in the dark at 4°C. 
 
2.5.3 Agonists & antagonists 
Pharmalogical agonists and antagonists (Table 2-3) were reconstituted in either tissue 
culture grade dimethyl sulphoxide (DMSO; Sigma) or sterile distilled water (dH20) according to 
the manufacturer‘s instructions. This was stored in single use aliquots at -20°C as 
recommended. Prior to use, all compounds were titrated using the cell viability assay (CellTiter 
96® AQueous One Solution Cell Proliferation Assay; Promega, UK, Cat # G3581) to determine 
the effective and non-toxic dosage. All reagents used in this study were purchased from the 
indicated supplier.  
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Table2. 3 Agonists & antagonists 
Compound Target Supplier Stock concentration Effective concentration 
N-acetyl L-cysteine (NAC) ROS Sigma 30mM (culture media) 30mM 
DPI NADPH Oxidase Sigma 10mM (DMSO) 0.5µM 
SP600125 JNK Enzo 20mM (DMSO) 5µM 
NDGA AP-1 Sigma 20mM (DMSO) 5µM 
SB202190 p38 Sigma 20mM (DMSO) 5µM 
PX-12 Thioredoxin Sigma 20mM (DMSO) 1-3µM 
Diethyl Maleate Gluthathione Sigma 6.45 Molar 75µM 
Staurosporine Protein Kinases Sigma 100µM 1-10µM 
Caspase-8 Inhibitor Caspase-8 R&D systems 20mM 25µM 
Caspase-9 Inhibitor Caspase-9 R&D systems 20mM 100µM 
Caspase-10 Inhibitor Caspase-10 R&D systems 20mM 100µM 
General caspase Inhibitor (Z-VAD) Caspases R&D systems 20mM 100µM 
Hydrogen peroxide N/A Sigma 9.79M 100µM-3200µM 
G28-5 CD40 N/A 1.1mg/ml 10µg/ml 
NOK1 FasL (CD95L) Gift of Prof Yagita, Japan 1mg 100µg 
RIK2 TRAIL Gift of Prof Yagita, Japan 1mg 100µg 
Agonists and antagonists used in this study, their target molecule, the supplier, the stock and effective concentrations are shown. 
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2.6 Tissue culture 
2.6.1 General 
All tissue culture work was undertaken using aseptic techniques within a HEPA 
filtration CellGard class II biological safety cabinet (NUAIRE). Prior to and after use, internal 
working areas within the hood were disinfected using 70% (w/v) ethanol (Fisher). To do so 
99% Ethanol was diluted appropriately (150ml: 350ml) with purified autoclaved dH20. Internal 
hood spillages were disinfected using Mikrozid® (Gompel Healthcare Cat# 32644) and this 
was also used for a monthly routine sterilisation. Any unwanted cells, exhausted media or 
solutions were aspirated into a large conical flask containing 10% (w/v) Virkon and were then 
left for a minimum of 30 minutes before being decanted and washed into sewage.  
All cell culture reagents were of tissue culture grade, and were a product of Sigma 
unless otherwise stated. To separate cells from solution, cell suspensions were spun for 5 
minutes at 1500 RPM (210 RCF) using a Hettich Zentrifugen Universal 320 bench top 
centrifuge. Cell counts were performed from cell suspensions using a Marienfield Neubauer 
improved bright line haemocytometer before cells were seeded at the required cell density. 
When cells were not being manipulated they were kept in an Iso class 5 Nuaire Autoflow direct 
heat CO2 incubator with a HEPA filtration system at 37°C in a 5% CO2 humidified atmosphere 
(incubator contained dH2O supplemented with Sigma clean (Sigma cat# S5525-40Z). Cultured 
cells were routinely observed by phase contrast microscopy using an EVOS XL (PeqLab) 
inverted microscope at x100 magnification. 
2.6.2 Cryo-preservation and recovery of cell lines 
Cells were cryo-preserved and kept in liquid nitrogen in a Statebourne storage dewar 
at -196°C. For cryopreservation of cell lines, cultures were collected as for passaging (as 
explained in section 2.6.3) and collected by centrifugation. The cell pellet was re-suspended in 
the appropriate ice-cold growth medium supplemented with 10% (v/v) FBS and 10% (v/v) 
dimethylsulphoxide (DMSO) at a cell density not less than 1x106 cells/ml. Cells were aliquoted 
in a total of 1-1.5ml to polypropylene cryovials (Sarstedt) and then transferred to an ice-cold 
Nalgene ―Mr Frosty‖ (Fisher) containing β50ml of isopropanol (Fisher) to control the cooling 
rate to 1°C per minute. Cells were then placed within a -80°C freezer for 4-6 hours prior to 
transfer to liquid nitrogen.  
Cells were recovered by thawing rapidly at 37°C, before 5-10ml of pre-warmed growth 
medium was added. Cells were centrifuged at 1500RPM/210g for 5 minutes and then seeded 
to tissue culture flasks as required. 
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2.6.3 Carcinoma cell culture 
In this study three colorectal cancer cell lines were used; HCT116 which naturally 
expresses CD40 receptor on the cell membrane (as shown in Chapter 3), SW480 were used 
as negative control (as they do not express CD40) and SW480-CD40, which is an SW480 
isogenic derivative that was transduced with a CD40-expressing retrovirus to express CD40 
(Georgopoulos et al., 2007, Hill et al., 2008a). The malignant bladder carcinoma cell line was 
also often used as a positive control for CD40 ligation studies as previously (Georgopoulos et 
al., 2007, Hill et al., 2008a). 
HCT116 was initially grown in complete DMEM 10% FBS but was then adapted in D:R 
medium with 1% L-Glutamine, supplemented with 5% FBS (adaptation of cells is shown in 
Chapter γ). All colorectal cancer cells were maintained in a 50:50 (v/v) mixture of Dulbecco‘s 
modified eagle medium (DMEM Sigma cat # D6546-6X500ML) and Roswell Park Memorial 
Institute 1640 (RPMI Sigma cat # R0883-6X500ML) (referred to as D:R medium). This medium 
was supplemented with 5% fetal calf serum (FCS Biosera cat # S1810/500) and 1% L-
Glutamine (Sigma cat #G7513-100ML). The SW480-CD40 cell line was grown in D:R medium 
with 1% L-glutamine, supplemented with 10% FBS, and 1.0mg/ml G418, while the original line 
SW480 was cultured in D:R medium without antibiotic (G418). All cell lines were maintained in 
T75 flasks with 12-14ml medium or T25 flasks in 5ml medium and were incubated at 37ºC 
under 5% CO2. All cell lines were sub-cultured every 2 to 3 days, when they were 80-95% 
confluent. At all times cell lines were cultured in the above mentioned medium and incubated 
at 37°C in 5% CO2 unless otherwise stated. 
For routine passaging, cells were collected by washing with 0.1% (w/v) EDTA in 
phosphate buffered saline (PBS) (without Ca and Mg) free (Invitrogen Cat# 14200-067) for 5 
minutes and then addition of Trypsin-EDTA (Sigma Cat# T41474-20ml) in Calcium and 
Magnesium free Hanks-balanced salt solution (HBSS, Sigma Cat# H9394-6X500ML) until 
cells detached from culture flask. Trypsin was inactivated by the re-addition of the respective 
serum-supplemented culture medium when cells were re-suspended.  
 
2.6.4 Murine fibroblast (3T3) cell culture 
The mouse fibroblast cell line NIH3T3 has been previously stably transfected with two 
expression plasmids, the first one bearing the sequences coding for CD40L and Neomycin  
resistance gene (3T3-CD40L cells) and the second with Neomycin resistance alone (3T3-Neo 
cells) as described in Bugajska et al. (2002). During routine culture, these 3T3 derivatives 
were maintained in D:R supplemented with 10% FCS, 1% L-Glutamine (DR: 10%FCS/1% L-
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G) and 0.5µg/ml G418 (Invivogen Cat# ant-gn-1; supplied by Source BioScience LifeSciences) 
to ensure cells maintained transgene expression. At all times cell lines were cultured in the 
mentioned medium and incubated at 37°C in 5% CO2 unless otherwise stated. 3T3 cells were 
harvested and passaged as carcinoma cells with the exemption of a very short 0.1% (w/v) 
EDTA in PBS treatment, as extended periods risked cell detachment.  
2.7 Molecular Biology 
2.7.1 shRNA design 
Short hairpin RNA (shRNA) sequences were designed using the Invitrogen siRNA 
design tool (http//rnaidesigner.invitrogen.com/rnaiexpress) and incorporating BamHI and 
EcoR1 overhangs as well as an internal MluI restriction site to aid in selection of positive 
clones. A minimum of two shRNA oligos were created improving probability of successful 
knockdown. Some designed shRNAs were based using published literature and some created 
using the online design tool from Invitrogen. 
2.7.2 Cloning 
Molecular cloning, transformation of competent E.coli, and purification of plasmid DNA 
was previously performed by Dr Nik Georgopoulos at the Leeds Institute of Molecular 
Medicine (LIMM), Cancer Research UK, St James Hospital (University of Leeds). A range of 
shRNAs were created using the designed oligonucleotides (supplied by Eurofins, former MWG 
Biotech) shown in Table 2-4. 
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 Table2. 4 shRNA Oligonucleotides 
TARGET 
mRNA Complete sequence (target) of Oligonucleotides (orientated 5’ to 3’) Design source 
TRAF3 GATCCGAGTCAGGTTCCGATGATCTTCAAGAGAGATCATCGGAACCTGACTCTTTTTTACGCGTG (TRAF3siR1-for) AATTCACGCGTAAAAAAGAGTCAGGTTCCGATGATCTCTCTTGAAGATCATCGGAACCTGACTCG (TRAF3siR1-rev) Liao et al., 2004 
TRAF3 GATCCGCCCACTGGAGAGATGAATTTCAAGAGAATTCATCTCTCCAGTGGGCTTTTTTACGCGTG (TRAF3siR2-for) AATTCACGCGTAAAAAAGCCCACTGGAGAGATGAATTCTCTTGAAATTCATCTCTCCAGTGGGCG (TRAF3siR2-rev) Invitrogen design tool 
BAX GATCCGCATGGAGCTGCAGAGGATGTTCAAGAGACATCCTCTGCAGCTCCATGTTTTTTACGCGTG (BaxsiR1-for) AATTCACGCGTAAAAAACATGGAGCTGCAGAGGATGTCTCTTGAACATCCTCTGCAGCTCCATGCG (BaxsiR1-rev) 
Ray and Almasan 
2003 
BAX GATCCGGTGCCGGAACTGATCAGATTCAAGAGATCTGATCAGTTCCGGCACCTTTTTTACGCGTG (BaxsiR2-for) AATTCACGCGTAAAAAAGGTGCCGGAACTGATCAGATCTCTTGAATCTGATCAGTTCCGGCACCG (BaxsiR2-rev) Bidere et al., 2003 
The table shows the forward and reverse oligonucleotides for the construction of shRNA delivery vectors and expression by retroviral transduction using the 
pSIREN RetroQ system.  
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2.7.3 RNAi delivery plasmid 
RNAi ready pSIREN RetroQ (Clontech) is a self-inactivating retroviral expression 
vector designed to express shRNAs via a U6 promoter. The vector encodes a 5‘ long 
terminal repeat (LTR) containing a cytomegalovirus type 1 (CMV) enhancer region and a 
mouse sarcoma virus (MSV) promoter to drive transcription of the RNA packaging signal 
Ψ+, shRNA of interest and Puromycin resistance cassette in eukaryotic cells. When 
expressed in the packaging cell line PT67, the plasmid will produce infectious but 
replication-incompetent viral particles which lack the structural genes necessary for virus 
formation and can infect a wide host range but cannot replicate. Insertion of the target 
shRNA sequence is via BamHI and EcoRI restriction sites (Figure 2.1).  
 
Figure 2. 1 pSIREN RetroQ plasmid vector  
pSIREN RetroQ plasmid is based on the Moloney mouse leukemia virus (MMLV) and can be used for 
targeted gene silencing using RNAi. Oligonucleotides encoding short-hairpin RNA sequences can be 
cloned between the BamHI and EcoRI restriction enzyme sites. Plasmid is then propagated in 
competent E.coli bacteria using the ColE1 origin of replication ColE1ORI) and successfully 
transformed cells are selected via expression of the ampicillin resistance gene (Ampr). Upon 
transfection into the packaging cell line, PT67, the RNA packaging signal (Ψ+), shRNA of interest and 
Puromycin resistance cassette (Puror) is transcribed via a 5‘ long terminal repeat (LTR) containing a 
cytomegalovirus type 1 (CMV) enhancer region and a mouse sarcoma virus (MSV) promoter. During 
reverse transcription of the retroviral RNA, the γ‘ LTR is copied and replaces the 5‘ LTR, resulting in 
inactivation of the 5‘ LTR CMV enhancer sequences. Vector is then packaged and the resulting 
retroviral particles can be utilised in a variety of mammalian cells. In target cells, expression of the 
short hairpin RNA and Puror is driven via a U6 promoter, an RNA polymerase III-dependant 
promoter. Imaged reproduced from the Clontech pSIREN RetroQ manual PT3737-5.  
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2.8 Methodologies for induction of CD40 ligation 
CD40 receptor ligation for the experiments described in this study was carried out by 
membrane CD40L. Delivery of membrane-presented CD40L (mCD40L) was achieved by 
co-culture of 3T3CD40L cells (mCD40L) with CD40-positive target epithelial cells. As a 
negative control, epithelial cells were co-cultured with equal numbers of 3T3Neo cells 
(Controls). mCD40L and Control cells were growth arrested by treatment with 10 µg/ml of 
Mitomycin C (Sigma) for two hours in D:R before they were washed, harvested and seeded 
into 96 well plates at 1x104 cells/well or in 10cm2 culture dishes at 3x106/dish, for apoptosis 
detection assays and preparation of protein lysates, respectively. After mCD40L and Control 
cells were attached to either both 96 wells plates or dishes (in most cases following 
overnight incubation), epithelial cells were added at a ratio of 0.8 or 1.0 of epithelial cells, as 
optimised in this study (and detailed in Chapter 3). More specifically, 1x104 epithelial cells 
were seeded into 3T3 cell-containing 96 well plates and 3x106 cells were seeded into 10cm2 
culture dishes, respectively.  
 
2.9 Detection of cell growth, death (apoptosis) and reactive oxygen 
species (ROS) production  
2.9.1 General 
Previously published guidelines regarding the use and interpretation of assays for 
monitoring cell death (Galluzzi et al., 2009)  have recommended that a minimum of two 
assays are utilised for the detection of cell apoptosis. The current research made use of a 
cell proliferation assay (MTS) in addition to four apoptosis detection-specific assays; a) 
CytoTox-Glo b) caspase 3/7 activation  c) DNA fragmentation and d) the loss of cell 
membrane integrity were all used as markers for apoptosis.  
These assays were based on measurement of absorbance, fluorescence or 
luminescence. 96 well Nunc white, tissue treated culture plates (Fisher cat # TKT-186-
010C) were used for luminescence and fluorescent based assays, 96 well Costar 
transparent tissue treated culture plates (Fisher Cat # TKT-186-010C) for absorbance, and 
96 well ELISA microplates (Greiner bio one Cat # 655101) for ELISA. For most assays 
epithelial cells were co-cultured with either 3T3-CD40L (mCD40L) or 3T3-Neo (Control) 
cells. To calculate cell death background fluorescence and luminescence readings were 
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subtracted pairwise as appropriately, (e.g. ―mCD40L/EJ – mCD40L‖ and ―Control/EJ – 
Control‖ readings). The exemption was DNA fragmentation as this was unnecessary due to 
the pre-labelling of target epithelial cells. Finally, in all experiments blank controls were 
included as appropriate. 
 
2.9.2 Detection of cell growth (biomass) 
 Detection of cell viability via determination of cell biomass was assessed using the 
CellTiter 96® AQueous One Solution Cell Proliferation assay. The CellTiter 96® AQueous One 
Solution Cell Proliferation assay involves the use of the MTS tetrazolium (yellow) which is 
reduced to a formazan derivative (brown Colour) by respiring cells. The observed change in 
colour is proportional to the total number of viable/proliferating cells. Epithelial cells were 
plated into 96 well plates with 6 replicate wells and then left to adhere overnight before the 
addition of culture medium containing pharmacological agonists or inhibitors. 20µl of 
CellTiter 96® AQueous One Solution was added to appropriate wells and plates were 
incubated at 37°C in 5% CO2 for a total of four hours. Total levels of formazan formation/cell 
viability were assessed using a FLUOstar OPTIMA (BMG Labtech) plate reader at a 
wavelength of 492nm and data was acquired using MARS software (BMG Labtech) and 
assessed using Microsoft Excel. Cell viability was calculated as percentage viability in 
comparison to controls using the following formula: (T/C) x100, where T= treated cells and 
C= controls cells.  
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Figure 2. 2 The structure of MTS tetrazolium and its reaction product   
This assay is a colorimetric method containing only one solution reagent consist of a new tetrazolium 
compound includes 3-(4,5-dimethythiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyle)-2H-
tetrazolium, inner salt: MTS and also contains phenazine ethosufate (PES), which uses as an 
electron coupling reagent that can bind with MTS to form a constant solution. This reagent can be 
reduced by cells into coloured product which is soluble in the medium which is known as formazan. 
The number of living/viable cells proportional with the absorption resulting of the interaction 
(formazan colour).  
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2.9.3 Detection of apoptosis using caspase3/7 assays 
The activation of Caspases 3/7 is a well-established feature of cell apoptosis. Caspases 3 
and 7 target a specific amino acid sequence located on many proteins which leads to overall 
cell demise by an organised apoptotic event. The activation of Caspases 3/7 was 
determined using the SensoLyte® Homogenous AFC Caspase-3/7 substrate (Anaspec Cat 
# 71114, supplied by Cambridge Bioscience), or the caspase3/7-Glo substrate assay 
(Promega Cat # g8091).  
 
2.9.3.1 SensoLyte® Homogenous AFC Caspase-3/7 assay 
The assay utilises the cleavage of the recognition sequence of caspase -3 and -7 
that is Asp-Glu-Val-Asp (DEVD). The SensoLyte® Homogeneous AFC Capase-3/7 assay kit 
uses Ac-DEVD-AFC as the fluorogenic indicator for assaying caspase-3/7 activity. Upon 
caspase-3/7-mediated cleavage, Ac-DEVD-AFC generates the AFC fluorophore which has 
bright blue fluorescence and can be detected at Excitation / Emission = 380nm/500nm. The 
degree of production of the strongly fluorescent fluorophore is relative to total levels of 
caspase-3/7 activation as shown in figure 2.3.  
Epithelial cells were treated with membrane CD40 agonist in 96 well plates as 
described in section 2.8 before the addition of 50µl SensoLyte® Homogenous AFC 
Caspase-3/7 substrate. Fluorescence was measured using a FLUOstar OPTIMA (BMG 
Labtech) plate reader using Excitation/Emission 355nm/520nm filters, following calibration 
of the reader using the Gain function on the MARS software to ensure the measurements 
were taken within the dynamic range of the instrument. Plates were kept away from light 
and left at room temperature (RT) overnight after which fluorescence measurements were 
taken. To account for background created by fibroblasts, these were cultured alone and 
their relative fluorescent units (RFU) subtracted from the representative co-culture in a pair 
wise fashion (as explained in Section 2.9.1).  
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Figure 2. 3 Proteolytic cleavage of Ac-DEVD-AFC substrate  
The amount of fluorescent product generated is proportional to the amount of caspase-3/7 cleavage 
activity present in the sample. Cleavage of the weakly-fluorescent caspase-3/7 Ac-DEVD-
aminoluciferin substrate Z-DEVD by Caspase-3/7 to create the strongly fluorescent compound.  
2.9.3.2 Caspase-Glo® 3/7 Assay 
The assay utilises a pro-luminescent caspase-3/7 DEVD-aminoluciferin substrate 
and a thermostable luciferase in a reagent optimized for caspase-3/7 activity, luciferase 
activity and cell lysis. As the cells are lysed in situ, the luminescence can be detected 
immediately after substrate addition.  
Epithelial cells were treated with membrane CD40 agonist as described in section 2.8 
before the addition of 50µl caspase 3/7-Glo substrate. Luminescence was detected using a 
FLUOstar OPTIMA (BMG Labtech) plate reader, following calibration of the reader using the 
Gain function on the MARS software to ensure the measurements were taken within the 
dynamic range of the instrument. Plates were kept away from light and left at RT for 15 
minutes before measurements were taken. Data was acquired using MARS software (BMG 
Labtech) and analysed by Microsoft Excel. 
2.9.4 Detection of cell death using the CytoTox-Glo™ assay 
The CytoTox-Glo assay is based on detection of the activity of a proprietary, specific 
protease normally present inside cells. During apoptosis, as the cell membrane is 
compromised the protease is released and it cleaves the AAF-Glo™ substrate thus 
generating a luminescence signal (Figure 2.4). The intensity of the luminescence signal 
indicates the degree of apoptotic cells in a population. Before the experiment, all reagents 
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were thawed at room temperature and all components mixed to ensure homogeneity. The 
CytoTox-GloTM cytotoxicity reagent was prepared by transferring the contents of one bottle 
of assay buffer to the AAF-GloTM substrate bottle, and then mixed to ensure homogeneity. 
The Lysis reagent was prepared by transferred 33 µl from digitonin to 5ml assay buffer. 
Epithelial cells were treated with membrane CD40 agonist as described in section 
2.8 before the addition of 50µl CytoTox-Glo substrate. Luminescence was detected using a 
FLUOstar OPTIMA (BMG Labtech) plate reader, following calibration of the reader using the 
Gain function on the MARS software to ensure the measurements were taken within the 
dynamic range of the instrument. Plates were kept away from light and left at RT for 15 
minutes before measurements were taken. Data was acquired using MARS software (BMG 
Labtech) and analysed by Microsoft Excel. In cases where the percentage of dead cells was 
calculated the detergent Digitonin was added to lyse all cells according to the 
manufacturer‘s recommendations and a further reading was taken 15 minutes initial 
readings taken. To calculate percentage cell death the equation used was: (Background-
corrected RLU before digitonin / background-corrected RLU after digitonin) x100, where 
RLU indicates relative luminescence units.   
 
Figure 2. 4 The principle of the CytoTox-GloTM assay 
The first cleavage of luminogenic AAF-GloTM substrate occurs by dead-cell protease activity and the 
second cleavage, and a substrate for luciferaase (aminoluciferin) is released resulting in the 
luciferase-mediated production of light. 
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2.9.5 Detection of apoptosis using the DNA fragmentation ELISA 
The fragmentation of DNA is often a hallmark of apoptosis and the DNA 
fragmentation ELISA assay uses 5-bromo-2'-deoxyuridine (BrdU) specific antibodies to 
detect BrdU-labelled fragments of DNA. Greater amounts of fragmented DNA labelled with 
BrdU represent a greater number of cells that have undergone apoptosis (the principle of 
the assay is schematically illustrated in Figure 2.5).   
Exponentially growing epithelial cells were loaded with the DNA labelling agent BrdU 
for β hours at a concentration of 10µM according to the manufacturer‘s instructions. Cells 
were then treated with mCD40L by co-culture as described in section 2.8. An ELISA plate 
was coated with an anti-DNA antibody and then blocked to remove any non-specific binding 
sites. After washing of the ELISA plate to remove any blocking buffer, supernatants from cell 
cultures were added; these may contain DNA fragments pulsed with BrdU. The labelled 
fragments of DNA stick to the plate via the anti-DNA antibody and then a secondary, 
enzyme-linked antibody that specifically recognises BrdU was added. Finally, an enzyme 
substrate was added which is converted into a blue colour by the secondary, enzyme-linked 
antibody. The increased amount of colour change is relative to the amount of secondary 
antibody bound to BrdU labelled fragments of DNA. Diluted sulphuric acid (H2SO4) was 
used to stop the reaction after sufficient colour change, and following this, a deep yellow 
colour represented the degree of cell apoptosis. The plates were used to measure 
absorbance at using a 455-10nm filter on a FLUOstar OPTIMA (BMG Labtech) plate reader. 
Data was acquired using MARS software and analysed by Microsoft Excel. Although 
background controls were included to ensure the accuracy of measurements taken, no 3T3 
cell alone background controls were necessary for this assay, as only epithelial cells were 
pulsed with the DNA labelling agent BrdU.  Staurosporine was used as positive control (5µM).   
   
% of apoptotic cells = ሺ୘a୰ge୲ cellୱ +Kille୰ cellୱሻ ୘a୰ge୲ cell+ୗ୲a୳୰୭ୱ୮୭୰i୬e  x ͳͲͲ 
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Figure 2. 5 Principle of DNA fragmentation assay.  
Microtiterplate was coated with anti DNA antibody, BrdU-labelled fragments of DNA from co-culture 
supernatants which are fixed and denaturing by using microwave at 500watt for 5 minutes this was 
followed by the secondary antibody (anti-Brdu-Fab). Plate was incubated 90 minutes at room 
temperature and substrate was added. Once yellow colour was developed, sulphuric acid was added 
to stop the reaction. 
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2.9.6 Detection of Reactive oxygen species using H2DCFDA 
6-carboxy-β', 7‘-dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen Cat # 
c2938) is a cell permeable, chemically-reduced, acetylated form of fluorescein used as an 
indicator for reactive oxygen species (ROS) in cells. This non-fluorescent molecule is readily 
converted to a green-fluorescent form when the acetate groups are removed by intracellular 
esterases and ROS-associated oxidation within the cell. As it is oxidation sensitive, 
H2DCFDA was reconstituted in oxygen-free conditions (in a nitrogen environment) before 
aliquoting and storage at -80°C, as recommended by the manufacturer. 
Epithelial cells were treated with membrane CD40 agonist as described in section 
2.8. Notably, however, when co-cultures were performed, 3T3 fibroblasts used in this 
instance were not growth-arrested using Mitomycin C. Following co-culture, cells were first 
washed with PBS to remove any culture medium and were then treated with 1µM of 
H2DCFDA in pre warmed (37°C) PBS for 30 minutes 37°C in 5% CO2. The reduced forms of 
the substrate lack any fluorescence until acetyl groups are removed by intracellular 
esterases and oxidation is occurring in the cell. When this occurs the charge of the 
molecules makes it much less likely to leave the cell and it also emits detectable 
fluorescence. Following treatment with H2DCFDA for the indicated time periods, 
fluorescence was measured on a FLUOstar OPTIMA (BMG Labtech) plate reader at 
Excitation 485nm/Emission 520nm, following calibration of the reader using the Gain 
function on the MARS software to ensure the measurements were taken within the dynamic 
range of the instrument.  
2.10 SDS-PAGE and Immunoblotting (Western Blotting) 
2.10.1 General  
Western bolting is a powerful technique widely used in different fields in biological 
research to detect specific proteins throughout a cell lysate. Proteins from within a cell 
lysate can be gently extracted and maintained in buffers to ensure their integrity. Under 
denaturing conditions multiple proteins are size fractionated using SDS-PAGE, a form of gel 
electrophoresis. As electrophoretic any technique enables the SDS-PAGE separation of the 
particles made according to their electrical charge and to identical loads according to their 
size.  
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SDS-PAGE separation was performed under denaturing conditions due to the 
addition of SDS (sodium dodecyl sulfate). SDS is a strong detergent having a long 
hydrophobic hydrocarbon tail and a negatively charged end. It interacts with the protein in its 
hydrocarbon portion binder their hydrophobic regions. By binding to the protein, SDS 
prevents its folding and imparts a net negative charge. The native structure of the protein is 
denatured and an apparent negative charge is imparted to the protein. In the presence of 
SDS, the protein will thus have a negative apparent charge, so they all will migrate towards 
the anode. This means that only the molecular weight of the protein is factor separation. The 
proteins having a small molecular weight will be retained within the pores of the 
polyacrylamide gel and therefore will migrate farther than larger. Indeed, electrophoresis 
utilises the electrophoretic mobility of proteins to run them down a gel and specific gel pores 
separate them by size and charge. Proteins separated by this method are then transferred 
toward a transfer membrane which has high binding affinity for them. Stably bound to a 
membrane, size fractionated and denatured proteins are detected using epitope specific 
primary antibodies. A near-infrared (NR) fluorophore conjugated secondary antibody raised 
against the primary antibody is then added to the membrane and the membrane is scanned 
using an infrared scanner.  
2.10.2 Co-culture and treatment to investigate intracellular signalling 
3T3-Neo and 3T3-CD40L cell which express their CD40L surface were treated with 
MMC as explained in section (2.8). Cells were cultured in dish 10cm2 at 3x106 cells/. 
(Duplicate dishes for every cell line 5ml each) Figure2.6. All dishes were incubated at 37ºC 
and 5% CO2 for 24hours. The medium was replaced by SW480-CD40 (5 ml; 3.0 x106 
cells/dish) and dishes were incubated at 37ºC and 5% CO2 for the required times (6, 12 and 
24hrs). Upon completion of incubation time lysates were made as explained in section 
(2.10.3). Protein concentration was measured in every lysates as explained in section 
(2.12.3). Lyastes were also used in immuonoblotting to detect intracellular protein 
expression in target cell (CRC cells). 
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A 
   
B 
                
Figure 2. 6 Co-culture of CRC cells with 3T3 fibroblasts; 3T3-CD40L (A) and 3T3Neo   
 
2.10.3 Protein extraction  
Co-cultures of mCD40L and Control cells with target epithelial cells were grown in 
10cm2 culture dishes and lysed in situ. In some cases (where stated) cultures were 
maintained in the presence of pharmacological agonist/antagonists as indicated. Culture 
medium was aspirated and cell sheets were washed 2x in ice-cold D-PBS to remove any 
excess proteins. 20µl of ice-cold 2x sodium dodecyl sulphate (SDS) buffer (Appendix II) 
containing 2mg/ml DTT and 0.2%(v/v) protease inhibitor cocktail set 3 (Calbiochem) was 
pipetted onto the cell monolayer and the cells were scraped using a cell scraper (Fisher 
Cat# FB55199) into a lysate solution. The solution was then transferred to a chilled micro-
centrifuge tube kept on ice. Samples were sonicated using an ultrasonic probe (Sonics 
Vibra cell) for 10-second bursts until lysate resembled froth like consistency it was then 
cooled on ice for 30 minutes. The lysates were centrifuged at 12,000-14000g, 4°C for 30 
minutes to pellet the insoluble material, before aliquoting the supernatant and storing at -
20°C.  
2.12.4 Protein Quantification 
The protein concentration of each sample was determined using a Coomassie 
protein reagent assay kit (Pierce cat# PN23236). Samples were diluted 4:46 in dH2O and 
10µl was a liquoted in quadruplicates into a transparent 96-well flat bottomed plate. A seven 
point standard curve of 0-1mg/ml (0, 25, 125, 250, 500, 750 100µg/ml) BSA (Pierce Cat# 
PN23208) was included on each plate. 200µl of ambient temperature Coomassie reagent 
was added to each well and mixed gently by pipetting. The absorbance was then measured 
3T3-CD40L +  
CRC cells  
3.0x10
6
/dish   
3T3-Neo +  
CRC cells  
3.0x10
6
/dish/ 
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using a FLUOstar OPTIMA (BMG Labtech) plate reader at Abs 595nm against a dH2O 
Control. MARS analysis software 2.0 (BMG Labtech) was used to plot a standard curve for 
the BSA and to estimate the protein concentration for each lysate (Appendix III).  
2.10.5 SDS-Polyacrylamide gel Electrophoresis (SDS-PAGE) 
20-40µg of protein lysate was made up to 13µl with dH2O then this was totalled to 
20µl by the addition of 5µl 4x lithium dodecyl sulphate sample buffer (LDS; Invitrogen Cat# 
NP0007) and 2µl of 10x reducing agent (500mM Dithiothreitol) (Invitrogen Cat#NP0009). 
The sample was denatured by heating 10 minutes in a 70°C water bath. 10-well NuPAGETM 
Novex electrophoresis pre-cast gels (Invitrogen Cat# NP0321) were placed into an Xcell 
SurelockTM mini-cell upright electrophoresis tank (Invitrogen). 200ml and 600ml of 1x 
NuPAGETM MES SDS running buffer (Invitrogen Cat# NP0002) was poured into the inner 
and outer chambers, respectively. 200µl of NuPAGETM antioxidant (Invitrogen Cat # 
NP0005) was added to the inner chamber prior to loading of the samples. 5µl of All-Blue 
Precision Plus ProteinTM standard (Bio-Rad #161-0373) was loaded alongside the samples 
as a marker of protein size (Figure 2.7) and gel was run at 200V for 35 minutes. 
 
 
Figure 2. 7 Precision plus Protein standard  
All Blue standards are a mixture of ten blue-stained recombinant proteins (10–250 kD), including 
three reference bands (25, 50, and 75 kDa. 
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2.10.6 Electrophoretic membrane transfer 
Electrophoretically-seperated proteins were transferred onto Immobilon-FLTM 
polyvinylidine difluoride membrane (PVDF; Millipore) using an Xcell IITM blot module 
(Invitrogen). PVDF membranes were dipped in methanol, rinsed in dH2O and then soaked in 
0.5x ―Towbin‖ transfer buffer with 20% (v/v) methanol along with the required number of 
blotting pads and WhatmanTM filter paper (Fisher). The gel membrane sandwich was 
assembled cathode to anode as follows; 2x blot pads, filter paper, gel, PVDF membrane, 
filter paper and 2x blot pads (as shown in figure 2.7). The blot module was secured into the 
Xcell SureLockTM Mini-Cell and filled with transfer buffer. The outer chamber was filled with 
ice-cold dH2O and the transfers were performed on ice at 25V for 2 hours.  
A  B  
Figure 2. 8 A and B. Single sandwich and double sandwich.  
The diagram illustrates protein transfer during immunoblotting 
2.10.7 Membrane immunolabelling and visualisation using the Li-Cor Odyssey 
system 
To minimise non-specific binding, membranes were blocked in 50:50 (v/v) Odyssey 
blocking buffer (Li-Cor Cat# 927-4000):10mM TBS pH 7.6 at ambient temperature on a 
plate rocker for 1 hour. Membranes were then probed with 5-8ml of pre-titrated primary 
antibody diluted in TBS+0.1% (v/v) Tween-20. All primary antibody incubations were 
performed on a rocking platform overnight at 4°C. Membranes were then washed 3 x 5 
minutes in TBS+0.1% (v/v) Tween-20 prior to addition of 10ml appropriate infra-red 
secondary antibodies (Table 2-2) for 1 hour at ambient temperature on a rocker in. 
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Membranes were washed as for primary antibody and then washed 1x for 5 minutes with 
TBS prior to visualization using an OdysseyTM Infra-red Imaging system (Li-Cor). Where 
available, a positive control lysate known to express the protein of interest was included. 
Equal loading of epithelial lysate was verified using an antibody raised against the house 
keeping genes Cytokeratin 8 or 18 (or both, depending on the specificity of the antibody 
used). Densitometry was performed using Odyssey V3.1 software (Li-Cor) and protein 
expression was normalised relative to Cytokeratin 8/18, cytokeratin 8 and cytokeratin 18.  
2.11 Flowcytometry 
2.11.1 Background  
Flow cytometry is used to analyse the chemical and physical characteristics of 
particles a technology, and interestingly used in immunology to highlight and count 
molecules or dead or alive cells by making them pass through a laser. The particles move at 
high speed in the laser beam, and a computer analysis of their physical characteristics and 
their number. Using flow cytometry to study cell morphology is determined and used to 
highlight any cell defects. This technique uses widespread in haematology, oncology and 
immunology. 
2.11.2 Flow Cytometric Detection of CD40  
To detect CD40 receptor on CRC cell surface, one monolayer about 80-85% 
confluent cells was harvested from flask by trypsinisation, spin to collect the cells and 
suspended again with 5 ml of DR medium. The cells were counted by using 
haemocytometer, then 1x106 ,  cells were collected and re-suspended in 400µl of  Facs 
buffer  (1X  PBS/1% FBS). Then divided to four tubes 100µl was added to each tube; two 
for non-stain (NS), one for PE (Phycoerythrin) and one for CD40 antibody. 10 µl of diluted 
PE stain was added to the one tube used as negative control (diluted 1/10 in FACS buffer), 
and 15 µl of CD40 antibody (direct without dilution) added to the Ab tube to detect CD40, 
and the other two tubes without addition for non-stain (To detect live and death cells). Then 
all tubes incubated 25 minutes at 4ºC. All tubes were washed with 700µl of FACS buffer 
then centrifuged at 15 RPM for 5 minutes in 25ºC. Then 400µl of FACS buffer was added to 
each tube and all tubes mexed very well and read using flow cytometry, and data analysed 
by in Cyte 26 guava software (Millipore). 
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2.12 Separation of subcellular fractions for Western Blotting 
2.12.1 Nuclear fractionation 
In order to determine the localisation of certain proteins in response to CD40 ligation, 
the nuclei of cells were isolated using the Fisher Nuclear extraction kit (Fisher cat# 
PN78833) as instructed by the manufacturer. Nuclear pellets from co-cultures carried out in 
10cm2 dishes (3x106 3T3 cells and 3x106 epithelial cells) were lysed with the provided lysis 
buffer and were processed in the same manner as for normal cell lysates and 
immunoblotting (Section 2.12). The kit also allows the isolation of the Cytoplasmic proteins 
which are used to compare the localisation of proteins between the nucleus and cytoplasm. 
Nuclear fractions and cytoplasmic fractions of cell cultures were screened for the presence 
of CD40, which is cytoplasmic only, to validate separation of the two cellular compartments. 
The required primary and secondary antibodies were added and then membranes were 
scanned as normal for western blotting techniques. 
2.12.2 Mitochondrial fractionation  
Part of the intrinsic pathway that executes cell death involves release of Cytochrome 
C from the mitochondrial matrix. In order to examine this phenomenon the mitochondria 
were isolated from co-cultures performed in 10cm2 dishes (3x106 3T3 cells and 2.7x106 
epithelial cells) using a Dounce homogeniser (Fisher 11582443) and centrifugation as 
instructed by the manufacturers of the Millipore mitochondrial isolation kit (Cat # MT1000). 
Mitochondrial pellets were then lysed as instructed and processed the same way as for 
normal cell lysate and Western Blotting. The kit also allows the isolation of the Cytoplasmic 
proteins which are used to compare the localisation of proteins. Mitochondrial fractions of 
cell cultures were screened for the presence of Bcl-2 a protein located in the mitochondrial 
membrane and Cytochrome c a protein found within the mitochondrial matrix. Cytoplasmic 
fractions were also tested for Cytochrome C to determine any release and also for the 
cytoplasm-specific protein GAPDH. All antibodies for related proteins were supplied along 
with the kit along with recommended dilution factors. Appropriate primary and secondary 
antibodies were added and then membranes were scanned as normal for western blotting 
techniques.2.15 Mycoplasma testing Mycoplasma spp. contamination is a huge problem in 
eukaryotic cell culture and can lead to unreliable experimental results (Capes‐Davis et al., 
2010). All cell lines were routinely tested for intracellular bacteria Mycoplasma spp. using 
the MycoProbe™ Mycoplasma detection assay (R&D systems Cat # CUL001B) which is 
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designed for screening of cultured cells. This assay detects Mycoplasma 16S ribosomal 
RNA (rRNA) using a colorimetric signal amplification system with sensitivity comparable to 
PCR. The assay was performed as recommended by the manufacturer‘s instructions which 
involved sample preparation in 96 well plates, and an ELISA based detection of 16S 
Ribosomal RNA and signal detection at absorbance 492nm measured on a FLUOstar 
OPTIMA (BMG Labtech) plate reader. Results were compared to positive control samples 
that were included in the kit.  
 
2.13 Statistical analysis 
Data analysis was carried out using Excel® (Microsoft) and as the mean of all 
replicates (minimum 5-6), with error bars representing ± the standard error of mean 
(S.E.M.). Statistical analysis was performed using Minitab 15 statistical software. Two tailed, 
paired or unpaired t-tests were used to compare two sample means with levels of 
significance cited in the text. Comparisons were assumed to be biologically significant 
where P<0.05. 
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CHAPTER 3: Optimization of experimental techniques to 
investigate CD40-mediated apoptosis in CRC cells 
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3.1 Background 
CD40, a member of the tumour necrosis factor receptor (TNFR) family, is expressed 
in a variety of epithelial cells. Furthermore CD40 can be detected on endothelial cells, 
keratinocytes, smooth muscle cells, and fibroblast cells (Kooten and Banchereau, 1997, 
Schönbeck and Libby, 2001, van Kooten and Banchereau, 2000). Though its cognate ligand 
CD40L, which also is known as CD154, is mainly expressed on activated T-cells, it can also 
be found on basophils, eosinophils, monocytes, macrophages, dendritic cells, neutral killer 
cells, B lymphocytes, platelets, mast cells, endothelial cells, smooth muscle cells and in 
some cases epithelial cells (Schönbeck and Libby, 2001). 
Previous studies have reported that CD40 engagement by CD40 agonists has the 
potential to regulate tumour cell growth (Eliopoulos and Young, 2004, Tong and Stone, 
2003). Although a number of studies have shown that soluble CD40 agonists can induce 
growth inhibition in carcinoma cells of various origins (as reviewed by (Vonderheide, 2007, 
Tong and Stone, 2003), these agonists are mainly growth inhibitory or weakly pro-apoptotic 
and only become significantly pro-apoptotic by pharmacological intervention (Hess and 
Engelmann, 1996, Afford et al., 2001, Ahmed-Choudhury et al., 2003, Bugajska et al., 
2002). By contrast, previous work in our laboratory has demonstrated that unlike soluble 
agonists (soluble trimeric CD40L or agonistic anti-CD40 antibody) which are weakly pro-
apoptotic (Bugajska 2002; Georgopoulos 2007), membrane-presented CD40L is a highly 
pro-apoptotic signal (Shaw et al 2005; Georgopoulos et al 2006; Georgopoulos et al 2007; 
Hill et all 2008) that induces extesnive apoptosis in malignant cells but not their normal 
epithelial counterparts (Bugajska 2002; Shaw et al 2005).  
In order to achieve CD40 ligation by membrane CD40 ligand (mCD40L), epithelial 
(target) cells are co-cultured with third-party (effector) cells engineered to express 
membrane CD40L. At the beginning of this research, and following the move of the 
Georgopoulos laboratory to Huddersfield University, it was essential to ensure the 
reproducibility of the co-culture system and to establish and optimise a series of 
experimental techniques for the detection of apoptosis for use with this co-culture system, 
that would permit accurate and reliable detection and quantification of mCD40L-mediated 
apoptosis based primarily on 96-well plate format assays. In addition, optimisation of 
immunoblotting techniques for use in the co-culture system for CRC cells was equally 
essential. 
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3.2 Co-culture model for CD40 ligation by mCD40L 
For the ligation of CD40 on target cells, a membrane CD40 ligand signal was 
delivered by their co-culture with pharmacologically growth-arrested effector cells (See 
section 2.10). The effector cells (killer cells) are murine fibroblasts (NIH3T3) that have been 
genetically manipulated to express membrane CD40L (Bugajska et al., 2002). Throughout 
this thesls effector cells displaying CD40L on their membrane were termed ―γTγCD40L‖ 
cells. To ensure that 3T3CD40L cells retained CD40L expression (due to possible culture-
related genetic drift) continuous culture in the presence of G418 antibiotic (0.5mg/ml)  was 
performed, as a neomycin resistance gene was co-transfected as part of the CD40L gene 
expression construct. Homologous NIH3T3 cells with a gene cassette conferring G418 
resistance only were used as negative (background) controls and therefore from this point 
will be termed ―γTγNeo‖ cells throughout this study.  
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3.3 Objectives 
The objectives of this chapter were: 
- To demonstrate the expression of CD40 ligand by the effector (killer) cells and expression 
of CD40 receptor on the target cells (CRC cells) employed in this study for use in the co-
culture system.  
- To use this in vitro co-culture system and optimise its use for a variety of experimental 
techniques for the detection of mCD40L-mediated apoptosis in colorectal cancer (CRC) 
- To perform optimisation of immunoblotting techniques for epithelial cell protein detection 
using the co-culture system.  
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3.4 Confirmation of CD40 and CD40L expression 
For the purpose of performing co-cultures as described above, it was essential to 
ensure that effector and target CRC cells expressed CD40L and CD40, respectively. CD40 
on CRC cells lines and CD40L on 3T3 fibroblasts were detected by Western blotting. This 
study confirmed CD40 was expressed on CRC cells HCT116. SW480 cells are CD40-
negative in agreement with previous findings (Georgopoulos 2007), however retrovirus-
transduced derivatives expressing de novo CD40 as previously described were CD40-
positive (Figure 3.1), as was the positive control UCC line EJ as previously (Bugaska 2002; 
Georgopoulos 2007; Hill 2008). CD40 expression on these cells was also confirmed by flow 
cytometry, as shown in Figure 3.2.  
CD40L expression on 3T3 fibroblasts (3T3Neo and 3T3CD40L) was detected by 
western blotting. CD40L was detected in 3T3CD40L cells, while 3T3Neo showed no 
detectable of CD40L expression as shown in Figure 3.3.  
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             Figure 3. 1 Expression of CD40 detected by Western blotting 
Western blot analysis for CD40 expression in CRC cells (HCT116, SW480 and SW480-CD40 
cells) as well as the UCC line EJ). Total amount of protein loading was 20µg/well. The 
membranes were incubated with primary antibody (CD40 H-10 mouse monoclonal IgG 
diluted 1:500). Secondary antibody used was goat-anti mouse IgG, Alexa 680 dilution 
1:10000. ȕ-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody diluted at 1:50000 and secondary antibody goat-anti mouse 
IgG Alexa 680 diluted 1:10000. Membranes were scanned on Licor Odyssey Infra-Red 
Imaging System and images are shown in black and white. 
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Figure 3. 2 Flow cytometric analysis of CD40 expression  
Expression of CD40 receptor on the cell surface of CRC and EJ cells was detected by flow cytometry 
(section 1.12). Cells were cultured till approximately 80% confluent and were harvested by 
trypsinisation. Cells were counted and adjusted at 0.25 x106 cells/100µl of FACS buffer. Cells were 
incubated with PE-conjugated mouse anti-human CD40, and a control PE-conjugated isotype-
matched contorl Ab was also used. Cells were acquired on a Guava EasyCyte flow cytometer and 
results analysed using GuavaSoft software. A and B overlay histograms show SW480-CD40 and 
HCT116, which are positive for CD40 expression. C histogram show SW480 negative control cells for 
CD40 expression whereas, EJ cells in histogram D represent a positive control for CD40 expression. 
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Figure 3. 3 Expression of membrane CD40 ligand (mCD40L) on 3T3 effector cells by western 
blotting 
Western blot analysis for CD40L expression in 3T3s (3T3-Neo and 3T3CD40L). Total amount of 
protein loading was 20µg/well. The membranes were incubated with primary antibody (CD40 
ligand/TNFSFS antibody monoclonal Anti human was diluted 1:500). Secondary antibody used was 
donkey-anti goat IgG, Alexa 680 dilution 1:10000. ȕ-actin (AC-15-A5441) was used as specificity and 
loading control, the membrane was incubated with the antibody diluted at 1:50000 and secondary 
antibody goat-anti mouse IgG Alexa 680 diluted 1:10000. Membranes were scanned on Licor 
Odyssey Infra-Red Imaging System and images are shown in black and white. 
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3.5 Optimisation of experimental techniques (apoptosis assays) for 
the detection of mCD40L-mediated cell death 
According to previously published guidelines regarding the use and understanding of 
assays for detecting cell death (Galluzzi et al., 2009), it is recommended that at least two 
independent assays are used for the detection and demonstration of of apoptotic cell death. 
Moreover, previous studies into CD40-mediated apoptosis by the Georgopoulos group 
(Georgopoulos et al., 2007, Bugajska et al., 2002, Georgopoulos et al., 2006, Shaw et al., 
2005, Hill et al., 2008b) generally have used assays that a) involved use of radioactive 
precursors (such as the JAM test of DNA fragmentation, b) did not permit high-throughput 
96-well plate-based analysis (Annexin V/PI), and c) were not very sensitive (thus had a 
short linear dynamic range).  
Therefore, one of the aims of this study was to employ assays that would address these 
issues and weaknesses. The apoptosis assays optimised for the detection of CD40-
mediated cell death in this study were mainly the commercially available CytoTox-Glo 
cytotoxicity assay and the Sensolyte Homogenous Caspase3/7 assay (Materials and 
Methods). In addition, the DNA fragmentation ELISA assay assay was also investigated for 
its efficacy and practicality in this study.  
3.5.1 Detection of mCD40L-induced apoptosis using the CytoTox-Glo assay 
3.5.1.1 Optimization of apoptosis assays – detection of cell death and 
determination of optimal cell densities for the detection of CD40-mediated 
apoptosis 
The CytoTox-Glo assay was tested for its ability to detect CD40-mediated apoptosis 
using the co-culture system. Co-cultures were carried out and the assay was performed as 
detailed in Section 2.10. An important consideration for these experiments was that the 
CytoTox-Glo assay does not distinguish specifically between dead epithelial cells and 
effector (3T3CD40L and 3T3Neo) cells during co-culture. In order to account for background 
RLU attributable to 3T3CD40L and 3T3Neo cells, in addition to experimental replicates that 
contained co-cultured cell populations, 3T3CD40L and 3T3Neo cultures alone were 
included, and their luminescence measured following substrate addition. Therefore, pair-
wise subtraction of background readings was performed for each type of co-culture. 
3T3CD40L alone readings were subtracted from the appropriate co-culture RLU; e.g. 
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[(3T3CD40L/HCT116 – 3T3CD40L)] allowing the deduction of background-corrected RLU. 
For the control (3T3Neo) was treated in the same way to calculate the background 
corrected RLU, i.e.. [(3T3Neo/HCT116 – 3T3Neo)].  
It has been demonstrated previously by our group that CD40 ligation by membrane 
CD40L can induce apoptosis in carcinoma cells particularly in colorectal cancer cells 
(Georgopoulos 2007). In this study, different CRC cell numbers were used to optimise cell 
death via CD40 ligation. The target cells were co-cultured by seeding onto fibroblasts in 
white plates at different densities (8x103, 1x104, and 1.2x104 cells/well) with 3T3CD40L and 
3T3Neo. As mentioned in the Materials and Methods chapter 3T3s cell were treated with 
mitomycin C (MMC) to avoid artifacts of cell overgrowth; they were initially seeded at 1x104 
cells/well as previously determined (Georgopoulos et al., 2006, Georgopoulos et al., 2007). 
In this study, co-culture with 3T3CD40L resulted in high levels of death in HCT116 cells with 
1x104 cells/well, whilst lower level of death was detected with others (8x103 and 1.2x104 
cells/well), as shown in figure 3.4 where results are presented as background corrected 
RLU (A) and also presented as fold change (B).  
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Figure 3. 4 Optimization of apoptosis assay using different cell number of target cells for 
detection of CD40-mediated apoptosis 
1x104 cells/well of mouse fibroblast (3T3Neo and 3T3CD40L) were co-cultured in 96 well white plates 
with colorectal cancer cells (HCT116) seeded at different number of cells 8x103, 1x104 and 1.2x104 in 
DR medium supplemented with 5% FCS and 1% L-glutamine. Plates were incubated for 24 hours at 
37ºC/5% CO2. 50µl of CytoTox-Glo substrate were added and then plates were incubated 15 minutes 
and luminescence was measured by a FLUOStar Optima plate reader and background-corrected 
RLU readings deduced as described in the Materials and methods. Bars correspond to mean values 
of 4-6 replicates ± SD, ***p-value ≤0.001/**p-value ≤0.01. A) Background corrected RLU readings of 
CytoTox-Glo for HCT116/3T3CD4L and HCT116/3T3Neo. B) Fold change against control of 
background corrected RLU readings of CytoTox-Glo for HCT116.   
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3.5.1.2 CD40 ligation by mCD40L for 24 hours causes extensive CRC cell 
apoptosis 
Whilst performing further explorative experiments, it became apparent that the 
CytoTox-Glo assay was extremely sensitive and that background RLU arising from low level 
spontaneous in vitro cell death of target (epithelial) cells was significantly interfering with 
assay sensitivity. To reduce such ‗noise‘, it was ensured that target cells were harvested 
only during their log phase of growth. This use of ‗healthier‘ epithelial cells led to significant 
reductions in background RLU and allowed the cell apoptosis induced by 3T3CD40L 
(mCD40L) to be better detected (not shown).  
Another important consideration related to the effector 3T3 cells (3T3CD40L and 
3T3Neo). As these cells were treated with Mitomycin C to induce growth arrest, it was 
essential to ensure that this was efficient and they showed non-mitotic properties whilst 
remaining metabolically active (See section 2.10). If this treatment was insufficient, it could 
result in the continued growth of effector cells and such culture overgrowth, increased levels 
of spontaneous death and would interfer with the assay output. It was found that cell cycle 
arrest in combination with minimal cell toxicity was best achieved when 3T3CD40L or 
3T3Neo cells were MMC treated during their log phase of growth and at approximately 50% 
confluency (data not shown). 
Collectively, incorporation of these modifications and improvements in the 
experimental methodologies, led to a dramatic improvement in the results obtained using 
this assay, in comparison to earlier findings. Following these improvements. the results 
obtained following  background correction of relative luminescence unite (RLU) revealed a 
high level of death in both HCT116 and SW480-CD40 as shown in Figure 3.5 a and b. In 
addition, results are shown as fold change (from raw RLU data in Figure 3.5) by comparing 
3T3CD40L/HCT116 or 3T3CD40L/SW480-CD40 versus 3T3Neo/HCT116 or 
3T3Neo/SW480-CD40 co-cultures shown in Figure 3.6.  
Georgopoulos and colleagues have previously demonstarted mCD40L-mediated 
apoptosis in bladder carcinoma (EJ) and colorectal cancer cells (HCT116 and Colo320) 
(Georgopoulos et al., 2007, Georgopoulos et al., 2006, Bugajska et al., 2002) by also using 
Annexin V/PI and flow cytometry to demonstrate that maximal CD40-induced apoptosis 
occurred approximately 72 hours post CD40 ligation. Annexin V/PI is based on the detection 
of % cell apoptosis relying on the translocation of phosphatidylserine to the cell membrane, 
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while CytoTox-Glo depends on the exposure of substrate to a protease released during the 
loss of cell membrane integrity as shown previsouly in section 2.9.4 figure 2.4. Whilst both 
events (phosphatidylserine translocation and disruption of membrane integrity) are integral 
to apoptosis, it was important to determine the optimal time-point post CD40 ligation to 
perform CytoTox-Glo assays and whether perhaps an earlier time point might be more 
suitable. Although apoptosis by the Cytotox Glo assay was still detectable at 48 (or even 72) 
hours (data not shown), in this study results showed that mCD40L resulted in rapid cell 
death detected optimally at 24 hours post-ligation.  
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Figure 3. 5 mCD40L mediated apoptosis detection using CytoTox-Glo 
1x104 CRC cells (HCT116 and SW480-CD40) were co-cultured with 1x104 MMC-treated mouse 
fibroblast cells 3T3CD40L (mCD40L) or 3T3Neo (Control) in DR medium supplemented with 5% FCS 
and 1%LG in white 96-well plates. 50µl CytoTox-Glo substrate was added after 24 hours incubation 
at 37ºC/5% CO2. After 15 minutes incubation at room temperature, luminescence was measured by 
plate reader and background-corrected. RLU readings deduced as described in material and 
methods. Bars correspond to mean values of 4-6 replicates ± SD, ***p-value<0.001. The figure 
shows background corrected RLU readings of CytoTox-Glo for HCT116/mCD4L and 
HCT116/Control, and the background corrected RLU readings of CytoTox-Glo for SW480-CD40. 
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Figure 3. 6 Detection of mCD40L-mediated apoptosis by Cytotox Glo (expressed as fold 
change against control). 
Results from Figure 3.5 are presented as fold increase for 3T3CD40L co-cultures in comparison to 
controls (3T3Neo).  
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3.5.1.3 Determination of percentage of cell death 
In addition to using the detection of luminescence by the CytoTox-Glo assay as a 
surrogate marker of apoptosis, the assay may also be used to determine the percentage of 
apoptosis. When percentage of cell death was calculated (as detailed in Section 2.9.4) it 
was found that in line with previous results by our group (Georgopoulos et al., 2006, 
Georgopoulos et al., 2007) mCD40L results in approximately 75-85% cell death, which 
corresponds to a fold change of ~2.5-3.0 (Figure 3.7).  
Membrane-CD40L can stimulate apoptosis in malignant cells (Bugajska et al., 2002, 
Georgopoulos et al., 2007, Georgopoulos et al., 2006)  Previous studies by Georgopoulos et 
al have been reported that co-culture of urothelial carcinoma cells (UCC) with membrane-
CD40L resulted in at least 60-70% apoptosis of the tumor cells at 48-72hrs as detected 
using Annexin V-FITC/PI and flow cytometry (Georgopoulos et al., 2006). In the present 
study, co-culture of SW480-CD40 with 3T3CD40L resulted in ~84.50% death for 
3T3CD40L/HCT116 compared with control 35.74% as shown in figure 3.7a. As for the other 
cell line SW480-CD40,  the precentage of cell death was 76.48% compared with control 
33.83% as shown in figure 3.7b. For these experiments the Cyto Tox-Glo asses was used 
and percentage of death was calculated as described in the Materials and methods.  
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Figure 3. 7 Percentage of mCD40L-mediated cell death (based on the Cytotox Glo assay) 
1x104 colorectal cancer cells (HCT116 and SW480-CD40) were co-cultured with 1x104 MMC treated 
3T3CD40L (mCD40L) and 3T3Neo (control) in white 96 well plates in DR medium supplemented with 
5% FBS and 1%  L-glutamine. After 24 hours of co-culture, CytoTox-Glo test was used to detect 
apoptosis in colorectal cancer cells (HCT116) as described in chapter 2 (Materials and Methods). 
Percentage cell death was calculated for A) HCT116 co-cultures and B) SW480-CD40 co-cultures at 
24 hours post-ligation.  Bars correspond to mean values of 4-6 replicates ± SD, ***p-value ≤0.001. 
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3.5.2 Detection of apoptotic cell death using the SensoLyte caspase-3/7 assay 
For optimisation of the caspase detection assay, staurosporine was used as a 
positive control. Staurosporine is a DMSO soluble compound derived from Streptomyces 
Staurosporeus that inhibits a range of protein kinases essential for normal cell function. 
Staurosporine is often used as a positive control to induce apoptosis by the intrinsic 
pathway via MOMP and caspase-3/7 activation, as previously described by our group 
(Chopra et al., 2009) and others (Zhang et al., 2004). As shown in HCT116 cells treated 
with staurosporine, the compound caused the activation of caspase-3/7 activity in a dose-
dependent manner (see appendix IV).  
Most recent studies indicate that caspases 3 and 7 have some overlapping, but also 
some distinct roles in programmed cell death (apoptosis), which includes the extrinsic and 
intrinsic (mitochondrial) pathway (Lakhani et al., 2006). Caspase 3 has an important role in 
driving DNA fragmentation and morphological changes of apoptosis, while caspase 7 plays a 
minor role in these possesses (Lakhani et al., 2006). In this study we measured the caspase 
3/7 activity in colorectal carcinoma cells after co-culture for 24, 48, and 72 hours. The results 
demonstrated that interaction between mCD40L (3T3-CD40L) and the target cells HCT116 
and SW480-CD40 induced caspase 3/7 activity in CRC cells (see below). For the analysis of 
results from these assays, the same principle, as in the CytoTox-Glo assays (Section 3.4.1), 
was employed, which involved a) appropriate calculations for background 3T3 cell-related 
readings and b) the optimisation of target cell ‗health‘ and effector cell MMC treatment 
(Section 3.4.1.1 & 3.4.1.2).  
Georgopoulos et al (2006) had previously shown using FAM FLICA caspase 
detection assays and flow cytometry that Caspase-3 becomes active within 48 hours post 
CD40 ligation, which also coincided with the detection of DNA fragmentation (Georgopoulos 
et al., 2006), a direct downstream consequence of caspase activation during apoptosis. In 
this study the detection of caspase 3/7 activity was carried out at 24, 48 and 72 hours post 
ligation in 3T3CD40L/HCT116 or 3T3CD40L/SW480-CD40 co-cultures compared with 
3T3Neo/HCT116 or 3T3Neo/SW480-CD40 ones. At 24 hours post CD40 ligation only little 
caspase 3/7 activity could be detected (Figure 3.8). However, by 48 hours there was a 
marked increase in caspase activity (Figure 3.9) which was sustained at even slightly higher 
levels even at 72 hours of co-culture (Figure 3.10), with an approximately 2.5-3.5 fold 
increase consistently detectable.  
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Figure 3. 8 Detection of CD40-induced caspase 3/7 activation after 24hours post-ligation 
1x104cells/well colorectal carcinoma cells (HCT116 and SW480-CD40) were co-cultured with 1x104 
cells/well of mouse fibroblasts (3T3CD40L and 3T3Neo) in 96 well plates in DR medium 
supplemented with 5% FCS and 1% L-glutamine. Plates were incubated for 24 hours at 37ºC/5% 
CO2. 50µl substrate of the Anaspec assay was added to each well and then plates were incubated 60 
minutes in the dark and fluorescence was measured and background-corrected RFU (Relative 
Fluorescence Units) calculated as described in the Materials and methods. Bars correspond to mean 
values of 4-6 replicates ± SD ***p-value ≤0.001. A) Background corrected RFU readings of caspase 
3/7 activity for HCT116 and SW480-CD40/3T3CD4L and HCT116 and SW480-CD40/3T3Neo. B) 
Fold change against control was calculated by using background corrected RFU readings of caspase 
3/7 activity for HCT116 and SW480-CD40.  
0
2000
4000
6000
8000
10000
mCD40L Control mCD40L Control
HCT116 SW480-CD40
R
F
U
 
A 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
HCT116 SW480-CD40
F
o
ld
 c
h
a
n
g
e
 a
g
a
in
st
 c
o
n
tr
o
l 
B 
  
129 
 
 
 
Figure 3. 9 Detection of CD40 induced caspase 3/7 activation after 48hours co-culture 
1x104cells/well colorectal carcinoma cells (HCT116 and SW480-CD40) were co-cultured with 1x104 
cells/well of mouse fibroblasts (3T3CD40L and 3T3Neo) in 96 well plates in DR medium 
supplemented with 5% FCS and 1% LG. Plates were incubated for 48 hours at 37ºC/5% CO2. 50µl 
substrate of the Anaspec assay was added to each well and then plates were incubated 60 minutes 
in the dark and fluorescence was measured and background-corrected RFU (Relative Fluorescence 
Units) calculated as described in the Materials and methods. Bars correspond to mean values of 4-6 
replicates ± SD ***p-value ≤0.001. A) Background corrected RFU readings of caspase γ/7 activity for 
HCT116 and SW480-CD40/3T3CD4L and HCT116 and SW480-CD40/3T3Neo. B) Fold change 
against control was calculated by using background corrected RFU readings of caspase 3/7 activity 
for HCT116 and SW480-CD40.  
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Figure 3. 10 Detection of CD40 induced caspase 3/7 activation after 72hours co-culture 
1x104cells/well colorectal carcinoma cells (HCT116 and SW480-CD40) were co-cultured with 1x104 
cells/well of mouse fibroblasts (3T3CD40L and 3T3Neo) in 96 well plates in DR medium 
supplemented with 5% FCS and 1% LG. Plates were incubated for 72 hours at 37ºC/5% CO2. 50µl 
substrate of the Anaspec assay was added to each well and then plates were incubated 60 minutes 
in the dark and fluorescence was measured and background-corrected RFU (Relative Fluorescence 
Units) calculated as described in the Materials and methods. Bars correspond to mean values of 4-6 
replicates ± SD ***p-value ≤0.001. A) Background corrected RFU readings of caspase γ/7 activity for 
HCT116 and SW480-CD40/3T3CD4L and HCT116 and SW480-CD40/3T3Neo. B) Fold change 
against control was calculated by using background corrected RFU readings of caspase 3/7 activity 
for HCT116 and SW480-CD40.  
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3.5.3 DNA fragmentation detection following CD40 ligation by mCD40L in CRC 
cells 
  
Previous studies have demonstrated that membrane-CD40L can induce extensive 
cell death in CRC cells (60-70%) which were confirmed in this study. In addition to the 
detection of apoptosis by Cytotox-Glo (as a surrogate marker of loss of membrane integrity) 
and SensoLyte/Anaspec (for the detection of caspase activity), cell death (apoptosis) was 
also measured by means of a DNA fragmentation ELISA assay (see section 2.9.5). Results 
obtained from such experiments indicated that a high level (and high percentage) of death 
based on DNA fragmentation was observed in HCT116 cells (80% compared with 35.5% for 
controls) (Figure 3.11a/b), similar to results for SW480-CD40 cells (83.70% in comparison to 
33.50% for controls) (Figure. 3.12a/b).  
Although the DNA fragmentation assay used is a reliable, well characterised method 
to assess cell death (Bugajska et al., 2002, Georgopoulos et al., 2006, Shaw et al., 2005), it 
detects only one of the hallmarks of apoptosis. Moreover, apoptosis activated by members 
of the TNFR superfamily is not always accompanied by DNA fragmentation, as previous 
studies have demonstrated in colorectal cells by other groups (Wilson and Browning, 2002) 
and in bladder cancer cells in our laboratory (Steele et al., 2006). More importantly, for this 
work, although the DNA fragmantation test gave similar results to the CytoTox-Glo assay, it 
was however less cost-effective, and though reliable, was particularly laborious in 
comparison to the other assays. Therefore, for the majority of apoptosis detection 
experiments carried out in this work (following chapters), the Cytotox-Glo and 
SensoLyte/caspase-detection assays were mainly used (and confirmation using DNA 
fragmentation performed where appropriate).  
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Figure 3. 11 DNA fragmentation assay for the detection of apoptosis in HCT116 cells mediated 
by mCD40L 
1X104 BrdU labeled CRC cells (HCT116) was co-cultured with 1x104/well 3T3CD40L (mCD40L) or 
3T3Neo (Control) (5µM staurosporine was used as positive control for cells alone). Absorbance (455-
10nm) was measured by a plate reader and percentage was calculated as described in Chapter 2 
(Materials and Methods). Data are represented means ± S.D for two to three experiments. ***P 
≤0.001 DNA fragmentation of co-cultures of CRC cells with 3T3CD40L was statistically significantly 
higher (in comparison to controls) in all cell lines. Raw data are presented in A and percentage cell 
death in B (calculated as described in the Materials and Methods).  
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 Figure 3. 12 DNA fragmentation assay for detection of apoptosis in SW480-CD40 cells 
mediated by mCD40L 
1X104 BrdU labeled CRC cells (SW480-CD40) was co-cultured with 1x104/well 3T3CD40L (mCD40L) 
or 3T3Neo (Control) (5µM staurosporine was used as positive control for cells alone). Absorbance 
(455-10nm) was measured by a plate reader and percentage was calculated as described in Chapter 
2 (Materials and Methods). Data are represented means ± S.D for two to three experiments. ***P 
≤0.001 DNA fragmentation of co-cultures of CRC cells with 3T3CD40L was statistically significantly 
higher (in comparison to controls) in all cell lines. Raw data are presented in A and percentage cell 
death in B (calculated as described in the Materials and Methods).  
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3.6 Optimisation of immunoblotting (Western blotting) for protein 
detection using co-cultures   
 
As described previously for urothelial cell-3T3 fibroblast co-cultures (Georgopoulos 
et al 2006), preparation of whole cell lysates from co-cultures and performing Western 
blotting poses a challenge, as the lysate contains a mixture of proteins from both effectors 
(fibroblasts) and target (epithelial) cells. For this purpose, and as detailed previously 
(Georgopoulos et al 2006), expression of epithelial-specific markers (cytokeratins) has been 
employed to ensure equal loading based on cytokeratin (CK) expression.   
Routine immunoblotting experiments that were performed to detect CK expression 
showed that CRC cell lines HCT116 and SW480-CD40 undergo rapid and extensive 
apoptosis, evident by the progressive loss of epithelial lysate in co-culture protein extracts 
(indicated by the reduction in expression of epithelial marker Cytokeratin CK8, 18, and 8/18 
within less than 12 hours post-CD40 ligation, with severe loss of CK8 and CK8/18 observed 
by 24 hours as shown in Figures 3.13 and 3.14, respectively. Moreover, it was clear that as 
3T3Neo co-cultures progressed, there was a progressive increase in epithelial lysate in 
such control cultures. Therefore, it was essential to ensure that equal loading could be 
achieved for both 3T3Neo and 3T3CD40L co-cultures. For this purpose, densitometric 
analysis (using LiCor Odyssey Infra-Red imaging software) was carried out for all prepared 
lysates from such co-cultures. This allowed the correction (following cytokeratin band 
intensity-based normalisation) of gel loading for all subsequent experiments. As shown in 
Figures 3.15a and 3.15b, equal expression of CK in HCT116 and SW480-CD40 co-cultures 
was achieved.  
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Figure 3. 13 Detection of protein expression based on CK8 in CRC cells following co-culture   
Western blot analysis of cytokeratin 8 expression in CRC cells (SW480-CD40 and HCT116) after 
incubation with 3T3 Neo and 3T3CD40L. Total amount of protein was loaded was 20µg/well. The 
membranes were incubated with primary cytokeratin 8 monoclonal mouse monoclonal IgG (diluted 
1:1000) and secondary antibody goat-anti mouse IgG, Alexa 680 (dilution 1:10000). ȕ-actin AC-15-
A5441 was used as specificity and loading control, membranes were incubated with primary 
monoclonal antibody (diluted 1:20000) and secondary antibody goat-anti mouse IgG Alexa 680 
(diluted 1:10000). The membranes were scanned and images shown in black and white. 
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Figure 3. 14 Detection of protein expression based on CK8/18 in CRC cells following co-
culture 
Western blot analysis of cytokeratin 8 and 18 expression in CRC cells (SW480-CD40 and HCT116) 
after incubation with 3T3 Neo and 3T3CD40L. Total amount of protein was loaded was 20µg/well. 
The membranes were incubated with primary cytokeratin 8/18 for HCT116 and CK18 of SW480-
CD40 monoclonal mouse monoclonal IgG (diluted 1:1000) and secondary antibody goat-anti mouse 
IgG, Alexa 680 (dilution 1:10000). ȕ-actin AC-15-A5441 was used as specificity and loading control, 
membranes were incubated with primary monoclonal antibody (diluted 1:20000) and secondary 
antibody goat-anti mouse IgG Alexa 680 (diluted 1:10000). The membranes were scanned and 
images shown in black and white. 
Keys: N: 3T3Neo                                                L: 3T3CD40L                                       S: SW480-CD40 
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Figure 3. 15  Detection of 8 and CK18 after normelise the amount of protein expression in CRC 
cells  
Western blot analysis of cytokeratin 8 and 18 expression in CRC cells (SW480-CD40 and HCT116) 
after incubation with 3T3 Neo and 3T3CD40L. Amount of normalize lysates were loaded was 
20µg/well following correction by using densitometry of the band of cytokeratin in CRC cells before 
correction. The membranes were incubated with primary cytokeratin 8 for HCT116 and CK18 of 
SW480-CD40 monoclonal mouse monoclonal IgG (diluted 1:1000) and secondary antibody goat-anti 
mouse IgG, Alexa 680 (dilution 1:10000). ȕ-actin was used as specificity and loading control, 
membranes were incubated with primary monoclonal antibody (diluted 1:20000) and secondary 
antibody goat-anti mouse IgG Alexa 680 (diluted 1:10000). The membranes were scanned and 
images shown in black and white. An A and B show the equal loading of CK8 and CK18 for both 
HCT116 and SW480-CD40. 
Keys:  NH: 3T3Neo co-cultured with HCT116                 LH: 3T3CD40L cocultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40         LS: 3T3CD40L cocultured with SW480-CD40 
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3.7 Summary: 
 The main objective of this chapter was to confirm that the fidelity of co-culture 
system for stimulation of CD40 in CRC cells in vitro and establish a number of cell 
cytotoxicity and caspase activity detection assays.    Two main death assays were used for the detection of mCD40L-mediated 
death:   The CytoTox-Glo assay to detect loss of cell membrane integrity and 
subsequent apoptosis   The Sensolyte Homogenous caspase-3/7 assay to detect caspase 3/7 
activity in apoptotic cells.  The DNA fragmentation test was also used to detect cell death and 
provide an additional confirmatory assay.  The results have confirmed that CRC (target) cells expressed CD40 by western 
blotting; this was also confirmed by using Flow cytometry.   Immunoblotting also confirmed that 3T3CD40L cells (killer/effector cells) expressed 
CD40 ligand compared with 3T3Neo, which were used as a negative isogenic 
control.     The results indicated for the first time that CD40-mediated CRC cell death 
happened very rapidly (within less than 24 hours post CD40 ligation, approximately 
between 6 and 12 hours post ligation).  
 Routine immunoblotting experiments performed to detect cytokeratin (CK) 
expression also provided indirect evidence that CD40+ve CRC cell lines undergo 
rapid and extensive apoptosis evident by the progressive loss of epithelial lysate in 
co-culture protein extracts. In particular, the results demonstrated rapid and 
extensive loss of CK8 and CK8/18 observed at 12 and even more at 24 hours in 
CRC cells. 
 Densitometric analysis, normalisation and subsequent lysate loading correction to 
confirm equal amount of CRC cells protein (based on CK8 or CK18 band intensity) 
permitted the establishment of the appropriate methodologies in order to follow 
CD40-mediated signalling in CRC cells.  
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CHAPTER 4: Investigation into the activation and 
functional involvement of key intracellular mediators in 
CD40-mediated apoptosis in CRC cells 
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4.1 Objectives  
The specific aims of this chapter were: 
 To optimise immunoblotting methods for the correct and sensitive detection of 
intracellular proteins associated with CD40-mediated apoptosis. 
  To perform retrovirus-mediated transduction of CRC cell lines and optimise the 
selection of carcinoma cells expressing virally-transduced shRNAs for RNAi-
mediated protein knockdown. 
  To utilize RNAi, immunoblotting and cell death assays to determine the functional 
role of key intracellular mediators, for instance whether TRAF3 regulates a) JNK 
phosphorylation, b) Bak and Bax induction and c) CD40-mediated apoptosis overall. 
  To employ specific pharmacological inhibitors to determine whether JNK/p38 
regulate a) Bak and Bax expression and b) CD40-mediated apoptosis. 
  To delineate the precise nature of the molecular pathways of cell death through  
o a) RNAi-mediated reduction of Bax, immunoblotting and cell death assays, 
and  
o b) loss of mitochondrial membrane permeability by cell fractionation 
(cytoplasm and mitochondria). 
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4.2 Expression of TRAF -1, -3 and -6 following CD40 ligation in CRC 
cells 
The mechanisms of CD40 signalling, particularly the role of TRAF adaptor 
molecules, have been mainly studied in the context of CD40-mediated B cell activation 
(Bishop, 2004); however, a lot less is known with regards to CD40 signalling in epithelial 
cells. In fact, relatively little is known in terms of the role of the TRAFs as proximal signalling 
activators in non-lymphoid cells at all. Depending on the cell context, the TRAFs orchestrate 
a diverse range of cell responses such as proliferation, differentiation or apoptosis (Bishop, 
2004).  
Despite the ability of CD40 to induce extensive and rapid apoptosis in CRC cells, as 
shown previously (Georgopoulos et al., 2007, Hill et al., 2008a) and extensively 
characterised in this thesis using multiple assays, no investigations have so far examined 
which of the TRAFs may be regulated by CD40 and play a functional role in apoptosis. It 
has been previously demonstrated in urothelial carcinoma cells lines (UCC) lines that CD40 
ligation by mCD40L (but not soluble agonists) specifically promotes the expression of 
TRAF1, TRAF2 and TRAF3 (Georgopoulos et al., 2006), but how mCD40L triggers CD40 
TRAF signalling in CRC cells, remain unexplored. Of note, due to the inability of soluble 
agonists (e.g. agonistic antibody G28-5) to induce any apoptosis in CRC cells 
(Georgopoulos et al., 2007, Hill et al., 2008a), this project focused on ligation of CD40 by 
membrane ligand (mCD40L).  
This study screened only for TRAFs which have been implicated in CD40 
signalling. To do so, CRC cell lines were co-cultured with control and mCD40L expressing 
effector cells and TRAF adaptor protein expression was investigated by immunoblotting 
using human specific antibodies. Following co-culture with mCD40L-effectors, both 
HCT116 and SW480-CD40 CRC cell lines showed rapid and dramatic increases in TRAF1 
expression after 6, 12 and 24 hours compared with co-culture with the control cells as 
shown in Figure 4.1. Immunoblotting also showed the induction of TRAF3, which was 
markedly and rapidly increased as early as 1.5 hour, with further increases at 3, 6, 12 and 
maximal expression occurring 24 hours post CD40 ligation in both HCT116 and SW480-
CD40 as shown in Figure 4.2.  Interestingly, there was also rapid but very transient 
induction of TRAF6 expression with high expression levels observed after 1.5 hours in 
HCT116 cells but the expression disappeared at 3, 6, and 24 hours.  
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Similar trends of TRAF expression were observed in the transduced SW480-CD40 
cells. In fact, there was a near identical pattern of TRAF1 (Figure 4.1) and TRAF3 (Figure 
4.2) regulation to that observed in HCT116 cells. However, the pattern of TRAF6 protein 
expression showed some difference, as in SW480-CD40 cells, TRAF6 expression after the 
3 hour time point did not disappear but showed marked reduction as shown in Figure 4.3. 
Although an explanation for such minor differences in TRAF expression could not be 
provided, a good degree of similarity was observed between naturally CD40 expressing 
(HCT116) and engineered, de novo CD40 expressing (SW480-CD40) CRC cell lines, 
suggesting that the proximal signalling events triggered following CD40 by mCD40L 
appear to be similar. 
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Figure 4. 1 The regulation of TRAF1 expression by CD40 ligation  
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells /dish, and co-cultured with 3x106 
cells /dish MMC treated fibroblast cells 3T3-Neo (N) or 3T3-CD40L (L). Co-cultured cells were 
incubated for various times, 3, 6, 12 and 24 hours in DR 5% supplemented with 5% of FCS and 1% 
L-glutamine in 10cm2 culture dishes. After each of incubation time period, cells were lysed by using 
2x SDS-lysis buffer and protein concentration determined. Whole lysates, following normalisation on 
the basis of CK8 and CK18 expression (see chapter 3) were separated under denaturing conditions 
by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membranes. 
The membrane was probed for overnight at 4ºC with primary polyclonal antibody (anti-TRAF1) in 
TBS/Tween 0.1% (1:250 dilution) and then with an anti CK8 and anti-CK18 antibody in TBS/Tween 
0.1% (1:2000 dilution). The membrane was then incubated for one hour with secondary antibody 
[goat anti-rabbit IgG IRDye 800nm (1:10000 dilution)] for TRAF1 detection and with goat anti-mouse 
antibody Igg IRDye 680 (1:10000 dilution) for CK8 and CK8/18. Antibody binding was visualised at 
700nm using an OdysseyTM Infra-red Imaging system (CK8/18 and CK8 were used as loading 
controls).   
  
Key:   NH: 3T3Neo co-cultured with HCT116         LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40     LS: 3T3CD40L cocultured with SW480-CD40 
            L:  3T3CD40L                                              
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Figure 4. 2 The regulation of TRAF3 expression by CD40 ligation 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish, and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, 12 and 24 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine 
in 10cm2 culture dishes. After each of incubation time, cells were lysed using 2x SDS-lysis buffer and 
protein concentration determined. Whole lysates, following normalisation on the basis of CK8 and 
CK18 expression (see chapter 3) were separated under denaturing conditions by SDS-PAGE using 
4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membranes. The membrane was 
probed for overnight at 4ºC with primary polyclonal antibody (anti-TRAF3) in TBS/Tween 0.1% (1:250 
dilution) and then with an anti-CK8 and anti-CK18 antibody in TBS/Tween 0.1% (1:2000 dilution). The 
membrane was then incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 
(1:10000 dilution) for TRAF3 detection and with goat anti-mouse antibody IgG IRDye 680 (1:10000 
dilution) for CK8 and CK18. Antibody binding was visualised at 700nm and 800nm using an 
OdysseyTM Infra-red Imaging system (CK8 and CK18 were used as loading controls).    
Key:   NH: 3T3Neo co-cultured with HCT116              LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40    LS: 3T3CD40L cocultured with SW480-CD40 
           L: 3T3CD40L 
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Figure 4. 3 The regulation of TRAF6 expression by CD40 ligation  
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells /dish, and co-cultured with 3x106 
cells /dish MMC treated fibroblast cells 3T3-Neo (N) or 3T3-CD40L (L). Co-cultured cells were 
incubated for various times, 1.5, 3, 6, 12, and 24 hours in DR 5% supplemented with 5% of FCS and 
1% L-glutamine, in 10cm2 culture dishes. After each of incubation time, cells were lysed by using 2x 
SDS-lysis buffer and protein concentration determined. Whole lysates, following normalisation on the 
basis of CK8 and CK18 expression (see chapter 3) were separated under denaturing conditions by 
SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membranes. The 
membrane was probed for overnight at 4ºC with primary monoclonal antibody (anti-TRAF6) in 
TBS/Tween 0.1% (1:250 dilution) and then with an anti CK8/18 and anti-CK8 antibody in TBS/Tween 
0.1% (1:2000 dilution). The membrane was then incubated for one hour with secondary antibody 
[goat anti-mouse IgG IRDye 680nm (1:10,000 dilution)] for TRAF6 detection and with goat anti-
mouse antibody IgG IRDye 680 (1:10000 dilution) for CK8 and CK8/18. Antibody binding was 
visualised at 700nm using an OdysseyTM Infra-red Imaging system (CK8/18 and CK8 were used as 
loading controls).    
Key:   NH: 3T3Neo co-cultured with HCT116           LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40    LS: 3T3CD40L cocultured with SW480-CD40 
            L:  3T3CD40L                                                     H: HCT116  
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4.3 Expression of MKK4 and MKK7 during CD40-mediated 
apoptosis in CRC cells 
The regulation of pro-apoptotic transcriptional activators, such as JNK and p38, by 
upstream MAPKKs (and particularly MKK4 and MKK7) is well documented (Wagner and 
Nebreda, 2009). The MAPK pathway is an important key signal transduction regulating 
apoptosis, cell proliferation and differentiation. This is a successive complex 
phosphorylation cascade involving a large number of proteins. The MAPK pathway may be 
separated into three groups of proteins: MAPKKK (MAP kinase kinase kinase), the MAPKKs 
(MAP kinase kinase) and MAPK (MAP kinase). The principle of their activation is simple: 
activated MAPKKKs activate MAPKK by loop phosphorylation of two seryl residues. The 
MAPKKs turn trigger the MAPK (JNK and p38) phosphorylation by a tyrosyl and threonyl 
phosphorylation. MAPKKs proteins include MKK-3, -4, 6, and -7 as well as MEK1/2. MKK3 
activates p38 MAPK alpha and beta (p38-α, and –ȕ) while MKK6 can activate both isoforms 
equally. CD40-mediated MKK3/6 and p38 activation have been shown important for IL-6 
and IL-10 monocyte secretion during inflammation (Inoue et al., 2004). Furthermore, it has 
been shown that MKK4 is mainly activated by environmental stress and MKK7 by cytokines; 
MKK4 and MKK7 activate JNK in response to external stimuli, whilst it has been reported 
that MKK4 and MKK7 phosphorylate members of the family of p38 in vitro when 
overexpressed. (Davis, 2000). No studies have investigated or demonstrated a link between 
CD40-mediated MKK -4 or -7 JNK or p38 activation, although activation of JNK in CD40-
mediated apoptosis has been reported by our laboratory and others (Elmetwali et al., 2010b, 
Georgopoulos et al., 2006).  
This work for the first time aimed to examine whether MKK4 and/or MKK7 are active 
during CD40 signalling. Immunoblotting using human phospho-specific antibodies 
demonstrated that MKK4 was activated in response to mCD40L as shown by its 
phosphorylation at Ser257 (Figure 4.4); phosphorylation of MKK4 was detected within 3 
hours in both HCT116 and SW480-CD40. MKK4 expression further increased 6 hours post 
CD40 interaction but then decreased after 12 hours while completely disappearing at 24 
hours, indicating a relatively transient mode of activation (Figure 4.4). Interestingly this 
pattern of expression was essentially identical in both HCT116 and SW480-CD40 cells.   
Previous studies have been reported that both MKK4 and MKK7 are required for full 
activation of JNK in vitro (Fleming et al., 2000, Kishimoto et al., 2003). Also some studies 
showed that loss of MKK7 in fibroblasts cells leads to increase proliferation suggesting a 
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role for this kinase in negatively regulating growth (Wada and Penninger, 2004). Similarly to 
MKK4, phospho-MKK7 dramatically increased within 1.5 hours post CD40 ligation in both 
CRC cell lines. MKK7 expression was readily detectable  in SW480-CD40 at 3, 6, 24 hours 
post CD40 ligation, while in the HCT116 cells it decreased 6 hours post CD40 ligation 
(Figure 4.5). Therefore these findings demonstrate for the first time that CD40 ligation 
induces activation of both MKK4 and MKK7 in CRC cells.   
 
4.4 Expression of JNK and p38 MAPK during CD40-mediated 
apoptosis in CRC cells 
MAP kinases are activated through phosphorylation by MAP kinase kinases (MKK or 
MAP2K) which themselves are stimulated by MAP kinase kinase kinase (MAP3K) located 
most upstream (see Figure 1.24); for example, JNK is primarily activated by two upstream 
kinases MKK4 and MKK7 (Weston and Davis, 2002, Dhanasekaran and Reddy, 2008, 
Kyriakis and Avruch, 2012).. Activated JNK stimulates the transcription factor c-Jun, which 
can then form the complex of transcription factors AP-1 (complex transcription-factor 
activator protein) by homodimerization or heterodimerization by partnering with another 
family member factors Jun and Fos transcription. AP-1 has a ubiquitous distribution and 
controls, the expression of metalloproteinases (MMP), inflammatory cytokines etc. The 
same activation cascades exist for the other two MAPK: MEK1 and MEK2 activate ERK1 
and ERK2 as MKK3 / 6 activate p38 MAP kinase. The activation of MAPK is closely 
controlled (temporally and spatially) in each cell and its inactivation is dependent on serine / 
threonine phosphatase, tyrosine phosphatase, and dual specificity phosphatases (dual-
specificity phosphatases; DUSP).  
As mentioned above, CD40 ligation by mCD40L has been shown to activate JNK in 
UCC cells (Georgopoulos et al., 2006), whilst a number of previous studies have reported 
that activation of the JNK pathway is usually associated with the regulation of cell death 
(Sabapathy and Wagner, 2004, Johnson and Lapadat, 2002b). Furthermore, activation of 
the p38 pathway is also generally associated with the activation of transcription factors and 
protein kinases involved in the regulation of differentiation and inflammatory response and 
also cell death (Zhang and Liu, 2002). This study aimed to decipher whether JNK and/or 
p38 (collectively known as stress activated protein kinases) were activated during CD40 
mediated apoptosis in CRC cells. Immunoblotting demonstrated that JNK phosphorylation 
  
148 
 
occurs within1.5 hours post CD40 ligation for HCT116 then this expression was attenuated 
after 6 hours (Figure 4.6). By contrast, in SW480-CD40 cells there was rapid JNK 
phosphorylation occurring within 1.5 hours, which was sustained until peaking at 12 hours 
post mCD40L treatment (Figure 4.6). Also by immunoblotting, expression of activated p38 
MAPK was shown in both CRC cell lines. The detection of p-p38 following CD40 ligation 
was rapid, increasing in HCT116 and SW480-CD40 within 1.5 hours after mCD40L-CD40 
interaction, and in both cases reaching maximal expression at 12 hours (Figure 4.7). 
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Figure 4. 4 The activation of MKK4 following CD40 ligation  
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells /dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (3, 6, 12 and 24 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine, in 
10cm2 culture dishes. After each of incubation time, cells were lysed by using 2x SDS-lysis buffer and 
protein concentration determined. Whole lysates, following normalisation on the basis of CK8 and 
CK18 expression (see chapter 3) were separated under denaturing conditions by SDS-PAGE using 
4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membranes. The membrane was 
probed for overnight at 4ºC with primary polyclonal antibody (anti-p-MKK4) in TBS/Tween 0.1% 
(1:500 dilution) and then with an anti-CK8 and anti-CK18 antibody in TBS/Tween 0.1% (1:2000 
dilution). The membrane was then incubated for one hour with secondary antibody [goat anti-rabbit 
IgG IRDye 680 (1:5000 dilution)] for MKK4 detection and with goat anti-mouse antibody IgG IRDye 
680 (1:10000 dilution) for CK8 and CK18. Antibody binding was visualised at 700nm and 800nm 
using an OdysseyTM Infra-red Imaging system (CK8 and CK18 were used as loading controls). 
Key:   NH: 3T3Neo co-cultured with HCT116                 LH: 3T3CD40L cocultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40      LS: 3T3CD40L cocultured with SW480-CD40 
            L: 3T3CD40L           
  
150 
 
 
Figure 4. 5 The activation of MKK7 following CD40 ligation 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells /dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (3, 6, 12 and 24 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine, in 
10cm2 culture dishes. After each of incubation time, cells were lysed by using 2x SDS-lysis buffer and 
protein concentration determined. Whole lysates, following normalisation on the basis of CK8 and 
CK18 expression (see chapter 3) were separated under denaturing conditions by SDS-PAGE using 
4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membranes. The membrane was 
probed for overnight at 4ºC with primary polyclonal antibody (anti-p-MKK7) in TBS/Tween 0.1% 
(1:500 dilution) and then with an anti-CK8/18 and anti-CK18 antibody in TBS/Tween 0.1% (1:2000 
dilution). The membrane was then incubated for one hour with secondary antibody [goat anti-mouse 
IgG IRDye 680 (1:10,000 dilution)] for MKK7 detection and with goat anti-mouse antibody IgG IRDye 
680 (1:10000 dilution) for CK8/18 and CK18. Antibody binding was visualised at 700nm and 800nm 
using an OdysseyTM Infra-red Imaging system (CK8/18 and CK18 were used as loading controls). 
Key:  NH: 3T3Neo co-cultured with HCT116            LH: 3T3CD40L cocultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40     LS: 3T3CD40L cocultured with SW480-CD40 
            L: 3T3CD40L                                     
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Figure 4. 6 The activation of JNK following CD40 ligation  
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells /dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, 12 and 24 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine, 
in 10cm2 culture dishes. After each of incubation time, cells were lysed by using 2x SDS-lysis buffer 
and protein concentration determined. Whole lysates, following normalisation on the basis of CK8 
and CK18 expression (see chapter 3) were separated under denaturing conditions by SDS-PAGE 
using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membranes. The membrane 
was probed for overnight at 4ºC with primary monoclonal antibody (anti-p-JNK) in TBS/Tween 0.1% 
(1:500 dilution) and then with an anti-CK18 and anti-CK8/18 antibody in TBS/Tween 0.1% (1:2000 
dilution). The membrane was then incubated for one hour with secondary antibody [goat anti-mouse 
IgG IRDye 680nm (1:10,000 dilution)] for p-JNK detection and with goat anti-mouse antibody IgG 
IRDye 680 (1:10000 dilution) for CK18 and CK8/18. Antibody binding was visualised at 700nm using 
an OdysseyTM Infra-red Imaging system (CK8/18 and CK8 were used as loading controls). 
Key:  NH: 3T3Neo co-cultured with HCT116            LH: 3T3CD40L cocultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40    LS: 3T3CD40L cocultured with SW480-CD40 
           S: SW480-CD40 
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Figure 4. 7 The activation of p38 following CD40 ligation   
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells /dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, and 12 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine in 
10cm2 culture dishes. After each of incubation time, cells were lysed by using 2x SDS-lysis buffer and 
protein concentration determined. Whole lysates, following normalisation on the basis of CK8 and 
CK18 expression (see chapter 3) were separated under denaturing conditions by SDS-PAGE using 
4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membranes. The membrane was 
probed for overnight at 4ºC with primary monoclonal antibody (anti-p-p38) in TBS/Tween 0.1% (1:500 
dilution) and then with an anti-CK8 and anti-CK18 antibody in TBS/Tween 0.1% (1:2000 dilution). The 
membrane was then incubated for one hour with secondary antibody [goat anti-rabbit IgG IRDye 
800nm (1:10,000 dilution)] for p-p38 detection and with goat anti-mouse antibody IgG IRDye 680 
(1:10000 dilution) for CK8 and CK18. Antibody binding was visualised at 700nm and 800nm using an 
OdysseyTM Infra-red Imaging system (CK8 and CK18 were used as loading controls). 
Key:   NH: 3T3Neo co-cultured with HCT116         LH: 3T3CD40L cocultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40  LS: 3T3CD40L cocultured with SW480-CD40 
            L: HCT116                                                            S: SW480-CD40 
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4.5 mCD40L-induces activation of the extrinsic pathway of 
apoptosis: induction of the TRAIL pathway 
 
Earlier studies have reported that CD40-mediated apoptosis of some types of 
carcinoma cells may involve up-regulation of death receptors and ligands, specifically FasL 
and TRAIL (Eliopoulos et al., 2000), thus implying a CD40 signalling cross-talk with the 
extrinsic pathway for the induction of cell death in come cell types. Yet, no such finding was 
reported in UCC cells where a direct intrinsic pathway of apoptosis has previously been 
reported (Georgopoulos et al., 2006). Immunoblotting experiments showed that CD40 
ligation mediates rapid induction of the death ligand TRAIL within 1.5 hours in CRC cell 
lines. This expression of TRAIL continued at 3, 6, and 12 hours post ligation (Figure 4.8).  In 
contrast to the TRAIL observation, a FasL specific antibody was unable to detect induction 
of FasL expression for the same series of time points (Figure 4.9). Interestingly, when 
TRAIL receptor expression was also examined, TRAIL-RII (DR5) was found to be 
upregulated at 3 and 6 hours in both CRC cell lines (Figure 4.10).  
As these findings implied a cross-talk mechanism, the cleavage of Bid was also 
investigated. To detect the cleavage of Bid in vitro, a specific polyclonal antibody was used, 
and the results showed that, when HCT116 cells were treated with mCD40L to induce 
apoptosis, Bid was cleaved to t-Bid a truncated form known to induce apoptosis by 
mitochondrial cross-talk and by facilitating Bak/Bax activation. The cleavage of Bid occurred 
in the early stage of apoptosis in HCT116 (1.5 hours) (Figure 4.11). For unknown reasons 
SW480-CD40 showed no presence of t-Bid (not shown), however the functional significance 
of Bid cleavage was explored and confirmed in HCT116 cells, following the completion of 
this thesis, using a Bid-specific shRNA (see general Discussion). 
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4.5.1 mCD40L-mediated induction of TRAIL and FasL in CRC cells does not 
occur in a paracrine/juxtacrine fashion 
As TRAIL was detected to be upregulated, its functional significance in CD40-mediated 
apoptosis was addressed. For this purpose, CytoTox-Glo assays were performed with CRC 
cells treated with mCD40L in the presence of antagonistic antibodies RIK2 and NOK-1, 
which block TRAIL and FasL, respectively. The blocking antibodies had no effect on 
mCD40L-induced apoptosis at 10µg/ml in both cell lines and levels of apoptosis remained 
significant (p>0.05) (Figure 4.12). A previous study by Steele et al from our laboratory 
showed that the RIK2 antibody efficiently blocks TRAIL-mediated apoptosis when soluble 
preperations of TRAIL are applied to carcinoma cells (Steele et al., 2006). The lack of any 
reduction in CD40-mediated apoptosis in the presence of RIK2 implies that during CD40-
mediated apoptosis, TRAIL is possibly cytotoxic via an autocrine, but not 
paracrine/juxtacrine mechanism. In support of this, we confirmed also lack of surface TRAIL 
expression (following the completion of this thesis, using flow cytometry – Chris Dunnill 
unpublished observations). Following the completion of this thesis we also used a TRAIL 
siRNA to fully decipher whether TRAIL ligand was playing a functional role in CD40 
mediated apoptosis (see general discussion). As for blocking of FasL by using NOK1 
monoclonal antibody, co-culture with mCD40L cells and FasL blocking antibody (NOK1) as 
would be expected did not block apoptosis in HCT116 and SW480-CD40 (p>0.05) as shown 
in Figure 4.12.  
  
  
155 
 
 
 
 
Figure 4. 8 Induction of TRAIL expression by CD40 ligation 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish, and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, and 12 hours) in DR 5% FCS and 1% LG in 10cm2 culture dishes. After each of 
incubation time, cells were lysed using 2x SDS-lysis buffer and protein concentration determined. 
Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3) 
were separated under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membranes. The membrane was probed for overnight at 4ºC with 
primary polyclonal antibody (anti-TRAIL) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-
CK8 antibody for HCT116 and anti-CK18 for SW480-CD40 in TBS/Tween 0.1% (1:2000 dilution). The 
membrane was then incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 
(1:10000 dilution) for TRAIL detection and with goat anti-mouse antibody IgG IRDye 680 (1:10000 
dilution) for CK8 and CK18. Antibody binding was visualised at 700nm and 800nm using an 
OdysseyTM Infra-red Imaging system (CK8 and CK18 were used as loading controls).    
Key:   NH: 3T3Neo co-cultured with HCT116           LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40   LS:3T3CD40L cocultured with SW480-CD40 
            L: HCT116                                                             S: SW480-CD40 
  
  
156 
 
 
 
Figure 4. 9 Induction of FasL expression by CD40 ligation 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, and 12 hours) in DR 5% FCS and 1% LG in 10cm2 culture dishes. After each of 
incubation time, cells were lysed using 2x SDS-lysis buffer and protein concentration determined. 
Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3) 
were separated under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membranes. The membrane was probed for overnight at 4ºC with 
primary polyclonal antibody (anti-FasL) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-
CK8 antibody for HCT116 and SW480-CD40 in TBS/Tween 0.1% (1:2000 dilution). The membrane 
was then incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 (1:10000 
dilution) for FasL detection and with goat anti-mouse antibody IgG IRDye 680 (1:10000 dilution) for 
CK8. Antibody binding was visualised at 700nm and 800nm using an OdysseyTM Infra-red Imaging 
system (CK8 was used as loading control).    
Key:  NH: 3T3Neo co-cultured with HCT116          LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40  LS:3T3CD40L cocultured with SW480-CD40 
            L: HCT116                                                             S: SW480-CD40 
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Figure 4. 10 Induction of TRAIL-R2 (DR5) expression in CRC Cells by CD40 ligation  
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, and 12 hours) in DR 5% FCS and 1% LG in 10cm2 culture dishes. After each of 
incubation time, cells were lysed using 2x SDS-lysis buffer and protein concentration determined. 
Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3) 
were separated under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membranes. The membrane was probed for overnight at 4ºC with 
primary polyclonal antibody (anti-DR5) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 
and CK18 for HCT116 for SW480-CD40 antibody in TBS/Tween 0.1% (1:2000 dilution). The 
membrane was then incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 
(1:10000 dilution) for TRAIL-R2 (DR5) detection and with goat anti-mouse antibody IgG IRDye 680 
(1:10000 dilution) for CK8. Antibody binding was visualised at 700nm and 800nm using an 
OdysseyTM Infra-red Imaging system (CK8 and CK18 were used as loading controls).    
Key:   NH: 3T3Neo co-cultured with HCT116             LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40     LS: 3T3CD40L cocultured with SW480-CD40 
  
  
158 
 
 
 
 
 
 
 
 
 
 
Figure 4. 11 Induction of t-Bid expression by CD40 ligation 
HCT116 (H) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 MMC treated fibroblasts 
3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated time points (1.5, 3, 6, 
and 12 hours) in DR 5% FCS and 1% LG in 10cm2 culture dishes. After each of incubation time, cells 
were lysed using 2x SDS-lysis buffer and protein concentration determined. Whole lysates, following 
normalisation on the basis of CK8 and CK18 expression (see chapter 3) were separated by under 
denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a 
PVDF membranes. The membrane was probed for overnight at 4ºC with primary polyclonal antibody 
(anti-t-Bid) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 in TBS/Tween 0.1% 
(1:2000 dilution). The membrane was then incubated for one hour with secondary antibody goat anti-
rabbit IgG IRDye 800 (1:10000 dilution) for t-Bid detection and with goat anti-mouse antibody IgG 
IRDye 680 (1:10000 dilution) for CK8. Antibody binding was visualised at 700nm and 800nm using an 
OdysseyTM Infra-red Imaging system (CK8 was used as loading control).    
Key:   NH: 3T3Neo co-cultured with HCT116              LH: 3T3CD40L cocultured with HCT116 
             L: 3T3CD40L 
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Figure 4. 12 Effect of blocking antibodies NOK1 and RIK2 on CD40-mediated apoptosis 
1x104 CRC cells (HCT116 and SW480-CD40) were co-cultured with 1x104 MMC treated 3T3CD40L 
and 3T3Neo fibroblasts in 96 well plates in DR medium supplemented with 5% FCS and L-glutamine 
± 10 µg/ml  of NOK1 and RIK2 (or isotype control IgG mAb) to block FasL and TRAIL respectively. 
After 24 hour, apoptosis was measured by CytoTox-Glo assay. 50µl of substrate was added, 
luminescence measured (as described in the Materials and methods) and background-corrected 
relative luminescence unit (RLU) readings deduced by pair-wise subtraction of mCD40L and Control 
cell from the respective Co-cultures.Panel A and B show fold change against control and antibodies 
were blocked the ligands (TRAIL and FasL) in co-cultures for both HCT116 and SW480-CD40 
compared with control. Data shows no significant differences in both cell lines (HCT116 and SW480-
CD40). Bars show mean ± SD of 4-5 replicates and results are representative of three experiments. 
Results are presented as fold change and calculated as described in chapter 2. (Non-significant; 
p>0.05 
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4.6 CD40-mediated apoptosis involves both intrinsic and extrinsic 
mechanisms 
Previous studies in UCC cells reported that CD40 ligation activates apoptosis via 
activation of caspase-9 but not caspase-8 (Georgopoulos et al., 2006). In this project, 
functional investigations of caspases were performed using biochemical caspase inhibitors. 
CytoTox-Glo apoptosis assays were performed in mCD40L-treated HCT116 cells in the 
presence of caspase-8, -9, -10 inhibitors (Z-IETD, Z-LEHD, and Z-VEVD respectively) as 
well as pan-caspase inhibitor (z-VAD). Notably, inhibition of caspase-9 resulted in dramatic 
attenuation of apoptosis. Apoptosis of CRC cells (HCT116) following co-culture with 
mCD40L cells was also nearly completely blocked by the pan-caspase inhibitor z-VAD 
confirming that CD40-mediated apoptosis in CRC cells is caspase-dependent. More 
specifically, inhibitors of caspases 9 and 10 (Z-LEHD and Z-VEVD, respectively) caused 
less marked yet highly significant reductions in apoptosis (Figure 4.13) whereas a caspase-
8 inhibitor (Z-IETD) had no effect on cell death in HCT116 at all (Figure 4.14).  
 
It is well established that Bak and Bax regulate apoptotic cell death by facilitating 
MOMP, subsequent cytochrome c release and activation of caspase-9 during the intrinsic 
pathway (Kroemer et al., 2007). Because of this, we examined expression of Bak and Bax 
following CD40 ligation in CRC cells. In what would support an intrinsic mediated 
mechanism of cell apoptosis, it was found that CD40 engagement caused the marked and 
rapid induction of Bak within 3, 6, 12, and 24 hours in HCT116. In SW480-CD40 this 
occurred even faster than 3 hours (1.5 hours) and continued gradually increased expression 
at 6 to 12 hours (Figure 4.15). Also Bax protein expression was detected in HCT116 within 6 
hours post interaction with mCD40L and this continued at 12 and 24 hour time points. In 
contrast with SW480-CD40 has rapid expression of Bax at 1.5 and this gradually increased 
following CD40 ligation (Figure 4.16). 
We also next examined whether apart from an increase in Bak/Bax expression there 
was induction of MOMP and release of cytochrome c. mCD40L-treated HCT116 and 
SW480-CD40 cells tested 6 hours post-ligation (as this is when optimal Bak and Bax 
expression was detected – see figures 4.15 and 4.16) and then the mitochondrial and 
cytosolic fractions were separated as described in section 2.13.2 in the Methods.  Further, 
fractions for control and mCD40L treated cells were screened for mitochondrial cytochrome 
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c, mitochondrial Bcl-2 and cytoplasmic GAPDH through immunoblotting (Figure 4.17). 
mCD40L caused CRC cells to induce MOMP and cytochrome c release into their cytoplasm 
thus confirming a role for the mitochondria in the induction of CD40-mediated apoptosis. 
This is in agreement with previous studies in UCC cells that demonstrated that CD40 
engagement by mCD40L induces expression of the pro-apoptotic molecules Bak and Bax, 
whilst down-regulating anti-apoptotic Bcl-2 protein (Bugajska et al., 2002). 
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Figure 4. 13 Effect of caspase -9 and -10 inhibition on CD40 ligation by mCD40L   
1x104 cells/well CRC cells (HCT116) were co-cultured with1x104 cells/well MMC treated 3T3CD40L 
and 3T3Neo fibroblasts in 96 well plates in DR /5% FCS / L-glutamine ± 100µM of caspase -9 (Z-
LEHD-FMF) or -10 (Z-AEVD-FMK) inhibitor and general caspases inhibitor (z-VAD). After 24 hour at 
37ºC / 5% CO2, apoptosis was measured by CytoTox-Glo assay.  50µl of substrate was added, 
luminescence measured (as described in the Materials and methods) and background-corrected 
relative luminescence unit (RLU) readings deduced by pair-wise subtraction of mCD40L and Control 
cell from the respective Co-cultures. Figure shows fold change against control and caspase -9 and -
10 inhibitor inhibit apoptosis in HCT116. Bars show mean fold change of apoptosis ± SD of 4-5 
replicates and results are representative of three experiments. Stats: ** P<0.01, paired student t-test, 
HCT116 compared with control cells. 
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Figure 4. 14 Effect of caspase -8 inhibition on CD40 ligation   
1x104 cells/well CRC cells (HCT116) were co-cultured with1x104 cells/well MMC treated 3T3CD40L 
and 3T3Neo fibroblasts in 96 well plates in DR /5% FCS / L-glutamine ± 100µM of caspase -8 
inhibitor (Z-IETD-FMK) inhibitor and general caspases inhibitor (z-VAD) used as positive control. 
After 24 hour at 37ºC / 5% CO2, apoptosis was measured by CytoTox-Glo assay.  50µl of substrate 
was added, luminescence measured (as described in the Materials and methods) and background- 
corrected relative luminescence unit (RLU) readings deduced by pair-wise subtraction of mCD40L 
and Control cell from the respective Co-cultures. Results show fold change against control and 
caspase -8 inhibitor did not inhibit apoptosis and there is no significant difference between control 
and caspase -8 inhibitor. Bars show mean fold change of apoptosis ± SD of 4-5 replicates and results 
are representative of three experiments. Stats:  NS p>0.07/ ***p<0.001, paired student t-test, 
HCT116 compared with control cells. 
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Figure 4. 15 The activation of Bak following CD40 ligation 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, 12 and 24 hours) in DR / 5%FCS / 1%L-glutamine in 10cm2 culture dishes. 
After each of incubation time, cells were lysed using 2x SDS-lysis buffer and protein concentration 
determined. Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see 
chapter 3) were separated under denaturing conditions by SDS-PAGE using 4 -12% (w/v) Bis-Tris 
gels and then immunoblotted onto a PVDF membrane. The membrane was probed for overnight at 
4ºC with primary monoclonal antibody (anti-Bak) in TBS/Tween 0.1% (1:500 dilution) and then with an 
anti-CK8/18 and anti-CK18 antibody in TBS/Tween 0.1% (1:2000 dilution). The membrane was then 
incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 (1:10000 dilution) for 
Bak detection and with goat anti-mouse antibody IgG IRDye 680 (1:10000 dilution) for CK8/18 and 
CK8/18. Antibody binding was visualised at 700nm and 800nm using an OdysseyTM Infra-red Imaging 
system (CK8/18 and CK18 were used as loading controls).    
Key:  NH: 3T3Neo co-cultured with HCT116             LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40    LS: 3T3CD40L cocultured with SW480-CD40 
            L: 3T3CD40L   
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Figure 4. 16 The activation of Bax following CD40 ligation 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time points (1.5, 3, 6, 12 and 24 hours) in DR / 5%FCS / 1%L-glutamine in 10cm2 culture dishes. 
After each of incubation time, cells were lysed using 2x SDS-lysis buffer and protein concentration 
determined. Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see 
chapter 3) were separated under denaturing conditions by SDS-PAGE using 4 -12% (w/v) Bis-Tris 
gels and then immunoblotted onto a PVDF membrane. The membrane was probed for overnight at 
4ºC with primary monoclonal antibody (anti-Bax) in TBS/Tween 0.1% (1:500 dilution) and then with an 
anti-CK8/18 and anti-CK18 antibody in TBS/Tween 0.1% (1:2000 dilution). The membrane was then 
incubated for one hour with secondary antibody goat anti-mouse IgG IRDye 680 (1:10000 dilution) for 
Bax detection and with goat anti-mouse antibody IgG IRDye 680 (1:10000 dilution) for CK8/18 and 
CK8/18. Antibody binding was visualised at 700nm using an OdysseyTM Infra-red Imaging system 
(CK8/18 and CK18 were used as loading controls).    
Key:   NH: 3T3Neo co-cultured with HCT116            LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40    LS: 3T3CD40L cocultured with SW480-CD40 
            L: 3T3CD40L 
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Figure 4. 17 Induction of MOMP by mCD40L in CRC cells 
HCT116 cells (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 
3x106 cells/dish MMC treated fibroblast cells 3T3-Neo (N) or 3T3-CD40L (L). Co-cultured cells were 
incubated for 6 hours, in DR /5% FCS and 1% LG, in 10cm2 culture dishes. After incubation, cells 
were harvested by trypsinisation and processed accordingly to the manufacturer‘s protocol (Merck 
mitochondrial isolation kit see section 2.11.2). After that protein concentration determined. 
Cytoplasmic and mitochondrial fraction were separated under denaturing conditions by SDS-PAGE 
using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membrane. The membrane 
was probed for overnight at 4ºC with primary polyclonal antibody; an anti-Cytochrome C) in 
TBS/Tween 0.1% (1:500 dilution), anti-GAPDH antibody in TBS/Tween 0.1% (1:1000 dilution) and 
anti-Bcl-2 antibody in TBS/Tween 0.1% (1:500 dilution). The membrane was then incubated for one 
hour with goat anti-rabbit IgG Alexa 800 (1:10000 dilution) to detection of Cytochrome C and one 
hour with goat anti mouse to detect both GAPDH and Bcl2 (loading controls for cytosolic and 
mitochondrial fractions respectively). Antibody binding was visualised at 700nm and 800nm using an 
OdysseyTM Infra-red Imaging system.  
 Key;  NH: 3T3Neo co-cultured with HCT116             LH: 3T3CD40L co-cultured with HCT116 
             NS: 3T3Neo co-cultured with SW480-CD40    LS: 3T3CD40L co-cultured with SW480-CD40 
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4.7 Use of shRNA-based RNAi by retrovirus-mediated delivery to 
study the functional role of intracellular mediators in CD40-
mediated apoptosis 
Short-hairpin RNAs (shRNAs) are a form of RNA interference (RNAi) and are used 
as a mechanism to specifically knockdown proteins of interest (Rao et al., 2009). A panel of 
retroviral shRNA expression vectors were prepared (Section 2.7.1) for the stable knockdown 
of proteins of interest for functional studies, including TRAF3 (below) and Bax. Replication-
incompetent retroviral particles were used to transduce the target CRC cell line HCT116 (as 
explained in section 2.8.4). For selection of stable shRNA HCT116 expressers, puromycin 
antibiotic selection was used, as the viral expression cassette comprises a puromycin 
resistance gene (section 2.7.2).  
 
The CellTiter 96® AQueous One Solution Cell Proliferation assay (section 2.9.2) was 
used to perform titration experiments to determine adequately cytotoxic concentrations of 
puromycin for selection of antibiotic-resistant cell populations, following viral transductions. 
This proliferation assay involves the use of MTS tetrazolium (yellow) which is reduced to a 
formazan derivative (brown) by respiring cells. The increased absorbance at 492nm occurs 
due to the colour change induced by viable cells as they produce electron coupling reagents 
such as NADH that reduce a formazan substrate (yellow-brown). Following the combination 
of results from such pre-titration experiments (Figure 4.18) and routine phase contrast 
microscopic examination during antibiotic treatment, it was found that a concentration of 
0.25µg/ml of puromycin concentration effectively perished non-transduced control HCT116 
cells after several days, whilst allowing the proliferation of their virally-transduced 
counterparts. Figure 4.19 shows representative results for experiments involving HCT116 
transduction with a retrovirus expressing TRAF3 shRNA (to be discussed in detail in 
subsequent sections).  
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4.7.1 The role of TRAF3 in CD40-mediated apoptosis 
After retroviral transduction for the expression of an shRNA for knockdown of TRAF3 
(Table 2.4), HCT116 cells were selected in puromycin as previously described (section 
4.1.1); for the purposes of this thesis, HCT116 derivatives bearing the TRAF3 shRNA will be 
termed TRAF3-KD cells. The ability of the designed shRNAs to knockdown TRAF3 protein 
expression in TRAF3-KD cells was confirmed by immunoblotting (Figure 4.20). 
Densitometric analysis was also used to confirm that, the expression of TRAF3 was reduced 
after 1.5 and 3 hours CD40 ligation compared with control as illustrated in Table 4.1 and 
Figure 4.21.   
 
As TRAF3 protein is induced only when CD40 was engaged by mCD40L to give a 
pro-apoptotic signal in UCC cells (Georgopoulos et al., 2006) it was next determined 
whether this is the case in CRC cell lines. Results demonstrated that TRAF3-KD cells had a 
significant reduction (P<0.05) of apoptosis compared with HCT116 as determined by 
CytoTox-Glo assays (Figure 4.22). This was further confirmed using the caspase-3/7 
activation-based apoptosis assay, where TRAF3 knockdown led to a significant reduction 
(P<0.05) also in caspase-3/7 activity (Figure 4.23).  
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Figure 4. 18 HCT116 and TRAF3-KD cell proliferation following treatment with a range of 
puromycin concentrations  
1x104 HCT116-TRAF3-KD and HCT116 cells were seeded in 96 well plates and then treated with the 
indicated concentrations of puromycin antibiotic in DR/5%FCS/1%L-G for 24 hours. 20µl of CellTiter 
96® AQueous One Solution was added to appropriate wells and plates were incubated at 37°C in 5% 
CO2 for a total of four hours. To assess cell viability, total levels of formazan formation were 
measured using a FLUOstar OPTIMA (BMG Labtech) plate reader at a wavelength of 492nm. Bars 
correspond to mean absorbance values of 5-6 technical replicates ± SEM and results are 
representative of three independent experiments.  
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Figure 4. 19 Antibiotic (Puromycin) selection of transduced HCT116 cells with TRAF3 shRNA-expressing retrovirus 
 Transduced and non-transduced HCT116 cells were cultured in DR/5%FCS/1%L-G supplemented with 0.25µg/ml puromycin compared 
with non-treated cells as control (the transduced cells shown here are cells in which an anti-TRAF3 shRNA is expressed, denoted TRAF3-KD). 
HCT116 were also cultured with DR/5%FCS/1%L-G alone to demonstrate their normal growth pattern (Control). Note non-resistant HCT116 
perish from the flask within 24 hours, however resistant cell populations continue to proliferate. Images are representative phase contrast 
micrographs (taken at 100x magnification).  
                           TRAF3-KD (0.25µg/ml)                       HCT116 (0.25µg/ml) 
    
                                                                           
 
                                                                                     Control (No antibiotic) 
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Figure 4. 20 The effect of TRAF3 knockdown on the regulation of TRAF3 expression following 
CD40 ligation  
3x106 control HCT116 cells (H) and HCT116 cells expressing TRAF3 shRNA (TRAF3-KD) were co-
cultured with 3x106 MMC treated mCD40L (L) and Controls (N) for 1.5 and 3 hours in DR / 5%FCS / 
1%L-glutamine in 10cm2 culture dishes in order to lyse with 2X SDS-lysis buffer. Whole lysates, 
following normalisation on the basis of CK8 and CK18 expression (see chapter 3) were separated 
under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted 
onto a PVDF membrane. The membrane was probed overnight at 4ºC with primary polyclonal 
antibody (anti-TRAF3) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 antibody in 
TBS/Tween 0.1% (1:2000 dilution). The membrane was then incubated for one hour with secondary 
antibody [goat anti-rabbit IgG IRDye 800nm (1:10000 dilution)] for TRAF3 detection and with goat 
anti-mouse antibody IgG IRDye 680 (1:10000 dilution) for CK8 (used as loading control).  
Key:  NH: 3T3Neo co-cultured with HCT116           LH: 3T3CD40L cocultured with HCT116 
            L: 3T3CD40L         
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Table 4. 1 Densitometric analysis to calculate fold change in TRAF3 protein expression 
Densitometry was used to normalise data using Cytokeratin 8 as the loading Control. Readings 
represent band intensity values generated by the LiCor Odyssey analysis software. Data was 
normalised against densitometry values for Controls and then fold change was calculated by the 
following equation: mCD40L/HCT116 ÷ Control/HCT116. BC - blank corrected. The table above is 
representative of the values obtained from the blot shown in Figure 4.20. 
 
 
 
Figure 4. 21 Densitometric analysis to calculate fold change in TRAF3 protein expression 
following shRNA-mediated knockdown 
Densitometry was used to normalise data using Cytokeratin 8 as the loading Control. Readings 
represent band intensities values generated by the LiCor Odyssey analysis software. Data was 
normalised against densitometry values for Controls and then fold change was calculated by the 
following equation (mCD40L/HCT116 ÷ Control/HCT116). BC - blank corrected. The table above is 
representative of values shown in Figure 4.20. 
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Figure4. 22 Effect of shRNA-mediated TRAF3 knockdown on CD40-induced apoptosis  
1x104 colorectal cancer cells (HCT116 and TRAF3-KD cells) were cocultured with 1x104 MMC 
treated 3T3CD40L (mCD40L)  and 3T3Neo (control) in white 96 well plates in DR medium 
supplemented with 5% FBS and 1%  L-glutamine. After 24 hours of coculter, CytoTox-Glo test was 
used to detect apoptosis in colorectal cancer cells (HCT116) as discribed in chepter 2 (Materials and 
Methods). Background corrected RLU readings deduced by substraction of mCD40L from coculture 
[(3T3CD40L + HCT116) – 3T3CD40L] and control [(3T3Neo + HCT116) -3T3Neo]. Bars show mean 
flod change of apoptosis ± S.D of 4 to 6 replicates and results are representative of three 
experiments. Results show significant differences between HCT116/3T3CD40L versus TRAF3-
KD/3T3CD40L indicated by **p<0.01 for HCT116 cells and TRAF3-KD cells.  
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Figure 4. 23 Effect of TRAF3 protein knockdown on caspase-3 and -7 activation during CD40-
mediated apoptosis  
1x104 HCT116 and TRAF3-KD cells were co-cultured with 1x104 MMC treated mCD40L or Controls in 
DR medium supplemented with 5% FCS and 1%L-glutamine in white 96-well plates. 50µl of 
SensoLyte 3/7 substrate  was added after 48 hours, fluorescence measured (as described in the 
Materials and methods) and background-corrected reletive fluorescence unit (RFU) readings 
deduced by pair-wise subtraction of mCD40L and Control values from respective co-cultures. Bars 
show mean fold change of caspase 3 and 7 activity ± S.D of 4 to 6 replicates and results are 
representative of three experiments. Stats: ** p<0.01, paired student t-test, HCT116 compared with 
knockdown cells. 
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4.7.2 Role of TRAF3 in the induction of JNK and p38 MAPK 
Previous studies on CD40-induced p38 (Sutherland et al., 1996, Salmon et al., 1997) 
and JNK (Elmetwali et al., 2010b, Georgopoulos et al., 2006, Li et al., 1996) activation 
indicated that CD40 may induce TRAF3-mediated activation of the kinase activities of these 
MAPKs protein. Moreover, TRAF3 appeared to play a critical role in CD40-induced up-
regulation of a variety of signal transduction mediators. 
TRAF3-KD cells were first used to investigate whether TRAF3 regulated 
downstream JNK activation during CD40-mediated apoptosis. As shown in Figure 4.24, 
TRAF3–KD cells had reduced activation of JNK within 3 and 6 hours post CD40 ligation 
compared with HCT116. Also, the results showed that TRAF3 regulates the expression of 
p38 at 6 hours post CD40 ligation as TRAF3 knockdown abolished the p38 phosphorylation 
normally observed in the HCT116 cells (Figure 4.25). These findings demonstrated for the 
first time a critical role for TRAF3 in the activation of p38 and particularly JNK.  
4.7.3 Role of TRAF3 in the expression of Bax  
As CD40 ligation by mCD40L causes the expression of Bax and because UCC cells 
following TRAF3 knockdown have decreased mCD40L susceptibility (Georgopoulos et al., 
2006), it was hypothesised that TRAF3 stabilisation may also regulate Bax expression. 
TRAF3-KD cells were used to explore this possibility. Results demonstrated conclusively 
that TRAF3-mediated signalling regulates the expression of pro-apoptotic regulator Bax, as 
TRAF3 knockdown completely abrogated the Bax expression that is normally seen in 
HCT116 (Figure 4.26). The complete inhibition of CD40-mediated Bax protein induction by 
TRAF3 knockdown suggested that loss of TRAF3 interferes with the induction of apoptosis 
in CRC cells.   
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Figure 4. 24 The role of TRAF3 knockdown on p-JNK  following CD40 ligation  
3x106 CRC cells [HCT116 (H)] and HCT116 cells expressing TRAF3 sh RNA (TRAF3-KD) were co-
cultured with 3x106 MMC treated mCD40L (L) and Controls (N) for 3 and 6 hours in DR / 5%FCS / 
1%LG in 10cm2 culture dishes in order to lyse with 2X SDS-lysis buffer. Whole lysates, following 
normalisation on the basis of CK8 and CK18 expression (see chapter 3) were separated under 
denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a 
PVDF membrane. The membrane was probed for overnight at 4ºC with primary monoclonal 
antibody/goat anti-mouse antibody (anti-p-JNK) in TBS/Tween 0.1% (1:500 dilution) and then with an 
anti-CK8 antibody in TBS/Tween 0.1% (1:2000 dilution). The membrane was then incubated for one 
hour with secondary antibody [goat anti-mouse IgG IRDye 680 (1:10000 dilution)] for p-JNK detection 
and membrane was incubated with goat anti-mouse antibody IgG IRDye 680 (1:10000 dilution) for 
CK8 (used as loading control).  
Key:  NH: 3T3Neo co-cultured with HCT116         LH: 3T3CD40L cocultured with HCT116 
            L: 3T3CD40L                                                                    
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Figure 4. 25 The role of TRAF3 knockdown on p-p38 expression following CD40 ligation   
 3x106 control HCT116 cells (H) and HCT116 cells expressing TRAF3 shRNA (TRAF3-KD) were co-
cultured with 3x106 MMC treated mCD40L (L) and Controls (N) for 3 and 6 hours in DR / 5%FCS / 
1%L-glutamine in 10cm2 culture dishes in order to lyse with 2X SDS-lysis buffer. Whole lysates, 
following normalisation on the basis of CK8 and CK18 expression (see chapter 3) were separated 
under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted 
onto a PVDF membrane. The membrane was probed overnight at 4ºC with primary polyclonal 
antibody (anti-p-p38) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 antibody in 
TBS/Tween 0.1% (1:2000 dilution). The membrane was then incubated for one hour with secondary 
antibody [goat anti-rabbit IgG IRDye 800nm (1:10000 dilution)] for p-p38 detection and with goat anti-
mouse antibody IgG IRDye 680 (1:10000 dilution) for CK8 (used as loading control).  
Key:  NH: 3T3Neo co-cultured with HCT116         LH: 3T3CD40L cocultured with HCT116 
            L: 3T3CD40L                                                                                   
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Figure 4. 26 Effect of shRNA-mediated TRAF3 knockdown on Bax induction during CD40-
mediated apoptosis  
3x106 HCT116 and TRAF3-KD and cells were co-cultured with 3x106 MMC treated mCD40L and 
Controls for 3 hours in DR/5%FCS/1%L-G and 10cm2 culture dishes prior to lysis with 2X SDS-lysis 
buffer. Whole lysates, following normalisation on the basis of CK8 expression (see chapter 3) were 
under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted 
onto a PVDF membrane. The membrane was probed overnight with an anti-Bax antibody (1:500 
dilution) and then with an anti-CK8 antibody (1:2000 dilution). The membrane was incubated for one 
hour with goat anti-mouse IgG IRDye 680 (1:10000 dilution) for the detection of CK8 (loading control) 
and Bax. Antibody binding was visualised at 700nm using an OdysseyTM Infra-red Imaging system.  
Key:  NH: 3T3Neo co-cultured with HCT116          LH: 3T3CD40L cocultured with HCT116 
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4.8 Role of JNK and p38 MAPK in CD40-mediated apoptosis in CRC 
cells 
In light of the finding above that JNK and p38 are activated in response to CD40 
ligation by mCD40L and that TRAF3 regulates apoptosis and the expression of both p38 
and particularly JNK, it was determined whether these phosphoproteins have a direct role 
on CD40-mediated apoptosis. Inhibition of both JNK by JNK inhibitor (SP600125) and p38 
by p38 MAPK inhibitor (SB202190) led to a significant reduction (P<0.001) of apoptosis in 
HCT116 and SW480-CD40 as determined by CytoTox-Glo death detection assays as 
shown in Figures 4.27 and 4.28. In addition to this, JNK inhibition significantly reduced 
(p<0.001) caspase-3/7 activity in both HCT116 and SW480-CD40 (Figures 4.29). Also the 
p38 inhibitor reduced caspase 3/7 activity during CD40-mCD40L ligation as determined by 
caspase 3/7 activity assay in both cell lines HCT116 and SW480-CD40 (Figure 4.30). The 
results showed a significant (p< 0.001) reduction of caspase 3/7 activity of SB202190 
treated cells compared with non-treated during CD40 activation.  
4.8.1 Effects of JNK and p38 inhibitors on JNK and p38 expression in CRC 
cells 
To find out the events that occur when the inhibition of JNK and p38 MAPK proteins in the 
CRC cells after mCD40L ligation by using JNK and p38 inhibitor (SP600125 and SB202190 
respectively), immunoblotting experiment was used with specific human antibodies to detect 
JNK and p38 expression. Results demonstrated that JNK inhibition by SP600125 reduced 
p-JNK expression, but did not stop p38 MAPK expression in CRC cells (HCT116 and 
SW480-CD40) within 3 and 6 hours post CD40 ligation as shown in Figures 4.31 and 4.32. 
By contrast, interestingly, inhibition of p38 by SB202190 clearly blocked not only p38 
activation but also expression of p-JNK within 3 and 6 hours post CD40L ligation in both cell 
line compared with positive control as shown in Figures 4.31 and 4.32. The significance of 
these findings remains unknown, however this result suggests that p38 may function 
upstream of JNK. 
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4.8.2 Role of JNK and p38 MAPK in the induction of TRAIL 
A possible role for JNK and/or p38 in TRAIL expression was also investigated using 
their respective inhibitors. Immunoblotting showed that CD40-mediated induction of TRAIL 
proteins in HCT116 and SW480-CD40 cells was completely inhibited by pharmacological 
inhibition of both JNK (SP600125) and p38 (SB202190). These findings imply that the 
expression of TRAIL is blocked by both inhibitors within 3 and 6 hours post CD40 ligation 
(Figure 4.33), and thus TRAIL is most likely to be transcriptionally regulated by the action of 
JNK and p38. These results suggest that SAPKs play a key role in regulation of many 
downstream pro-apoptotic events in CRC CD40 mediated apoptosis.  
 
4.8.3 Role of JNK and p38 MAPK in the induction of mitochondrial pathway 
pro-apoptotic proteins Bak and Bax 
Specific pharmacological inhibitors of JNK (SP600125) and p38 MAPK (SB202190) 
were used to inhibit apoptosis, and it was determined whether this would also prevent the 
expression of Bak and Bax in CRC cells treated with mCD40L. Both inhibitors JNK and p38 
inhibitors (SB600125 and SP202190) completely reduced Bak protein expression at 3 and 6 
hours in CRC cells as shown in Figure 4.34. Additionally, inhibition of JNK and p38 MAPK 
by SP600125 and SB202190 respectively, also significantly reduced Bax expression in 
HCT116 after CD40 ligation (Figure 4.35a). During inhibition of JNK and P38, only moderate 
inhibition of Bax protein was detected by immunoblotting in SW480-CD40 compared with 
HCT116 as shown in Figure 4.35b. Collectively however, results indicated that p38 and JNK 
play functional roles in regulation of Bak and Bax and this is in line with previous results 
showing that they also directly regulate apoptosis in this context.  
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Figure 4. 27 The effect of pharmacological inhibition of JNK on CD40-mediated apoptosis 
1x104 cells/well CRC cells (HCT116 and SW480-CD40) were co-cultured with 1x104 cells/well MMC 
treated (3T3CD40L and 3T3Neo) fibroblasts in 96 well plates in DR medium supplemented with 5% 
FCS and L-glutamine ± 5µM JNK inhibitor (SP600125). After 24 hour at 37ºC/ 5%CO2, apoptosis was 
measured using the CytoTox-Glo assay. After incubation, 50µl of substrate was added to each well, 
and luminescence was measured. Background corrected RLU readings deduced by pair-wise 
subtraction of mCD40L and Control values from respective co-cultures. Panels A and B show fold 
change against control in HCT116 and SW480-CD40 cells, respectively. Bars show mean ± S.D for 
4-5 technical replicates (p<0.001) expressed as fold activity in mCD40L-treated cells versus negative 
control. Results were calculated as described in Chapter 2 (Materials and Methods). 
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Figure 4. 28 The effect of pharmacological inhibition of p38 on CD40-mediated apoptosis   
1x104 cells/well CRC cells (HCT116 and SW480-CD40) were co-cultured with 1x104 cells/well MMC 
treated (3T3CD40L and 3T3Neo) fibroblasts in 96 well plates in DR medium supplemented with 5% 
FCS and L-glutamine ± 5µM p38 inhibitor (SB202190). After 24 hour at 37ºC/ 5%CO2, apoptosis was 
measured using the CytoTox-Glo assay. After incubation, 50µl of substrate was added to each well, 
and luminescence was measured. Background corrected RLU readings deduced by pair-wise 
subtraction of mCD40L and Control values from respective co-cultures. Panels A and B show fold 
change against control in HCT116 and SW480-CD40 cells, respectively. Bars show mean ± S.D for 
4-5 technical replicates (p<0.001) expressed as fold activity in mCD40L-treated cells versus negative 
control. Results were calculated as described in Chapter 2 (Materials and Methods). 
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Figure 4. 29 The effect of pharmacological inhibition of JNK on CD40-induced caspase-3/7 
activation 
1x104 cells/well CRC cells (HCT116 and SW480-CD40) were co-cultured with 1x104 cells/well MMC 
treated 3T3CD40L and 3T3Neo fibroblasts in 96 well plates in DR medium supplemented with 5% 
FCS and L-glutamine ± 5µM JNK inhibitor (SP600125). After 48 hour at 37ºC/5%CO2, 50µl of 
SensoLyte 3/7 substrate was added, fluorescence measured (as described in the Materials and 
methods) and background-corrected relative fluorescence unit (RFU) readings deduced by pair-wise 
subtraction of mCD40L and Control cell from the respective co-cultures. Bars show mean fold change 
of caspase 3/7 activity ± SD of 4-5 technical replicates and results are representative of three 
experiments. Stats: ** P<0.01, paired student t-test, HCT116 compared with control cells.  
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 Figure 4. 30The effect of pharmacological inhibition of p38 MAPK on CD40-induced caspase-
3/7 activation 
1x104 cells/well CRC cells (HCT116 and SW480-CD40) were co-cultured with 1x104 cells/well MMC 
treated 3T3CD40L and 3T3Neo fibroblasts in 96 well plates in DR medium supplemented with 5% 
FCS and L-glutamine ± 5µM p38 inhibitor (SB202190). After 48 hour at 37ºC/5%CO2, 50µl of 
SensoLyte 3/7 substrate was added, fluorescence measured (as described in the Materials and 
methods) and background-corrected relative fluorescence unit (RFU) readings deduced by pair-wise 
subtraction of mCD40L and Control cell from the respective co-cultures. Bars show mean fold change 
of caspase 3/7 activity ± SD of 4-5 replicates and results are representative of three experiments. 
Stats: ** P<0.01, paired student t-test, HCT116 compared with control cells.  
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Figure 4. 31 Effect of pharmacological inhibitors of JNK and p38 on JNK phosphorylation 
following CD40 ligation  
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time periods (3, 6 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine ± 5µM 
SP600125 (JNK inhibitor) and 5 µM SB202190 (p38 inhibitor) in 10cm2 culture dishes. After 
incubation, cells were lysed using 2x SDS-lysis buffer and protein concentration was determined. 
Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3) 
were separated under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membrane. The membrane was probed overnight at 4ºC with primary 
monoclonal antibody (p-JNK) in TBS/Tween 0.1% (1:250 dilution) and then with an anti-CK8 antibody 
for HCT116 and CK18 for SW480CD40 in TBS/Tween 0.1% (1:2000 dilution). The membrane was 
then incubated for one hour with secondary antibody goat anti-mouse IgG IRDye 680 (1:10000 
dilution) for p-JNK detection and with goat anti-mouse IgG Alexa 680 (1:10,000 dilution) for the 
detection of CK18.  A shows HCT116, B shows SW480-CD40 co-culture experiments. Antibody 
binding was visualised at 700nm using an OdysseyTM Infra-red Imaging system (CK8 and CK18 were 
used as loading controls in A and B, respectively).  
Key:  NH: 3T3Neo co-cultured with HCT116             LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40       LS: 3T3CD40L cocultured with SW480-CD40 
 +ve: 3T3CD40L cocultured with CRC cells (no inhibitor)  
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Figure 4. 32 Effect of pharmacological inhibitors of JNK and p38 on p38 phosphorylation 
following CD40 ligation 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time periods (3, 6 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine ± 5µM 
SP600125 (JNK inhibitor) and 5 µM SB202190 (p38 inhibitor) in 10cm2 culture dishes. After 
incubation, cells were lysed using 2x SDS-lysis buffer and protein concentration was determined. 
Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3) 
were separated under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membrane. The membrane was probed overnight at 4ºC with primary 
monoclonal antibody (p-p38) in TBS/Tween 0.1% (1:250 dilution) and then with an anti-CK8 antibody 
for HCT116 and CK18 for SW480CD40 in TBS/Tween 0.1% (1:2000 dilution). The membrane was 
then incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 (1:10000 
dilution) for p-p38 detection and with goat anti-mouse IgG Alexa 680 (1:10,000 dilution) for the 
detection of CK18.  A shows HCT116, B shows SW480-CD40 co-culture experiments. Antibody 
binding was visualised at 700nm and 800nm using an OdysseyTM Infra-red Imaging system (CK8 and 
CK18 were used as loading controls in A and B, respectively).  
  Key:  NH: 3T3Neo co-cultured with HCT116            LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40     LS: 3T3CD40L cocultured with SW480-CD40 
 +ve: 3T3CD40L cocultured with CRC cells (no inhibitor) 
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Figure 4. 33 Effect of pharmacological inhibitors of JNK and p38 on TRAIL expression during 
CD40-mediated apoptosis 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time periods (3, 6 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine ± 5µM 
SP600125 (JNK inhibitor) and 5µM SB202190 (p38 inhibitor) in 10cm2 culture dishes. After 
incubation, cells were lysed using 2x SDS-lysis buffer and protein concentration was determined. 
Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3) 
were separated under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membrane. The membrane was probed overnight at 4ºC with primary 
polyclonal antibody (anti-TRAIL) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 
antibody for HCT116 and CK18 for SW480-CD40 in TBS/Tween 0.1% (1:2000 dilution). The 
membrane was then incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 
(1:10000 dilution) for TRAIL detection and with goat anti-mouse IgG Alexa 680 (1:10,000 dilution) for 
the detection of CK8 and CK18.  A shows HCT116, B shows SW480-CD40 co-culture experiments. 
Antibody binding was visualised at 700nm and 800nm using an OdysseyTM Infra-red Imaging system 
(CK8 and CK18 were used as loading controls in A and B, respectively).  
Key:  NH: 3T3Neo co-cultured with HCT116          LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40   LS:3T3CD40L cocultured with SW480-CD40 
 +ve: 3T3CD40L cocultured with CRC cells (no inhibitor) 
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Figure 4. 34 Effect of pharmacological inhibitors of JNK and p38 on Bak induction during CD40-
mediated apoptosis 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 
MMC treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated 
time periods (3, 6 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine ± 5µM 
SP600125 (JNK inhibitor) and 5 µM SB202190 (p38 inhibitor) in 10cm2 culture dishes. After 
incubation, cells were lysed using 2x SDS-lysis buffer and protein concentration was determined. 
Whole lysates, following normalisation on the basis of CK8 or CK18 expression (see chapter 3) were 
separated under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membrane. The membrane was probed overnight at 4ºC with primary 
polyclonal antibody (anti-Bak) in TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 
antibody for HCT116 and CK8/18 for SW480-CD40 in TBS/Tween 0.1% (1:2000 dilution). The 
membrane was then incubated for one hour with secondary antibody goat anti-rabbit IgG IRDye 800 
(1:10000 dilution) for Bak detection and with goat anti-mouse IgG Alexa 680 (1:10,000 dilution) for 
the detection of CK8/18. A shows HCT116, B shows SW480-CD40 co-culture experiments. Antibody 
binding was visualised at 700nm and 800nm using an OdysseyTM Infra-red Imaging system (CK8 and 
CK8/18 were used as loading controls in A and B, respectively).  
Key:  NH: 3T3Neo co-cultured with HCT116            LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40    LS: 3T3CD40L cocultured with SW480-CD40 
+ve: 3T3CD40L cocultured with CRC cells (no inhibitor) 
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Figure 4. 35 Effect of pharmacological inhibitors of JNK and p38 on Bax induction during 
CD40-mediated apoptosis 
HCT116 (H) and SW480-CD40 (S) cells were seeded at 3x106 cells/dish and co-cultured with 3x106 MMC 
treated fibroblasts 3T3-Neo (N) or 3T3-CD40L (L). Co-cultures were incubated for the indicated time 
periods (3, 6 hours) in DR 5% supplemented with 5% of FCS and 1% L-glutamine ± 5µM SP600125 (JNK 
inhibitor) and 5 µM SB202190 (p38 inhibitor) in 10cm2 culture dishes. After incubation, cells were lysed 
using 2x SDS-lysis buffer and protein concentration was determined. Whole lysates, following 
normalisation on the basis of CK8 and CK18 expression (see chapter 3) were separated under denaturing 
conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF 
membrane. The membrane was probed overnight at 4ºC with primary monoclonal antibody (anti-Bax) in 
TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 antibody for HCT116 and CK8/18 for SW480-
CD40 in TBS/Tween 0.1% (1:2000 dilution). The membrane was then incubated for one hour with 
secondary antibody goat anti-mouse IgG IRDye 680 (1:10000 dilution) for Bax detection and with goat anti-
mouse IgG Alexa 680 (1:10000 dilution) for the detection of CK8/18. A shows HCT116, B shows SW480-
CD40 co-culture experiments. Antibody binding was visualised at 700nm and 800nm using an OdysseyTM 
Infra-red Imaging system (CK8 and CK8/18 were used as loading controls in A and B, respectively).  
Key:  NH: 3T3Neo co-cultured with HCT116              LH: 3T3CD40L cocultured with HCT116 
            NS: 3T3Neo co-cultured with SW480-CD40  LS: 3T3CD40L cocultured with SW480-CD40 
 +ve: 3T3CD40L cocultured with CRC cells (no inhibitor) 
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4.9 The role of Bax in CD40-mediated apoptosis 
  4.9.1 The knockdown of Bax using shRNA-mediated RNAi  
The functional role of the pro-apoptotic mitochondrial protein Bax in CD40-mediated 
apoptosis was investigated through shRNA-mediated RNAi. HCT116 cells were transduced 
with a retrovirus expressing Bax-specific shRNA (see Table 2.4). Following the combination 
of results from pre-titration experiments (Figure 4.36) and routine phase contrast 
microscopic examination during antibiotic treatment, it was found that a concentration of 
0.25µg/ml of puromycin concentration effectively perished non-transduced control HCT116 
cells after 72 hours of treatment. These derivatives will be referred to as Bax-KD.  
Of note, an interesting observation during the preparation of the Bax knockdown cell 
line (HCT116) was that following initial selection in antibiotic (Puromycin) and establishment 
in culture, the functional knockout cells demonstrated increased growth rates in comparison 
to control cells The increased growth rates appeared to be due to attenuation of 
spontaneous, culture stress-related apoptosis in vitro (Figure 4.37).  
 
 4.9.2 Bax knockdown attenuates CD40-mediated apoptosis 
Having established the Bax-KD cells, experiments were performed to examine 
whether the induction of Bax was of functional importance in CD40 killing. The ability of the 
designed shRNAs to knockdown Bax protein expression in Bax-KD cells was confirmed by 
immunoblotting (Figure 4.38). Densitometric analysis was also used to confirm that, the 
expression of Bax was reduced after 6 hours CD40 ligation compared with control as 
illustrated in Table 4.2 and Figure 4.39.   
Using CytoTox-Glo experiment assays, it was demonstrated that Bax knockdown 
significantly (p<0.01) reduced the apoptosis in CRC cells (HCT116) compared with control 
(Figure 4.40). Moreover, the results also showed that Bax inactivation significantly (p<0.001) 
abolished the activation of caspase 3/7 activity during CD40 mediated apoptosis Figure 
4.41); these findings suggested that Bax plays an important role during CD40-mediated 
apoptosis and thus may also be used as downstream marker of apoptosis mediated by JNK 
and TRAF3.  
  
  
191 
 
 
 
 
 
 
Figure 4. 36 HCT116 and Bax-KD cell proliferation following treatment with a range of 
puromycin concentrations 
1x104 HCT116-Bax-KD cells/ well and HCT116 cells/well were seeded in a transparent TC treated 96 
well plate and then treated with the indicated concentrations of puromycin antibiotic in 
DR/5%FCS/1%L-G for 24 hours. 20µl of CellTiter 96® AQueous One Solution was added to 
appropriate wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. To assess 
cell viability, total levels of formazan formation were measured using a FLUOstar OPTIMA (BMG 
Labtech) plate reader at a wavelength of 492nm. Bars correspond to mean absorbance values of 5-6 
technical replicates ± SEM and results are representative of three independent experiments. 
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Figure 4. 37 Antibiotic (Puromycin) selection of transduced HCT116 cells with Bax shRNA-expressing   retrovirus 
Transduced and non-transduced HCT116 cells were cultured in DR/5%FCS/1%L-G supplemented with 0.25µg/ml puromycin compared with non-
treated cells as control (the transduced cells shown here are cells in which an anti-Bax shRNA is expressed, denoted Bax-KD. HCT116 were also 
cultured with DR/5%FCS/1%L-G alone to demonstrate their normal growth pattern (Control). Note non-resistant HCT116 perish from the flask 
within 24 hours, however resistant cell populations continue to proliferate. Images are representative phase contrast micrographs (taken at 100x 
magnification). 
                          Bax-KD (0.25µg/ml)                                     HCT116 (0.25µg/ml) 
 
                                                                            Control (No antibiotic) 
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Figure 4. 38 The role of Bax knockdown in the regulation of Bax  during CD40-mediated 
apoptosis. 
3x106 control HCT116 cells (H) and HCT116 cells expressing Bax shRNA (Bax-KD) were co-cultured 
with 3x106 MMC treated mCD40L (L) and Controls (N) for 3 hours in DR / 5%FCS / 1%L-glutamine in 
10cm2 culture dishes in order to lyse with 2X SDS-lysis buffer. Whole lysates, following normalisation 
on the basis of CK8 expression (see chapter 3) were separated under denaturing conditions by SDS-
PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membrane. The 
membrane was probed overnight at 4ºC with primary monoclonal antibody (anti-Bax) in TBS/Tween 
0.1% (1:500 dilution) and then with an anti-CK8 antibody in TBS/Tween 0.1% (1:2000 dilution). The 
membrane was then incubated for one hour with secondary antibody [goat anti-rabbit IgG IRDye 
800nm (1:10000 dilution)] for Bax detection and with goat anti-mouse antibody IgG IRDye 680 
(1:10000 dilution) for CK8 (used as loading control).  
Key:  NH: 3T3Neo co-cultured with HCT116             LH: 3T3CD40L cocultured with HCT116 
            L:  3T3CD40L         
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HCT116 Bax-KD 
Time (h) 3 3 
Co-culturs NH LH NH LH 
Background band intensity 1010.23 1968.45 856.14 958.14 
CK8 BC band intensity 2245.45 2301.29 2014.58 2289.35 
Fold change 1.94852 1.11914 
 
Table 4. 2 Densitometric analysis to calculate fold change in Bax protein expression 
Densitometry was used to normalise data using Cytokeratin 8 as the loading Control. Readings 
represent band intensity values generated by the LiCor Odyssey analysis software. Data was 
normalised against densitometry values for Controls and then fold change was calculated by the 
following the equation (mCD40L/HCT116 ÷ Control/HCT116). BC - blank corrected. The table above 
is representative of the values obtained from the blot shown in Figure 4.38. 
 
 
 
  
Figure  4. 39 Densitometric analysis to calculate fold change in Bax protein expression following shRNA-
mediated knockdown 
Densitometry was used to normalise data using Cytokeratin 8 as the loading Control. Readings 
represent band intensities values generated by the LiCor Odyssey analysis software. Data was 
normalised against densitometry values for Controls and then fold change was calculated by the 
following equation (mCD40L/HCT116 ÷ Control/HCT116). BC - blank corrected. The table above is 
representative of values shown in Figure 4.38. 
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Figure 4. 40 Effect of shRNA-mediated Bax knockdown on CD40-induced apoptosis  
1x104 colorectal cancer cells/well (HCT116 and Bax-KD cells) were cocultured with 1x104 MMC 
treated 3T3CD40L (mCD40L) and 3T3Neo (control) in white 96 well plates in DR medium 
supplemented with 5% FBS and 1%  L-glutamine. After 24 hours of co-culture, the CytoTox-Glo 
assay was used to detect apoptosis in colorectal cancer cells (HCT116) as described in Chapter 2. 
Background corrected RLU readings deduced by substraction of mCD40L from coculture 
[(3T3CD40L + HCT116) – 3T3CD40L] and control [(3T3Neo + HCT116) -3T3Neo]. Bars show mean 
fold change ± S.D of 4 to 6 replicates and results are representative of three experiments. Results 
show significant differences between HCT116/3T3CD40L versus Bax-KD/3T3CD40L indicated by 
***p-value ≤0.001 for HCT116 cells and Bax-KD cells.  
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Figure 4. 41 Effect of Bax knockdown on caspase-3 and 7 activation during CD40-mediated 
apoptosis  
1x104 HCT116 and Bax-KD cells were co-cultured with 1x104 MMC treated mCD40L or Controls in 
DR medium supplemented with 5% FCS and 1%L-glutamine in white 96-well plates. 50µl of 
SensoLyte 3/7 substrate  was added after 48 hours, fluorescence measured (as described in the 
Materials and methods) and background-corrected reletive fluorescence unit (RFU) readings 
deduced by pair-wise subtraction of mCD40L and Control values from respective co-cultures. Bars 
show mean fold change of caspase 3 and 7 activity ± S.D of 4 to 6 replicates and results are 
representative of three experiments. Stats: *** p<0.001, paired student t-test, HCT116 compared with 
Bax knockdown cells. 
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4.10 Summary:  
 The main objective of this chapter was to identify the intracellular signalling 
mediators involved in CD40-induced signalling in CRC cells  
  Western blotting results demonstrated induction of TRAF1 in CRC cells at 6, 12 and 
24 hours following mCD40L-mediated CD40 ligation. 
  Dramatic and rapid induction of TRAF3 expression was observed at 1.5 hours with 
further increases at 3, 6, 12 and maximal expression occurring 24 hours post CD40 
ligation in CD40+ve CRC cell lines. 
  Interestingly, mCD40L-CD40 interaction caused rapid induction of TRAF6 at 1.5 
hours in CRC cell lines, however, the increase in TRAF6 expression was only 
temporary and TRAF6 expression was rapidly lost, thus indicating a transient effect.  
  Western blot experiments demonstrated that pro-apoptotic MAP kinases MKK4 and 
MKK7 were activated in response to mCD40L-CD40 ligation in CRC cell lines. 
  JNK activation (phosphorylation) occured rapidly following CD40 ligation within 1.5 
hours in CRC cell lines. 
  Detection of activated p-p38 following CD40 ligation was also rapid, being detectable 
in both HCT116 and SW480-CD40 cells within 1.5 hours. 
  The results have demonstrated that proapoptotic CD40 ligation in CRC cells induced 
both Bax and Bak expression. 
  By using pharmacological inhibitors, the results also documented that JNK and p38 
MAPK induced cell death involves the mitochondrial (intrinsic) pathway, requiring the 
pro-apoptotic Bax member of the Bcl-2 family to activate caspase-9.  
  The results have provided direct evidence that CD40-mediated cell death is 
dependent on activation of caspase-9 but also caspase-10, but not caspase-8, thus 
implying cross talk with an extrinsic, caspase-10 associated pathway. Apoptosis of 
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CRC cells was completely blocked by the pan-caspase inhibitor z-VAD (which 
confirmed that CD40-mediated apoptosis in CRC cells is entirely caspase-
dependent), as well as by specific inhibitors of caspases -9 and -10. 
  It was found that Bid was cleaved to t-Bid and cleavage of Bid occurred in the early 
stage of apoptosis in CRC cells lines at 1.5 hours, thus confirming the existence of a 
cross talk with an extrinsic apoptotic pathway.  
  Immunoblotting experiments showed that CD40 ligation mediated rapid induction of 
TRAIL expression within 1.5 hours of activation in CRC cell lines and it was 
sustained even at γ, 6, and 1β hours. 
  Induction of TRAIL receptor expression was also observed as a consequence of 
CD40 ligation, with TRAIL-RII (DR5) detected through immunoblotting at γ and 6 
hours in both CRC cell lines. 
  This is the first ever report that p38 and JNK are induced by CD40 which in turn 
activates TRAIL to induce a caspase-10-dependent pathway.  
  The results have demonstrated that cell death is caspase-dependent and that CD40 
triggers both intrinsic as well as extrinsic apoptotic cascades, as apoptosis involved  
- a) TRAIL/TRAIL-R induction and caspase-10 activation   
- b) Bak/Bax up-regulation, cytochrome c release and caspase-9     
activation. 
  The results indicated that in CRC cells mCD40L triggers rapid induction of apoptosis 
in less than 1β hours. Interestingly, CD40-induced, TRAIL-associated death appears 
to take place not by paracrine (juxtacrine) signalling but in an endogenous 
(autocrine) fashion (as indicated by well established, blocking antibodies). 
  Stable, retrovirus mediated TRAF3 knockdown caused significant reduction in 
apoptosis as determined by CytoTox-Glo assays and reduced the activity of caspase 
-3/-7 post CD40 ligation in CRC cells. 
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 Western blot results documented that TRAF3 KD abrogates JNK and p38 MAPK 
phosphorylation and completely abrogate Bax expression. 
  In short, the results have indicated that uniquely in CRC cells, CD40 ligation triggers 
rapid and dramatic cytotoxicity via a novel, cross-talk mechanism with the extrinsic 
apoptotic pathway. 
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CHAPTER 5: Reactive oxygen species and CD40-mediated 
apoptosis in CRC cells  
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5.1 Rationale for the study of ROS and antioxidant defence in CD40 
signalling 
 As discussed in Chapter 1, ROS are natural secondary products of mitochondrial 
oxidative metabolism, however they act as messengers to homeostatically stabilise cell 
proliferation and survival (Ray et al., 2012, Terada, 2006). ROS are elevated when reacting 
to extracellular stress for example cytokines, bacterial invasion and xenobiotics as to alert 
the cell that it is necessary to adapt (Jiang et al., 2011). In situations when ROS are not 
adequately ‗managed‘ by antioxidants, a cellular state forms that is called ‗oxidative stress‘ 
which often results in macromolecular damage (Sharma et al., 2004). At the same time its 
chronic persistence is involved in malignant transformation because it harms the DNA and, 
as a result, mediating an elevated rate of oncogene and/or tumor suppressor mutations 
(Valko et al., 2004). The controlling significance of oxidative stress is clinically demonstrated 
by an upsurge in cancer risks by way of mutation in the cellular antioxidants GSH and Trx. 
Yet, paradoxically, a lot of more advanced cancers over-express antioxidants in order to 
guard themselves against oxidative stress taking place due their extraordinary great energy 
generation demands (Halliwell, 2007). It has thus been hypothesised that tumours use 
continuous oxidative stress to initialize cell signaling pathways that support malignant 
transformation. 
 Nonetheless, it is similarly well known that ROS initialization performs significantly in 
pro-apoptotic responses (Biswas et al., 2006, Circu and Aw, 2010) and first and foremost 
those that involve mitochondrial pathways. Thus, collectively, ROS activation embodies a 
‗double-edged sword‘ (Pan et al., 2009), supporting increased proliferation ability at early 
stages of malignant transformation yet increasing sensitivity to pro-apoptotic signals due to 
oxidative stress ‗pushing‘ cells towards a ‗pro-apoptotic threshold‘. In other words, it has 
been suggested that tumour cells could be pushed over a pro-apoptotic ‗ROS limit‘ when 
compared to the other normal cells (Raj et al., 2011, Wang and Choudhary, 2011). Even 
though there are numerous factors to bear in mind in cellular redox management, there 
exists overall agreement that: a) diminished/low levels of ROS are a benchmark for normal 
cell homeostasis, b) elevated ROS levels initiate stress-responsive cell signaling pathways 
such as NF-κB and JNK, and lastly c) elevated ROS/oxidative stress can initiate cell 
apoptosis (D‘Autreaux and Toledano, β007, Terada, 2006). 
Most of the members of the TNFR superfamily use ROS to control cell survival and 
apoptosis by initializing oxidative stress responsive MAPK signaling pathway (Shen and 
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Pervaiz, 2006). The generation of is most of the time as a result of receptor-TRAF 
interaction with NADPH oxidases (Li et al., 2005, Ha and Lee, 2004, Chandel et al., 2001), 
which perform a critical role in ROS production (Jiang et al., 2011). A limited amount of 
evidence has suggested that CD40 ligation produces ROS through the 5-lipoxygenase 
pathway (Ha et al., 2011) and a TRAF3-NADPH oxidase association has in the past been 
suggested (Ha and Lee, 2004). B-cells research reveals that low levels of CD40 cross-
linking produces low levels of ROS and initiate NF-κB, however on the other hand enhanced 
receptor cross-linking produces elevated oxidative stress, prompting the initiation of JNK 
(Ha et al., 2011).  
Oxidative stress is associated with the positive regulation of apoptotic pathways as it 
directly activates responsive proteins (Circu and Aw, 2010). As discussed in the 
Introduction, oxidative stress results in activation of ASK1 by means of Thioredoxin release 
and auto phosphorylation (Liu and Min, 2002) and the initiation of MAPKs by means of their 
release from dual-specificity MAPK phosphatases (DS-MKPs) (Bermudez et al., 2010). 
Correspondingly, oxidative stress permits the initiation of JNK via GSTp discharge (Simic et 
al., 2009) and enhances AP-1 activity (Biswas et al., 2006), and there is evidence that 
reveals that pro-apoptotic members of the Bcl-2 family, like Bak/Bax are also altered by 
oxidative stress (Steckley et al., 2007, Tomiyama et al., 2006), as it is the same with 
enzymatic initiators of cell death, the caspases (Circu and Aw, 2010). In light of this 
evidence, it was hypothesised that ROS-associated signaling could possibly have a huge 
impact on CD40-mediated cell death in CRC cells.  
Up to this day, there are no comprehensive exploration functions of CD40-mediated 
ROS stimulation in apoptosis in cells of an epithelial origin. Because of this reason, the co-
culture system (Figure 3.1) together with apoptosis assays and immunoblotting methods 
were employed to examine in order, the likely stimulation of ROS by mCD40L and to 
understand the exact function of ROS production in the outcome of CD40 ligation in CRC 
cells.  
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5.2 Objectives 
The specific aims of this chapter are: 
 To optimise assays for the detection of ROS generation and investigate whether 
ROS are elevated as a result of CD40 ligation in CRC cells. 
 To utilize immunoblotting and cell death assays as well as pharmacological inhibitors 
to examine whether NADPH oxidases could be the crucial mediator of ROS 
generation and CD40-mediated apoptosis. 
 To define whether CD40 ligation modulates antioxidant pathways to influence the 
activation of ASK1 and downstream apoptotic signaling pathways.  
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5.3 The optimisation of ROS detection in CRC cells 
 
As explained above, this study aimed to provide detailed and functional evidence 
that mCD40L-induced apoptosis is dependent on production of ROS. To investigate the 
possibility of ROS production in CRC cell death the ROS detection fluorescent marker 6-
carboxy-β', 7‘-dichlorodihydrofluorescein diacetate (H2DCFDA) was used. 
  
The oxidation of 2,‘ 7‘ dichlorofluorescein (H2DCF) to β‘-7‘dichlorofluorescein (DCF) 
has been used rather widely for the quantitation of H2O2.  The di-acetate form, H2DCFDA 
and its acetomethyl ester H2DCFDA-AM are taken up by cells where nonspecific cellular 
esterases act upon it to cleave off the lipophilic groups, causing in a charged compound 
believed to be trapped inside the cell. Oxidation of H2DCF by ROS converts the molecule to 
β‘, 7‘ dichlorodihydrofluorescein (DCF), which is highly fluorescent (Figure 5.1).  The 
described wavelengths for the measurement of DCF fluorescence are 498 nm for excitation 
and 520 nm for emission. Initially, DCF was thought to be specific for hydrogen peroxide 
(H2O2), but current evidence has shown that other ROS such as nitrate and hypochlorous 
acid can oxidise H2DCF (Hoffman et al., 2008).  Most importantly is the fact that H2O2-
dependent oxidation of H2DCF requires ferrous iron (Rothe and Valet, 1990).  In addition, as 
H2DCF is no longer ionic it is not precluded from migrating out of the cell and accumulating 
in the media, where it is free to interact with oxidants.  
In initial experiments the two CRC cell lines HCT116 and SW480-CD40  were used 
to determine the concentration of H2DCFDA that would sensitively determine levels of 
intracellular ROS and discriminate between the different cell lines (as excessive amounts of 
reagent resulted in misleadingly high fluorescence levels in these cell lines) (Figure 5.2). By 
accounting for fluorescence background arising from differences in cell line dependent 
metabolism and division rate (which affects confluency) relative fluorescent values derived 
from treatment with H2DCFDA were optimised based on natural ‗auto-fluorescence‘ of the 
two cell lines HCT116 and SW480-CD40. During a long series of pre-titration experiments 
for the optimisation of conditions including a) H2DCFDA concentration, b) incubation periods 
and c) ROS activators as positive controls (staurosporine), it was found that the 
concentration of 0.5µM H2DCFDA sensitively and consistently discriminated between 
intracellular concentrations of ROS (Figure 5.3); these optimised methods for ROS detection 
were applied for all experiments.  
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Figure 5. 1 The principle of ROS detection using H2DCFDA 
6-carboxy-β', 7‘-dichlorodihydrofluorescein diacetate (H2DCFDA) is a derivative of reduced 
fluorescein that has cell permeability. The reduced forms of fluorescein lack any fluorescence until 
acetyl groups are removed by intracellular esterase(s) and oxidation is occurring within the cells. 
When this occurs the charge of the molecules makes it much less likely to leave the cell and also 
emits detectable fluorescence. The levels of fluorescence intensity deduced are therefore an 
indication of the intracellular concentration of ROS. Adapted from (Held, 2010) 
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Figure 5. 2 Optimisation experiments for the measurement of ROS production using H2DCFDA  
1x104 CRC cells/well (HCT116 and SW480-CD40) were plated for 24 hours in DR/5%FCS/1%L-G in 
white 96-well plates. The next day all wells were washed with PBS and the reagent at different 
concentrations was added and an incubation of 30 minutes at 37ºC in 5%CO2 was carried out 
Fluorescence was measured by using a plate reader at Excitation 485nm/Emission 520nm in the 
presence of PBS. Bars represent mean RFU values for 6-8 technical replicates ± S.D and results are 
representative of three independent experiments.  
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Figure 5. 3 Optimisation experiments for measurement of ROS activation in CRC cells 
(measurement of auto-fluorescence)  
1x104 CRC cells/well (HCT116 and SW480-CD40) were plated for 24 hours in DR/5%FCS/1%L-G in 
white 96-well plates. The next day all lines were assessed for their relative autofluorescence at 
Excitation 485nm/Emission 520nm in the presence of PBS. Bars represent mean RFU values for 6-8 
technical replicates ± S.D and results are representative of three independent experiments. 
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5.4 The induction of ROS by mCD40L in CRC cells 
This study further determined whether the optimised system for ROS detection could 
be used to demonstrate ROS induction as a consequence of mCD40L-CD40 engagement, 
as reported by others (Bhogal et al., 2012, Ha and Lee, 2004, Ha et al., 2011). Target cells 
(HCT116 / SW48CD40) were first screened for ROS elevation using the co-culture methods 
for CD40-mCD40L interaction (section 3.1.1) following fluorescence (RFU) 3T3 cell-
associated background correction, as described previously for cell death assays (section 
3.4.1.1). Preliminary experiments showed optimal detection of ROS at 2.5 hours post CD40 
ligation, significantly greater (p<0.05) degree of ROS production compared with the controls 
(Figure 5.4). (p<0.001) However, the earlier time points of 1.5, 2 hour ligation were 
investigated. 
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Figure 5. 4 mCD40L-mediated ROS induction in CRC cells 
1x104 cells/well HCT116 or SW480-CD40 were co-cultured with 1x104 3T3-CD40L (mCD40L) or 3T3-
Neo (Controls) in DR/5%FCS/1%L-G in white 96-well plates. Cells were first washed with PBS to 
remove any culture medium and were then treated with 0.5µM of H2DCFDA in pre warmed (37°C) 
PBS for 30 minutes 37°C in 5% CO2. Background-corrected RFU readings were deduced by pair-wise 
subtraction of mCD40L and Control cells from the respective co-culture. Bars represent mean RFU 
values for 5-6 technical replicates ± SEM and results are representative of three independent 
experiments. 
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5.5 The role of ROS in CD40-mediated cell death 
To determine whether ROS-mediated oxidative stress is essential to mCD40L- 
mediated apoptosis, the aim was to induce CD40 activation in the CRC cell lines 
HCT116 and SW480-CD40 by co-cultures as previously (Figure 3.1) in the presence of 
the antioxidant/ROS scavenger N-acetyl L-cysteine (NAC).  
To ensure that the optimal concentration of NAC was used so that it did not interfere 
with cell viability, pre-titration experiments were carried out using the CellTiter 96® 
AQueous One Solution Cell Proliferation assay to determine an effective dose for both the 
effector (killer) cells (3T3-CD40L and 3T3-Neo controls) (Figure 5.5) and target (CRC) 
cells (HC116 and SW480-CD40) (Figure 5.6). It was observed that doses of 2.5 and 
5mM were well tolerated by CRC cells; however, higher concentrations of NAC 
appeared toxic to CRC cells even though they well tolerated by the effector cells. 
Based on these optimisation experiments, addition of 2.5mM and 5mM NAC during 
co-culture completely and significantly (p<0.001) attenuated mCD40L-mediated 
apoptosis as determined by CytoTox-Glo assays (Figure 5.7).  
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Figure 5. 5 Determination of effective dose of NAC on effector (killer) cells (3T3- CD40L / 3T3-
Neo) 
1x104 cells/well were seeded in 96 well plate in DR medium supplemented with 5% FBS and 
1%LG. Cells were incubated overnight in 37⁰C/ 5% CO2. Then the cells were treated with 
different concentrations of NAC. After 24hours incubation, 20µl of CellTiter 96® AQueous One 
Solution was added to appropriate wells and plates were incubated at 37°C in 5% CO2 for a 
total of four hours. By using a plate reader at a wavelength of 492nm, absorbance was 
measured to know. Bars correspond to mean absorbance values of 5-6 technical replicates ± 
SEM and results are representative of three independent experiments. 
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Figure 5. 6 Determination of effective dose of NAC on CRC cells (HCT116/SW480-CD40) 
1x104 cells/well were seeded in 96 well plate in DR medium supplemented with 5% FBS and 1%LG. 
Cells were incubated overnight in 37⁰C/ 5% CO2. Then the cells were treated with different 
concentrations of NAC. After 24hours incubation, 20µl of CellTiter 96® AQueous One Solution was 
added to the appropriate wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
By using a plate reader at a wavelength of 492nm, absorbance was measured. Bars correspond to 
mean absorbance values of 5-6 technical replicates ± SEM and results are representative of three 
independent experiments. 
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Figure 5. 7 Effect of the antioxidant NAC on CD40-mediated apoptosis  
CRC cells (HCT116) were co-cultured at density 1x104cells/well with either 1x104 cells/well MMC 
treated fibroblast cells (3T3CD40L and 3T3Neo) in DR medium supplemented with 5%FCS/1% L-
glutamine. 2.5mM and 5mM of NAC was added to co-culture in 96 well plates and incubated for 24 
hours at 37ºC and 5%Co2. After the incubation time, apoptosis was measured by using CytoTox-Glo. 
50µM of substrate was added and then luminescence was measured by plate reader then 
background-corrected RLU reading deduced by pair-wise subtraction of mCD40L and control cell 
from the respective co-culture (Materials and methods). Bars presented mean RLU value for 5-6 
replicates ± S.D and results are representative of three experiments; ***p-value ≤ 0.001 and 
**p<0.01. A and B show background corrected raw data and fold change, respectively.   
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5.6 The role of NADPH oxidase in CD40-mediated cell death 
As it has been reported that CD40 may generate ROS in malignant B-cells via TRAF3 
and Nox (Ha and Lee, 2004) it was assumed that this may also happen in epithelial CRC 
carcinoma cells.  
Following initial pre-titration experiments (using the Cell Titer 96® AQueous One Solution 
Cell Proliferation assay) to determine an effective dose, as shown in Figure 5.8 for killer 
cells (3T3-CD40L and 3T3-Neo) and Figure 5.9 for target cells (HCT116 and SW480-
CD40), the highly specific Nox inhibitor DPI was added during in co-culture 3T3 and CRC 
cell co-cultures. The addition of DPI completely abrogated mCD40L-induced cell death in 
comparison to the control, as determined by CytoTox-Glo death detection assays in both 
HCT116 and SW480-CD40 cells (Figures 5.10 and 5.11). In addition to a significant 
reduction in apoptosis (p<0.001), DPI significantly reduce the activity of caspase-3/7 in 
CRC cells (HCT116 and SW480-CD40) (Figures 5.12 and 5.13) (p-value <0.05). These 
data suggest for the first time that CD40-mediated death by mCD40L in carcinoma cells is 
dependent on ROS induction by Nox.  
Immunoblotting was used to determine whether ROS production may be linked to the 
association of TRAF3 with the specific Nox subunit p40-phox as observed by others (Ha 
and Lee, 2004). Results implied that CD40 engagement generates ROS through p40-phox 
as this was phosphorylated by 1.5, 3, 6, 12 hours post CD40 ligation, however no changes 
were seen in the control (Figure 5.14). Although strictly no direct interaction of TRAF3 and 
p40-phox was demonstrated here, the results strongly imply that a similar mechanism for 
ROS production by CD40-mediated recruitment of TRAF3/Nox may occur in both malignant 
B-cells (Ha and Lee, 2004) and carcinoma (CRC) cells.  
Previous studies have indicated that the possible mechanism(s) for the CD40 induced 
production of ROS following activation of TRAF3 (Ha and Lee, 2004). The immunoblotting 
results on TRAF3-KD cells lysate co-culture with 3T3CD40L COMPARED WITH CONTROL 
(HCT116) also demonstrate that CD40-linked TRAF3 probably mediates the activation of 
NADPH oxidase via the recruitment of p40phox. As shown in Figure 5.15, TRAF3-KD 
completely abrogated p40phox expression subsequent to CD40 ligation. This result suggest 
that CD40 ligation produces ROS by the TRAF3 dependent motivation of NADPH oxidase  
(NOX) , and that ROS link the CD40 ligation to promote signalling events. 
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Interestingly, when CD40 ligation was initiated in CRC cells in the presence of the Nox 
inhibitor DPI, the activation of TRAF3 was severely diminished.  (Figure 5.16) thus implying 
a role for ROS in the stabilisation of TRAF3 in the first place.  
In addition to a significant reduction in apoptosis (p<0.001), DPI also prevented 
expression one of the pro-apoptotic protein Bax, as determined by western blotting (Figure 
5.17). These results suggested that CD40-mediated death by membrane CD40L ligand in 
CRC cells is dependent on ROS induction triggered by NOX.   
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Figure 5. 8 Determination of effective dose of DPI on effector (killer) cells (3T3-
CD40L/ 3T3Neo) 
1x104 cells/well were seeded in 96 well plates in DR medium supplemented with 5% FBS 
and 1%LG. Cells were incubated overnight in 37⁰C/ 5% CO2. Then the cells were treated 
with different concentrations of DPI compared with control (Untreated cells). After 24hours 
incubation, 20µl of CellTiter 96® AQueous One Solution was added to the appropriate wells 
and plates were incubated at 37°C in 5% CO2 for a total of four hours. By using a plate 
reader at a wavelength of 492nm, absorbance was measured. Bars correspond to mean 
absorbance values of 5-6 technical replicates ± SEM and results are representative of 
three independent experiments. 
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Figure 5. 9 Determination of effective dose of DPI on target cells (HCT116/ SW480-CD40) 
1x104 cells/well were seeded in 96 well plate in DR medium supplemented with 5% FBS and 
1%LG. Cells were incubated overnight in 37⁰C/ 5% CO2. Then the cells were treated with 
different concentrations of DPI compared with control (Untreated cells). After 24hours incubation, 
20µl of CellTiter 96® AQueous One Solution was added to the appropriate wells and plates were 
incubated at 37°C in 5% CO2 for a total of four hours. By using a plate reader at a wavelength of 
492nm, absorbance was measured. Bars correspond to mean absorbance values of 5-6 technical 
replicates ± SEM and results are representative of three independent experiments.  
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Figure 5. 10 NADPH oxidase (Nox) inhibition by DPI reduces CD40-mediated apoptosis 
in HCT116 cells 
CRC cells (HCT116) were co-cultured at density 1x104cells/well with 1x104 cells/well MMC-
treated fibroblasts (3T3CD40L and 3T3Neo) in DR medium supplemented with 5%FCS/ 1% 
L-glutamine. 0.125µM of DPI was added to the cultures in 96 well plates and incubated for 24 
hours at 37ºC and 5%CO2. After the incubation time, apoptosis was measured by using 
CytoTox-Glo by adding 50µM of substrate then luminescence was measured by a plate 
reader then background-corrected RLU reading deduced by pair-wise subtraction of mCD40L 
and control cells from the respective co-culture (Materials and methods). Bars represent 
mean RLU value for 5-6 replicates and results representative of three experiments; p-value ≤ 
0.001. A and B show background corrected readings and fold change in luminescence, 
respectively, following CD40 ligation in the HCT116 cell line.  
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Figure 5. 11 NADPH oxidase (Nox) inhibition by DPI reduces CD40-mediated 
apoptosis in SW480-CD40 cells 
CRC cells (SW480-CD40) were co-cultured at density 1x104cells/well with 1x104 cells/well 
MMC-treated fibroblasts (3T3CD40L and 3T3Neo) in DR medium supplemented with 
5%FCS/ 1% L-glutamine. 0.125µM of DPI was added to the cultures in 96 well plates and 
incubated for 24 hours at 37ºC and 5%CO2. After the incubation time, apoptosis was 
measured by using CytoTox-Glo. 50µM of substrate was added and then luminescence was 
measured by a plate reader then background-corrected RLU reading deduced by pair-wise 
subtraction of mCD40L and control cell from the respective co-culture (Materials and 
methods). Bars represent mean RLU value for 5-6 replicates and results representative of 
three experiments; p-value ≤ 0.001. A and B show background corrected readings and fold 
change in luminescence, respectively, following CD40 ligation in the SW480-CD40 cell line.  
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Figure 5. 12 NADPH oxidase (Nox) inhibition reduces caspases 3/7 activity in the 
HCT116 cell line following CD40 ligation  
CRC cells (HCT116) were co-cultured at density 1x104cells/well with either 1x104 cells/well 
MMC treated fibroblast cells (3T3CD40L and 3T3Neo) in DR medium supplemented with 
5%FCS/ 1% L-glutamine. 0.125µM of DPI was added to the cultures in 96 well plates and 
incubated for 24 hours at 37ºC and 5%Co2. After the incubation time, caspase 3/7 activity was 
assessed by using SensoLyte 3/7 reagent was added after 48 hours, fluorescence measured 
(Materials and methods) then background-corrected RFU reading deduced by pair-wise 
subtraction of mCD40L  and control cells from the respective co-culture. Bars represent mean 
RFU value for 5-6 replicates and results representative of three experiments; p-value ≤ 0.001. 
A and B show background corrected and fold change respectively for caspase 3/7 activity of 
NADPH oxidase inhibition by antioxidant following CD40 ligation.  
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Figure 5. 13 NADPH oxidase (Nox) inhibition reduces caspases 3/7 activity in the 
SW480-CD40 cell line following CD40 ligation 
CRC cells (SW480-CD40) were co-cultured at density 1x104cells/well with 1x104 cells/well 
MMC-treated fibroblasts (3T3CD40L and 3T3Neo) in DR medium supplemented with 
5%FCS/ 1% L-glutamine. 0.125µM of DPI was added to the cultures in 96 well plates and 
incubated for 48 hours at 37ºC and 5%Co2. After the incubation time, caspase 3/7 activity 
was assessed by using SensoLyte 3/7 reagent that was added after 48 hours, fluorescence 
measured (Materials and methods) then background-corrected RFU readings deduced by 
pair-wise subtraction of mCD40L and control cells from the respective co-culture. Bars 
represent mean RFU value for 5-6 replicates and results representative of three 
experiments; p-value ≤ 0.001. A and B show background corrected and fold change 
respectively for caspase 3/7 activity of NADPH oxidase inhibition following CD40 ligation.  
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Figure 5. 14 p40-phox phosphorylation induced by mCD40L  
HCT116 (H) and SW480-CD40 (S) cells were seeded at density 3x106 cells/dish, and co-
cultured with 3x106 MMC-treated 3T3-Neo (N) or 3T3-CD40L (L), as indicated. Co-cultured 
cells were incubated for various times 1.5, 3, 6, 12 hours in DR5% supplemented with 5% of 
FCS and 1% L-glutamine in 10cm2 culture dishes. After each incubation time, cells were lysed 
by using 2x SDS-lysis buffer. After that protein concentration was determined. Whole lysates, 
following normalisation on the basis of CK8 and CK18 expression (see chapter 3) were 
separated by western blotting under denaturing conditions by SDS-PAGE using 4-12% (w/v) 
Bis-Tris gels and then immunoblotted onto a PVDF membrane. The PVDF membrane was 
probed overnight at 4ºC with primary monoclonal antibody (anti-p40phox) in TBS/Tween 0.1% 
(1:250 dilution) and then with an anti-CK8 antibody for HCT116 and CK18 antibody for SW480-
CD40 in TBS/Tween 0.1% (1:2000 dilution). The membranes were then incubated for one hour 
with secondary antibody [goat anti-rabbit IgG IRDye 800 (1:10000 dilution)] for p40phox 
detection and with goat anti-mouse antibody IgG IRDye 680(1:10000 dilution) for CK8 and 
CK18. Antibody binding was visualised at 700nm and 800 using an OdysseyTM Infra-red 
Imaging system. 
 Keys: NH: 3T3Neo co-cultured with HCT116                LH: 3T3CD40L co-cultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40   LS: 3T3CD40L co-cultured with SW480-CD40 
            L: 3T3CD40L  
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Figure 5. 15 The role of TRAF3 knockdown on p40phox  following CD40 ligation  
3x106 CRC cells [HCT116 (H)] and HCT116 cells expressing TRAF3 sh RNA (TRAF3-KD) were co-
cultured with 3x106 MMC treated mCD40L (L) and Controls (N) for 3 and 6 hours in DR / 5%FCS / 
1%LG in 10cm2 culture dishes in order to lyse with 2X SDS-lysis buffer. Whole lysates, following 
normalisation on the basis of CK8 and CK18 expression (see chapter 3) were separated by western 
blotting under denaturing conditions by SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then 
immunoblotted onto a PVDF membrane. The membrane was probed for overnight at 4ºC with primary 
monoclonal antibody/goat anti-mouse antibody (anti-p40phox) in TBS/Tween 0.1% (1:520 dilution) and 
then with an anti-CK8 antibody in TBS/Tween 0.1% (1:2000 dilution). The membrane was then 
incubated for one hour with secondary antibody [goat anti-mouse IgG IRDye 680 (1:10000 dilution)] 
for p- p40phox detection and membrane was incubated with goat anti-mouse antibody IgG IRDye 680 
(1:10000 dilution) for CK8 (used as loading control).  
Keys: NH: 3T3Neo co-cultured with HCT116                      LH: 3T3CD40L co-cultured with HCT116 
           L:  3T3CD40L   
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Figure 5. 16 The Nox inhibitor DPI prevents the induction of TRAF3 following mCD40L-
mediated CD40 ligation  
3x106 MMC-treated 3T3-Neo (N) and 3T3-CD40L (L) were co-cultured with either 3x106 of HCT116 
cells (H) and SW480-CD40 (S). Co-cultured cells were incubated with 0.125µM DPI for 1.5 and 3 
hours. In control experiments, cells were co-cultured in the absence of DPI. Cell lysates were 
prepared and whole lysates, following normalisation on the basis of CK8 expression (see chapter 3) 
were loaded by western blotting. Cell proteins were separated under denaturing conditions by SDS-
PAGE using 4-12% (W/V) Bis-Tris gels and then immunoblotted onto a PVDF membrane. The PVDF 
membrane was probed overnight at 4ºC with primary polyclonal antibody (anti-TRAF3 antibody) in 
TBS/Tween 0.1% (1:500) and then with an anti-CK8 antibody for HCT116 [A] and CK18 for SW480-
CD40 [B] (1:2000 dilution). The membrane was incubated for one hour with goat anti-rabbit IgG Alexa 
800 (1:10000) for TRAF3 detection and one hour with goat anti-mouse IgG Alexa 680 (1:10000) for 
CK8 detection. Antibody binding was visualised at 700nm and 800nm using an OdysseyTM infra-red 
Imaging system.  
Keys: NH: 3T3Neo co-cultured with HCT116                    LH: 3T3CD40L co-cultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40           LS: 3T3CD40L co-cultured with SW480-CD40 
           L:  3T3CD40L                                                              DPI: Diphenyleneiodonium  
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Figure 5. 17 Nox inhibitor DPI prevents mCD40L-mediated induction of Bax  
3x106 MMC-treated 3T3-Neo (N) and 3T3-CD40L (L) were co-cultured with either 3x106 of HCT116 
cells (H) and SW480-CD40 (S). Co-cultured cells were incubated with 0.125µM DPI for 3 and 6 hours. 
In control experiment, cells were co-cultured with in the absence of DPI. Cell lysates were prepared 
and whole lysates, following normalisation on the basis of CK18 and CK8/18 expression (see chapter 
3) were resolved by western blotting. Cell proteins were separated under denaturing conditions by 
SDS-PAGE using 4-12% (W/V) Bis-Tris gels and then immunoblotted onto a PVDF membrane. The 
PVDF membrane was probed overnight at 4ºC with primary monoclonal antibody (anti-Bax antibody) 
in TBS/Tween 0.1% (1:500) and then with an anti-CK8/18 antibody for HCT116 as shown in A, while 
CK18 was used for SW480-CD40 as shown in B (1:2000 dilution). The membrane was incubated for 
one hour with goat anti-mouse IgG Alexa 680 (1:10000) for the detection Bax, CK8/18 and CK18. 
Antibodies binding were visualised at 700nm and 800nm using an OdysseyTM infra-red Imaging 
system.  
Keys: NH: 3T3Neo co-cultured with HCT116                    LH: 3T3CD40L co-cultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40          LS: 3T3CD40L co-cultured with SW480-CD40 
           L:  3T3CD40L            
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5.7 The role of ASK1 in CD40-mediated cell death  
Apoptosis signal-regulating kinase 1 (ASK1) is a member of the MAP3K (MAPKKK) 
family, which activates the MAPKK family, including MKK4 and MKK7 and MAPK such as 
JNK and p38 pathways (Takeda et al., 2011, Ichijo et al., 1997). ASK1 is specifically 
activated in response to different types of stress, such as ROS, TNF-α, lipopolysaccharide 
(LPS), and ER stress, and has pivotal roles in a wide variety of cellular responses, including 
apoptosis, differentiation, and inflammation (Ichijo et al., 1997, Nishitoh et al., 2002). 
Therefore, the extreme stimulation and dysregulation of ASK1 are closely linked to various 
diseases such as cancer and arteriosclerosis.  
In this project, the role of ASK1 in apoptosis following CD40-CD40L interaction was 
investigated. Immunoblotting showed that the activation of CD40 on CRC cells by its 
membrane ligand activated the expression of ASK1 within 1.5 hours post CD40 ligation 
(Figure 5.18).  Moreover, inhibition of apoptosis by using DPI (0.125µM) attenuated ASK1 
activation as shown in Figure 5.19  
Previous studies (Ha and Lee, 2004) have showed that ROS generation is triggered 
by CD40 ligation in B cells and recent work in our laboratory (Chris Dunnill, PhD thesis) in 
bladder (UCC) cells has demonstrated that ROS is important for early CD40-mediated 
signalling events that lead to the activation of JNK. In particular, Nox-generated ROS appear 
to be involved in the activation of JNK as inhibition of ROS production and subsequent JNK 
activation was achieved using DPI treatment.  Reducing elevation of ROS by pre-treating 
HCT116 and SW480-CD40 cells with 0.125µM DPI significantly reduced CD40 ligation-
induced phosphorylation of JNK (Figure 5.20). Thus implying that CD40 induces TRAF3 and 
NOX in a co-ordinated manner to activate ROS release and trigger subsequent ASK1 and 
JNK activation.  
5.8 Effect of CD40 ligation on Thioredoxin (Trx) expression  
As mentioned above, it was shown that CD40-mediated apoptosis triggers the 
activation of ASK1. ASK1 is regulated by Trx which under physiological ROS levels 
physically binds ASK1 and inhibits its auto-phosphorylation and thus activation. During 
oxidative stress, Trx scavenges ROS, however in doing so it releases ASK1 which 
undergoes activation via auto-phosphorylation at Thr845 (Soga et al., 2012).  
Based on the findings shown in this and the previous chapter, it was hypothesised 
that ROS elevation mediates Trx/ROS-‗occupancy‘ for rapid release of ASK1 within a few 
hours post-ligation. Moreover, recent findings in our laboratory in bladder (UCC) cells have 
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demonstrated that CD40 ligation can efficiently down-modulate Trx-1 expression during the 
course of CD40 ligation (Chris Dunnill, PhD thesis). Thus, immunoblotting was used to 
examine the expression of Trx over a 24 hour time window. Interestingly, it was found that 
Trx expression appeared to be moderately reduced by CD40 ligation particularly in HCT116 
cells. Notably also, there was a gradual increased expression of Trx in the Controls (HCT116 
and SW480-CD40/ 3T3-Neo) (Figure 5.21) suggesting that during in vitro cell culture, tumour 
cells progressively increase Trx possibly as a cyto-protective mechanism against their 
sustained oxidative stress associated with proliferation signaling. 
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Figure 5. 18 Activation of ASK1 evident by activatory Thr845 residue phosphorylation in 
response to mCD40L   
HCT116 (H) and SW480-CD40 (S) cells were seeded at density 3x106 cells /dish, and co-cultured with 
3x106 cells/dish MMC-treated 3T3-Neo (N) or 3T3-CD40L (L), as indicated. Co-cultures were 
incubated for 1.5, 3, and 6 hours in DR 5% supplemented with 5% of FCS and 1% L-glutamine, using 
10cm2 culture dishes. After each of incubation time, cells were lysed by using 2x SDS-lysis buffer and 
protein concentration was determined. Whole lysates, following normalisation on the basis of CK8 and 
CK18 expression (see chapter 3) were separated by western blotting under denaturing conditions by 
SDS-PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membrane. The 
PVDF membrane was probed for overnight at 4ºC with primary polyclonal antibody (anti-p-Ask1) in 
TBS/Tween 0.1% (1:250 dilution) and then with an anti-CK8 and CK18 antibody in TBS/Tween 0.1% 
(1:2000 dilution). The membrane was then incubated for one hour with secondary antibody [goat anti-
rabbit IgG IRDye 800 (1:10000 dilution)] for p-Ask1 detection. Also, membranes were incubated with 
[goat anti-mouse IgG IRDye 680 (1:10000 dilution) to detect CK8 and CK18. Antibody binding was 
visualised at 700nm and 800nm using an OdysseyTM Infra-red Imaging system. CK8/18 and CK8 were 
used as loading controls for HCT116 and SW480-CD40.    
Keys: NH: 3T3Neo co-cultured with HCT116                   LH: 3T3CD40L co-cultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40          LS: 3T3CD40L co-cultured with SW480-CD40 
           
 
 
 
 
  
229 
 
  
Figure 5. 19 The Nox inhibitor DPI blocks mCD40L-mediated ASK1 induction  
3x106 MMC-treated 3T3-Neo (N) and 3T3-CD40L (L) were co-cultured with both 3x106 of HCT116 
cells (H) or SW480-CD40 (S) shown in panels A and B, respectively. Co-cultures were incubated with 
0.125µM DPI for 3 and 6 hours. In control experiments, cells were co-cultured in the absence of DPI. 
Whole lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3)  
were separated under denaturing conditions by SDS-PAGE using 4-12% (W/V) Bis-Tris gels and then 
immunoblotted onto a PVDF membrane. The PVDF membrane was probed overnight at 4ºC with 
primary polyclonal antibody (anti-ASK1 antibody) in TBS/Tween 0.1% (1:500) and then with an anti-
CK8/18 antibody for HCT116 as shown in A, while CK18 was used for SW480-CD40 as shown in B 
(1:2000 dilution). The membrane was incubated for one hour with goat anti-mouse IgG Alexa 680 
(1:10000) for the detectionASK1, CK8/18 and CK18. Antibody binding was visualised at 700nm and 
800nm using an OdysseyTM infra-red Imaging system.   
Keys: NH: 3T3Neo co-cultured with HCT116                  LH: 3T3CD40L co-cultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40          LS: 3T3CD40L co-cultured with SW480-CD40 
           L:  3T3CD40L                                                         DPI: Diphenyleneiodonium       
A 
B 
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Figure 5. 20 The effect of DPI on mCD40L-mediated JNK activation   
3x106 MMC treated mouse fibroblasts cells (3T3-Neo (N) and 3T3-CD40L (L) were co-cultured with 
either 3x106 of HCT116 cells (H) and SW480-CD40 (S) shown in panels A and B, respectively. Co-
cultured cells were incubated with 0.125µM DPI for 1.5 and 3 hours. In control experiment, cells were 
co-cultured in the absence of DPI. Cell lysates were prepared by using lysis buffer and then Whole 
lysates, following normalisation on the basis of CK8 and CK18 expression (see chapter 3) were 
loaded by western blotting. Cell proteins were separated under denaturing conditions by SDS-PAGE 
using 4-12% (W/V) Bis-Tris gels and then immunoblotted onto a PVDF membrane. The PVDF 
membrane was probed overnight at 4ºC with primary monoclonal antibody (anti-phspho-JNK antibody) 
in TBS/Tween 0.1% (1:500) and then with an anti-CK8 antibody for HCT116 [A] and CK18 for 
SW480-CD40 [B] (1:2000 dilution). The membrane was incubated for one hour with goat anti-mouse 
IgG Alexa 680 (1:10000) for p-JNK, CK8 and CK18. Antibody binding was visualised at 700nm and 
800nm using an OdysseyTM infra-red Imaging system.   
Keys: NH: 3T3Neo co-cultured with HCT116                  LH: 3T3CD40L co-cultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40           LS: 3T3CD40L co-cultured with SW480-CD40 
           L:  3T3CD40L                                                          DPI: Diphenyleneiodonium   
A 
B 
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Figure 5. 21 The effect of CD40 ligation on thioredoxin-1 (Trx-1) expression   
HCT116 (H) and SW480-CD40 (S) cells were seeded at density 3x106 cells /dish, and co-cultured with 
3x106 MMC-treated 3T3-Neo (N) or 3T3-CD40L (L) as indicated. Co-cultures were incubated for 3, 6, 
12 and 24 hours in DR 5% supplemented with 5% of FCS and 1% L-glutamine, in 10cm2 culture 
dishes. After each of incubation time, cells were lysed by using 2x SDS-lysis buffer and protein 
concentration was determined. Whole lysates, following normalisation on the basis of CK8 and CK18 
expression (see chapter 3) were separated by western blotting under denaturing conditions by SDS-
PAGE using 4-12% (w/v) Bis-Tris gels and then immunoblotted onto a PVDF membrane. The PVDF 
membrane was probed for overnight at 4ºC with primary polyclonal antibody (anti-thioredoxin-1) in 
TBS/Tween 0.1% (1:500 dilution) and then with an anti-CK8 antibody in TBS/Tween 0.1% (1:2000 
dilution). The membrane was then incubated for one hour with secondary antibody [goat anti-rabbit 
IgG IRDye 800 (1:10000 dilution)] for thioredoxin detection. Antibody binding was visualised at 700nm 
and 800nm using an OdysseyTM Infra-red Imaging system CK8/18 and CK8 were used as loading 
control for HCT116 and SW480-CD40, respectively.    
Keys: NH: 3T3Neo co-cultured with HCT116                  LH: 3T3CD40L co-cultured with HCT116 
           NS: 3T3Neo co-cultured with SW480-CD40           LS: 3T3CD40L co-cultured with SW480-CD40 
           L: 3T3CD40L  
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5.9 Summary:  
The results presented in this chapter provided a series of observations on the 
mechanisms of mCD40L-mediated apoptosis: 
  The objective of this chapter was to further characterise the intracellular signalling 
pathway responsible for CD40-induced apoptosis in CRC cells by studying the role of 
ROS and associated signalling mediators.   
  CD40 ligation promoted rapid generation of reactive oxygen species in CRC cells. 
ROS production after CD40 ligation in CRC cells was detected with H2-DCFDA at 30 
min post ligation. 
  The results demonstrated that the ability of the NADPH oxidase inhibitor DPI and the 
ROS scavenger NAC to prevent mCD40L-induced apoptosis is linked to their ability 
to prevent the induction of ROS and thus oxidative stress. 
  DPI decreased the level of caspase -3 and -7 activity in CRC cells post CD40 ligation 
thus providing direct evidence for the role of the Nox family in CD40-mediated death. 
  Immunoblotting showed that mCD40L induced rapid phosphorylation of Nox enzyme 
subunit p40phox.  
  Collectively, the results provided evidence that mCD40L-mediated ROS generation is 
dependent on the induction of the p40phox sub-unit. 
  mCD40L induced TRAF3-mediated p40phox activation, which was detected rapidly 
at 1.5 hours post CD40 ligation. Hence TRAF3 may trigger ROS production via its 
interaction with p40phox. 
  TRAF3 KD prevented the expression of p40phox after 3 hours post CD40 ligation. 
  Inhibition of NOX by pharmacological drug (DPI) abrogated TRAF3 induction at 3 
hours following mCD40L ligation thus indicating the importance of Nox-mediated 
ROS generation in potential stabilisation of TRAF3. 
  Inhibition of NOX by DPI also abrogated Bax induction in CRC cells. 
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  For the first time ASK1 phosphorylation in response to mCD40L-mediated CD40 
ligation was also demonstrated and it occurred at 1.5 hours which is the point when 
maximal ROS elevation was detected. 
  Inhibition of NOX by DPI abrogated ASK1 induction at 3 and 6 hours as determined 
by immunoblotting in CRC cells. 
  Inhibition of Nox reduced JNK expression in CRC cells post CD40 ligation.  
  The results also demonstrated that Thioredoxin-1 (Trx) expression appeared to be 
abrogated by mCD40L-CD40 ligation beginning with low expression at 6 hours with a 
further gradual decrease over 12, and 24 hours intervals. 
  The results demonstrated that NOX has an important role in regulation cell apoptosis 
in response to the mCD40L-CD40 ligation. 
  Results suggested that for the first time CD40-mediated death by membrane CD40 
ligand in carcinoma cells is dependent on ROS induction by NOX and it involves 
activation of ASK-1 which in turns would be expected to trigger MKK activation and 
subsequent phosphorylation of JNK and p38 (as reported in the previous chapter). 
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CHAPTER 6: Discussion  
 235 
 
6.1 Thesis background and rationale  
It has been widely reported that CD40 ligation by CD40 agonists has the potential to regulate 
tumour epithelial cell growth (reviewed by (Eliopoulos and Young, 2004, Tong and Stone, 
2003). However, accumulating evidence suggests that the ‗quality‘ of the CD40 signal is very 
important in the functional outcome of CD40 ligation. In fact, although a number of studies 
have shown that soluble CD40 agonists can induce growth inhibition in carcinoma cells of 
various origins (reviewed by (Tong and Stone, 2003, Vonderheide, 2007), these agonists are 
at best weakly pro-apoptotic and only become significantly pro-apoptotic by pharmacological 
intervention (Bugajska et al., 2002, Afford et al., 2001, Ahmed-Choudhury et al., 2003, 
Eliopoulos et al., 2000, Hess and Engelmann, 1996). By contrast, work from our laboratory 
has demonstrated that CD40 ligation by cell-surface presented agonists and membrane 
CD40L (mCD40L) induces extensive apoptosis in carcinoma cells (Bugajska et al., 2002, 
Georgopoulos et al., 2007, Georgopoulos et al., 2006, Hill et al., 2008a). whilst sparing their 
normal epithelial counterparts (Lievens et al., 2009, Shaw et al., 2005, Bugajska et al., 2002). 
The necessity to deliver the signal in membrane, rather than soluble form, to achieve 
maximal pro-apoptotic capacity has also been supported by more recent work by Young and 
colleagues (Elmetwali et al., 2010a, Elmetwali et al., 2010b).  
Previous work from our laboratory has provided evidence that mCD40L, but not 
soluble agonist, consitututes a strong pro-apoptotic signal in CRC cells (Georgopoulos et al., 
2007, Hill et al., 2008a); however the mechanisms responsible for the induction of apoptosis 
remain unknown. In order to achieve CD40 ligation by membrane ligand (mCD40L) 
experimentally, target, epithelial cells are co-cultured with third-party cells engineered to 
express CD40L. At the beginning of this project, and following the move of the Georgopoulos 
laboratory to Huddersfield University a) it was essential to ensure the reproducibility of the 
co-culture system and thus b) part of the work aimed to establish and optimise a series of 
experimental techniques, for use with this co-culture system, that would permit accurate and 
reliable detection and quantification of mCD40L-mediated apoptosis based on 96-well plate 
format assays. 
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6.2 The mechanisms of mCD40L-mediated apoptotic death in CRC 
cells 
 The main aim of this thesis was to elucidate the molecular nature of CD40 signalling, 
i.e. the precise signalling pathways responsible for the activation of apoptosis in CRC cells. 
Whilst building on previous studies in our laboratory, this work has for the first time provided 
functional evidence for a TRAF3-Nox-ASK1-MKK4-JNK/p38 signalling pathway that drives 
CD40-induced CRC cell death and shown for the first time that unlike for instance urothelial 
cells, in CRC cells CD40 induces both intrinsic and extrinsic apoptotic mechanisms. The 
work has thus provided provided an explanation for the rapid nature of CD40-mediated death 
in CRC cells in comparison to other types of carcinoma cells. Of note, although previous 
work in our laboratory has studied the role of CD40 ligation in normal epithelial cells, as 
normal human colonic epithelial cells are CD40-negative both in vivo and in vitro (Gelbmann 
et al., 2003, Cruickshank et al., 2004), this study focused on the effect of CD40 ligation on 
malignant (CRC) cells. The following sections will discuss these observations in more detail.  
Besides the novelty of the observations presented here relating to CD40 and more 
generally the TNFR field, it is important to emphasise that unlike the vast majority of 
available studies reporting on the role of critical pro-apoptotic mediators, such as MKKs and 
p38/JNK and their interactions in apoptotic signalling, the present study has analysed the 
expression and functional roles of such signalling mediators in a ‗natural‘ system. This is 
based on endogenous protein expression and not engineered over-expression, which is the 
case with virtually all TNFR (and CD40) studies reported in the literature.  
 
6.3 Membrane CD40L (mCD40L) induces rapid activation of both intrinsic and 
extrinsic pathways of apoptosis 
This study has provided for the first time evidence that unlike the mechanism of 
CD40-mediated apoptosis in malignant urothelial (UCC) cells that is relatively slow 
(apoptosis requires over 36 hours to be detectable) (Bugajska et al., 2002) and appears to 
involve purely the intrinsic apoptotic pathway (Georgopoulos et al., 2006), CRC cell death 
triggered by mCD40L is rapid and occurs within less than 12 hours and it involves both 
apoptotic pathways, i.e. both the intrinsic and exstrinsic pathways.  
It is well established that the BCL-2 family of proteins, and particularly pro-apoptotic 
Bak and Bax can form oligomers and insert themselves stably into the mitochondrial outer 
membrane permeabilisation to induce MOMP and subsequently apoptosis (Chipuk and 
Green, 2008). Furthermore, previous studies have suggested that mCD40L can induce the 
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expression of Bak and Bax proteins (Bugajska et al., 2002, Georgopoulos et al., 2006). 
Moreover, recent studies in our laboratory have investigated the precise regulation and 
functional role of Bax and Bak in mCD40L-mediated apoptosis in UCC cells (Dunnill et al, in 
preparation). Those studies showed that Bak and Bax are activated by 24 hours post CD40 
ligation and are critical in CD40 killing in UCC cells. Interestingly, in agreement with these 
recent findings, in this project we confirmed that mCD40L-CD40 interaction activated MOMP, 
release of cytochrome c from mitochondria and induction of Bax and Bak, but this occured 
far more rapidly (within less than 6 hours). In addition, the current study has confirmed the 
pro-apoptotic role of Bax by shRNA-mediated protein knockdown as Bax knockdown 
attenuated CRC cell apoptosis mediated by CD40, and decreased caspase 3/7 activity. 
Previous studies have indicated that CD40-mediated apoptosis in hepatocytes 
requires induction of the Fas pathway (Afford et al., 2001, Afford et al., 1999). whilst a report 
using carcinoma cells showed that CD40 ligation may induce up-regulation of death receptor 
and ligand, specifically FasL and TRAIL (Eliopoulos et al., 2000). TRAIL and FasL are 
members of TNF-superfamily trigger apoptosis by binding to Fas (CD95), the DR4 (TRAIL-
R1) and/or DR5 (TRAIL-R2) respectively. Upon binding, death receptors recruit death 
domain of Fas associated with the adaptor molecule (FADD), caspase-8 and triggering of the 
protease in an apoptosis inducing signalling complex death (DISC), which in turn triggers the 
apoptotic pathway (Sayers, 2011). Due to the rapid nature of cell death in CRC cells we 
hypothesised that apoptosis might be amplified by engaging an additional pathway, in light of 
the speed by which for instance TRAIL induces apoptosis in carcinoma cells, as shown 
previously by our group (Steele et al., 2006).  
This study found that mCD40L-mediated CD40 ligation triggered rapid TRAIL 
induction (but not FasL upregulation) in CRC cells. Furthermore, TRAIL receptor expression 
(TRAIL-RII (DR5)) was also induced. Studies carried out following the completion of this work 
involving siRNA-mediated knockdown of TRAIL have suggested a partial role for TRAIL in 
apoptosis (unpublished observations). Moreover, this work suggested that TRAIL activates 
caspase-10 (but not caspase-8) and caspase-9 to cause extensive CRC cell death. Although 
classically TNF ligands activate mainly a caspase-8 associated extrinsic pathway, TRAIL-
mediated caspase-10 (and not caspase-8) activation to induce caspase-3/7 and cell death 
has previously been reported (Sprick et al., 2002, Sprick et al., 2000, Engels et al., 2005). 
Interestingly also, CD40-induced TRAIL-associated death appears to take place not by 
paracrine signalling (as anti-TRAIL blocking antibody did not affect apoptosis) but in 
endogenous/autocrine fashion, which is in agreement with our previous observation for a role 
of ‗intracellularly-signalling‘ TRAIL ligand in carcinoma cells (Steele et al., 2006).  
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These findings are suggestive for the first time of a signalling cross-talk between 
extrinsic and intrinsic apoptosis pathways in CRC cells, a finding supported by the 
observation that Bid is rapidly cleaved into t-Bid following CD40 ligation. Importantly, recent 
studies carried out following the completion of this work that have involved shRNA-mediated 
Bid knockdown demonstrated that complete knockdown of Bid results in 50% reduction of 
CD40 mediated apoptosis (unpublished observations). Collectively, our findings suggest that 
CD40 cross-talks with the extrinsic apoptotic pathway by inducing TRAIL-mediated, caspase-
10 (but not caspase-8) activation, mitochondrial disruption, tBid activation, Bak/Bax 
induction, and activation of caspase-9 and caspase-3/7 to cause extensive and rapid CRC 
cell death. However, TRAIL-induced apoptosis appears to be partially driving CD40-mediated 
death (findings presented here and unpublished data mentioned above).  
Despite the current findings on CD40-mediated apoptosis, it would be interesting to 
further investigate the role of mitochondria in apoptosis. Of interest would be the involvement 
of other mitochondrial death-related mediators, such as BH3-only proteins, or to study 
whether release of AIF or Endo G or SMAC/DIABLO (Norberg et al., 2010) may take place 
during apoptosis. SMAC/DIABLO shRNA-expressing retroviruses are available in our 
laboratory and could be used to produce HCT116 derivatives for future investigations. A 
good candidate for BH3-only protein exploration would be PUMA as it has been shown that it 
is important in p53-mediated induction of intrinsic apoptosis and it activates Bax during 
oxidative stress to induce apoptosis (Steckley et al., 2007).  
6.4 Unravelling the precise signalling pathways of pro-apoptotic 
CD40 signalling: role of JNK and p38 
The ‗stress‘ MAPK signaling pathways, and particularly those driven by pγ8 and JNK, 
can play an important role in the control of cell death. c-Jun N-terminal kinase/ stress kinase 
(JNK) can play a critical role in activating apoptosis (Shen and Pervaiz, 2006). JNK can be 
activated by several different stimuli including growth factors (Walsh et al., 2002), cytokines 
(Raingeaud et al., 1995) and stress factors (Nishitani and Matsumoto, 2006). JNK kinases 
are activated by phosphorylation of threonine and tyrosine residues of their activation loop by 
MAPKK kinases and particularly MKK4 and MKK7, which are themselves activated as 
several MAPKK kinases (such as ASK-1) (Kyriakis and Avruch, 2001, Kyriakis and Avruch, 
2012). On the other hand, p38 kinase isoforms can be activated by phosphorylation of 
threonine and tyrosine residues of their activation loop by MAPK kinases MKK3, 4 and 6 
(Brancho et al., 2003, Derijard et al., 1995). The MAPKKKs involved in the p38 and JNK 
pathway are mainly ASK1 and MLK3 (Zarubin and Jiahuai, 2005).   
 239 
 
We showed here for the first time that CD40 induced rapid upregulation of both p-JNK 
and p-p38 in CRC cells. Although the activation of JNK is in agreement with mCD40L-
mediated JNK activation in UCC cells (Georgopoulos et al., 2006), in this work interaction of 
mCD40L with CD40 on CRC cells caused both JNK and p38 activation and we also showed 
that this activation is necessary for apoptosis, whilst our functional blocking studies implied 
that JNK might be acting downstream of p38 in the CD40 signalling axis (p38 activates JNK, 
which in turn induces apoptosis, while JNK does not appear to activate p38) – although 
further experiments would be required to definitively clarify this.  
JNK and p38 MAPK activation mediated by mCD40L directly regulated Bax and Bak 
expression hence these pro-apoptotic mediators appear to be induced transcriptionally rather 
than being stabilised at the protein level. Similary, p38 and JNK appeared to be responsible 
for TRAIL induction in a similar fashion. We have also shown that that cytochrome c was 
released during CD40-mediated apoptosis, so we speculate that this protein in turns creates 
a complex (apoptosome) using Apaf1 and pro-caspase-9, and that this complex then 
proceeds to activate caspase-3/7 (and CAD) through the mitochondrial pathways of cell 
death (Shiozaki et al., 2002).   
6.5 Insights into the regulation (and functional role) of TRAFs and 
MAP2Ks in mCD40L-induced CRC cell apoptosis  
 Having identified for the first time that CD40-mediated signalling in CRC cells 
engages both extrinsic and intrinsic pathways with p38 and JNK being responsible for 
induction of apoptosis by Bak and Bax, which is triggered at least in part by TRAIL induction, 
t-Bid mediated cross-talk to mitochondria, and induction of caspase-10 and caspase-9 
dependent death, the study sought to identify the precise, more receptor-proximal (early), 
CD40-induced signalling events.  
As described previously (Introduction), the signals induced by CD40 are partly 
mediated through a family of proteins. These molecules include members of the TRAF family 
(TRAF-1, -2, -3, -4, -5, -6) (Aggarwal, 2000). Several studies have demonstrated that ligation 
of CD40 leads to quick recruitment of these TNFR-associated factors (TRAFs) molecules 
from the cytoplasm to the receptor's cytoplasmic domain. TRAF1, TRAF-2, TRAF5, and 
TRAF6 tend to act as positive regulators of CD40L-CD40 signalling, whereas TRAF3 has 
been implicated as a negative regulator (Hauer et al., 2005). However virtually all such 
studies, with the exception of TRAF regulation by CD40 in normal and malignant urothelial 
cells reported by our laboratory (Georgopoulos et al 2006; Dunnill et al, manuscript in 
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preparation), are reports on CD40-mediated effects in lymphoid cells (Bishop et al., 2002, 
Bishop, 2004, Bishop et al., 2007).  
Here we show for the first time that TRAF1, -3, and 6 were induced by mCD40L-
CD40 interactions in CRC cells. Our findings documented that the regulation of TRAF3 and -
6 by mCD40L was rapid as TRAF induction was observed as early as 1.5 hour post receptor 
ligation. Our studies have not only demonstrated a novel pattern of TRAF regulation in CRC 
cells but have also revealed for the first time that TRAF3 has an essential role in CD40-
mediated CRC cells death as shown by stable TRAF3 knockdown experiments. 
TRAF3 is a CD40-associated adaptor protein which relays signals for the activation of 
MAPKs. In general, such signals can generate multifaceted cell responses ranging from 
epithelial cell death to cell growth and survival (Häcker et al., 2011). TRAF3 has been shown 
in some instances to trigger growth inhibition, yet in others apoptotic signals in epithelial 
based models, although the mechanistic explanations for this are largely unknown 
(Eliopoulos et al., 1996, Dadgostar and Cheng, 2000). The ability of TRAF3 to mediate 
apoptotic signals is likely to be mediated by lipid raft formation (Dadgostar and Cheng, 2000) 
with more recent evidence suggesting that this process may be directly dependent on ROS-
mediated receptor clustering via acid sphingomyelinase activation and ceramide production 
(Zhang et al., 2007, Zhang et al., 2006).  
Based on expression detection analysis and stable shRNA-mediated knock-down 
experiments, this study has provided evidence for the first time that TRAF3 plays a critical 
role in CD40-mediated apoptosis (see Chapter 4) and has shown that mCD40L-CD40 
interactions cause TRAF3 induction in CRC cell lines that naturally express CD40 or are 
engineered to express the receptor. Although the study focused exclusively on mCD40L as a 
ligation signal, soluble CD40 agonists do not stabilise TRAF3 as effectively as does 
membrane agonist, further supporting the notion that CD40 cross-linking is a key factor for 
high TRAF3 expression (Elmetwali et al., 2010b, Georgopoulos et al., 2006). Moreover, we 
have shown that TRAF3 is central in the induction of apoptosis as not only does it attenuate 
apoptosis, but it also specifically abrogates p38 and JNK activation, induction of Bak/Bax and 
caspase-3/7 activation. Therefore, despite the existence to a dual apoptotic pathway being 
engaged in CRC cells, TRAF3 appears to be central in both of these signalling axes. These 
findings have therefore provided novel insights into a molecule the function of which in both 
normal and maligant epithelial cells has remained relatively unknown; they are also in 
agreement with a central role for TRAF3 in CD40-mediated UCC cell death (Georgopoulos et 
al 2006; Dunnill et al, manuscript in preparation), even though the precise molecular 
pathways driving CD40-mediated apoptosis in UCC and CRC cells appear to be distinct. 
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Finally, we also showed that CD40 ligation induced activation of MAPKKs MKK4 and MKK7 
as shown by immunoblotting. These results are also in agreement with our recent findings in 
UCC cells (Dunnill et al, manuscript in preparation) where we showed that MKK4 and MKK7 
are induced by CD40 in a TRAF3-dependent fashion, with MKK4 being critical in apoptosis.  
It should be noted that because of the previously reported important role of TRAF3 in 
CD40 killing in UCC cells (Georgopoulos et al 2006; Dunnill et al, manuscript in preparation) 
this study did not examine the functional role of other TRAFs in CD40-mediated apoptosis. 
Of interest would particularly be the role of TRAF6. Notably, we have previously reported that 
CD40 ligation does not appear to induce TRAF6 in UCC cells although it does induce TRAF1 
(Georgopoulos et al., 2006), yet TRAF1 induction appears to be a ‗consequence‘ of CD40 
ligation (our unpublished observations). Identifying whether TRAF6 is induced at the 
transcriptional or post-transcriptional level should form part of future work, whilst it would be 
important that such studies identify whether TRAF6 loss regulates CD40-mediated signalling 
and thus apoptosis in CRC cells.  
Therefore, collectively, we have demonstrated for the first time that CD40 triggers a 
signalling pathway that activates TRAF3 and in turn that appears to be responsible for 
activation of MKK4 and MKK7. And although future studies should also address whether it is 
MKK4 or MKK7 (or both) that are responsible for downstream signalling, it is tempting to 
speculate that one of these or both (as in UCC cells) trigger downstream activation of p38 
and JNK to activate pro-apoptotic CD40 signalling.  Interestingly, these findings did not 
reveal precisely how TRAF3 is linked with/activates the MKK4/7-p38/JNK signalling axis, i.e. 
which MAP3K is responsible for triggering MKK and subsequently p38/JNK activation. We 
believe that our findings in Chapter 5 have provided the molecular basis for this and 
identified the missing MAP3K (discussion below).   
6.6 The role of ROS and Nox in CD40-mediated pro-apoptotic 
signalling during CRC cell apoptosis  
ROS were originally thought to be molecules that caused cell damage, through lipid, 
protein and DNA oxidation. Yet, it is now widely recognised that they also play a crucial, 
secondary messenger role in activating intracellular signalling pathways (Terada, 2006). In 
fact, ROS are implicated in most of the hallmarks of cancer proposed by (Hanahan and 
Weinberg, 2011)Hanahan and Weinberg (2011) due to their diverse effects on cellular 
molecules and processes such as angiogenesis, invasion and proliferation(Paletta-Silva et 
al., 2013).  
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ROS are molecules derived from oxygen often produced by the NADPH oxidase 
(NOX) proteins, the family of ‗professional‘ ROS producers (Jiang et al., 2011). The family of 
NADPH oxidases in humans is composed of 7 members: NOX1 to NOX5, DUOX1 and 
DUOX2 (De Deken et al., 2000, Dupuy et al., 1999). Although the structures of the various 
isoforms of NOX are highly homologous, their tissue distributions, cellular and subcellular 
and their activation mechanisms, and therefore their physiological functions, are very 
different (Bedard and Krause, 2007). Nox may induce ROS in response to chemotherapeutic 
agents and members of the TNR-superfamily such as TNF-α or lymphotoxin (such as 
lymphotoxin-ȕ receptor) (LTȕR) (You et al., 2006), and this may be used to specifically target 
tumours cell due to their already raised oxidative stress state (Benhar et al., 2001, Jin et al., 
2008). Moreover, CD40 engagement by soluble CD40 agonist (sCD40L) has been reported 
to trigger the production of ROS in B-cells and normal hepatocytes, which is mediated 
through the action of NOX (Bhogal et al., 2012, Ha and Lee, 2004, Wheeler and DeFranco, 
2012).  
As shown in Chapter 5, ROS are rapildy induced in CRC cells by CD40 in what 
appears to be a Nox-dependent phenomenon and this plays an important role in CD40-
mediated killing. More specifically, CD40 activation appears to result in TRAF3-dependent 
p40phox activation as shown by p-p40phox immunoblotting experiments and functional, 
shRNA-mediated TRAF3 knockdown. We also show for the first time that CD40 regulates 
directly ROS scavenging mediators, as we detected modest yet clear reduction in Trx-1 
expression. In agreement with the observations, CD40 triggered activation of the Trx-
regulated pro-apoptotic kinase ASK-1, which provided direct molecular explanation for the 
importance of ROS in CD40 signalling and downstream activation of MKKs and p38/JNK.   
Although an unequivocal role for TRAF3 in the recruitment of Nox has not been 
provided, the work shown here has strongly implicated a TRAF3-Nox interaction in CD40-
killing, which is in agreement with a previous study in malignant B cells (Ha and Lee, 2004). 
In addition to performing co-immunoprecipitation studies to investigate whether TRAF3 and 
Nox indeed interact during mCD40L-induced signalling, the possible role of ROS in lipid raft 
formation should equally be explored in future work, as it appears that Nox activity shown in 
this thesis in CRC cells and ROS induction in UCC cells (Dunnill and Georgopoulos, 
unpublished observations) are necessary for TRAF3 stabilisation.  
Through stable, shRNA-mediated TRAF3 knockdown it has been shown by this study 
that mCD40L-induced phosphorylation of p38 and JNK and apoptosis is TRAF3 driven. As 
mentioned, it has been suggested that TRAF3 signalling may be dependent on lipid raft 
formation and its cell membrane interaction with Nox to generate ROS (Bhogal et al., 2012, 
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Ha and Lee, 2004, Wheeler and DeFranco, 2012). Thus, in light of the importance of ROS in 
apoptosis, the current study determined that a TRAF3-Nox functional link may underpin 
CD40-signalling responses, which is in agreement with our recent observations in maligant 
urothelial (UCC) cells (Dunnill et al, manuscript in preparation).  
It has been shown that CD40‘s intracellular domain recruits TRAFγ for NOX 
interaction via one of several sub-units, namely p40phox (Ha and Lee, 2004). These findings 
regarding TRAF3-Nox interactions were reported in B-cells via their overexpression. This 
study, and without being based on over-expression, suggests that this phenomenon may 
also occur in epithelial cells. Also in this study, through use of the Nox inhibitor DPI, it was 
shown that NOX inhibition prevents ASK-1 activation, expression of pro-apoptotic Bcl-2 
members Bax, and mCD40L-induced apoptosis suggesting that most probably p40phox 
regulates CD40-mediated cell death via ROS production and ASK-1 mediated p38/JNK 
activation. In support of this there are more recent reports that phospho-p40phox has a 
specific role of ROS production in endothelial cells (Fan et al., 2009), thus enforcing this 
common mechanism between Nox mediated ROS production. Finally, and despite not 
demonstrating a direct physical interaction between Nox and TRAF3, the importance of the 
ROS pathway in CD40 apoptosis is further supported by the observation that stable TRAF3 
knockdown attenuated p40phox phosphorylation by CD40 ligation.  
Although DPI is not a specific inhibitor of the p40phox Nox subunit, but a universal 
Nox inhibitor, clearly DPI prevented CD40-induced CD40-mediated death (shown here) as 
well as ROS generation (subsequently demonstrated following completion of the current 
thesis – Dunnill et al, in preparation). This has provided evidence that mCD40L-CD40-
TRAF3-NOX interaction utilises ROS for the activation of ASK-1/MKK/p38/JNK pro-apoptotic 
pathways in CRC cells. Future work should target p40-phox specifically through shRNA 
knockdown in order to firmly establish its role in CD40-mediated apoptosis.  
 ASK1 is a MAPγK that ‗sits‘ at the top of the MKK4/JNK signalling pathway 
responding primarily to oxidative cell stress mediated by reactive oxygen species (ROS). 
ASK1 is normally suppressed by a redox protein known as thioredoxin (Trx) making it an 
inactive protein kinase. Trx binds ASK1 through a reduced intramolecular disulphide bridge, 
however the bonds are broken through oxidation, and in turn ASK1 auto-phosphorylates at 
Thr845 to become an active signalling kinase (Soga et al., 2012). Our findings that CD40 
induced TRAF3 dependent p40phox activation, caused Trx down-regulation, and triggered 
ASK-1 phosphorylation are in agreement with our recent observations in UCC cells (Dunnill 
et al, in preparation) where we also showed that stable, retrovirus mediated ASK-1 protein 
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knockdown fully blocked CD40 apoptosis. It would be important that similar studies are 
carried out to study whether this is the case in CRC cells. 
 The above observations combined with the results presented in this study, provide 
novel mechanistic explanations on the molecular nature of the CD40 signalling ‗blackbox‘. It 
appears therefore that, despite the partial differences in the downstream signalling 
components and exact apoptotic pathways (intrinsic and/or extrinsic) that mediate apoptosis, 
induction of ROS by Nox, down-regulation of Trx and activation of ASK-1 may represent the 
core signalling component that drives CD40-mediated apoptotis. In UCC cells, abrogation of 
ASK1 via shRNA mediated knockdown not only prevented mCD40L-induced apoptosis, but 
also abrogated the phosphorylation of JNK (Dunnill et al, in preparation). Future studies in 
CRC cells could provide support to these observations and may confirm the universality of 
these mechanisms.  
Also such experiments will help clarify the exact point in the CD40 signalling axis 
where the MAPK pathways diverge. More specifically, as tBid and TRAIL knockdown appear 
to partially aborgate apoptosis (unpublished observations), we hypothesise that at some 
point the MAPK/p38/JNK pathway diverges to drive on one hand transcriptional upregulation 
of TRAIL, activation of tBid and cross talk to the mitochondria whilst the other p38/JNK 
pathway directly induces Bak/Bax to also induce MOMP and mitochondrial death, the latter 
being more reminescent of CD40-mediated cell death in UCC cells (Dunnill et al, in 
preparation). However, unlike UCC cells were the operation of only the latter pathway takes 
place means apoptosis requires a minimum of 24-36 hours to take place, in CRC cells there 
is rapid amplification of the pro-apoptotic signal and quick induction of cell death. To our 
knowledge, this is the first demonstration of such extensive and at the same time rapid 
carcinoma cell apoptosis triggered by CD40 ligation.    
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6.7 Future directions: utilising the CD40 pathway for therapeutic 
purposes 
The ability of CD40 ligation to induce such extensive and rapid apoptosis in CRC 
cells has clear therapeutic promise. However, the requirement to use membrane presented 
ligand poses significant therapeutic obstacles if CD40 is to be used as a therapeutic target in 
colorectal cancer therapy. We have previously shown that soluble CD40 agonist has little 
pro-apoptotic activity in CRC cells (Georgopoulos et al., 2007); Dunnill and Georgopoulos, 
unpublished observations) therefore a therapeutic approach that can render a soluble CD40 
agonist functionally equivalent to mCD40L would be an ideal therapeutic approach.  
However, whilst this project was taking place, work in our laboratory has led to a new 
combinatorial approach that involved treatment of carcinoma cells with soluble CD40 agonist 
(‗biologic‘) in combination with a pharmacological inhibitor of Trx  (pharmaceutic) that in 
combination a) elevated reactive oxygen species (ROS) and b) blocked anti-apoptotic 
Thioredoxin (Trx)-mediated cyto-protection (against ROS) – this formed part of the 
―Combinatorial use of Tumour Necrosis Factor Receptor agonists with pharmacological 
inhibitors of Thioredoxin proteins for carcinoma therapy‖, patent application # 1γ019β8.6.  
Based initially on the urothelial model, work in our laboratory showed that 
pharmacological Trx inhibition sensitised tumour cells to soluble CD40 agonists, that when 
normally used alone are non-cytotoxic to UCC cells (Bugajska et al., 2002). Notably, the 
soluble-agonist/Trx inhibitor combinatorial treatment was functionally equivalent to mCD40L-
induced CD40 ligation. Importantly, following completion of this thesis, it was found that CRC 
cell lines were even more sensitive to this combinatorial therapy than were UCC cells. This 
observation is interesting as Trx inhibitors have been suggested to hold promise for the 
treatment of CRC over other epithelial tumours (Lincoln et al., 2003). Therefore the 
administration of Trx inhibitors combined with soluble CD40 agonists merits further pre-
clinical testing to determine its universal efficacy not only against UCC, but also in CRC. In 
fact, were currently testing the efficacy of this combinatorial approach in SW480-CD40 
versus SW480 mouse xenografts in immunodeficient mice in collaboration with Prof Alan 
Melcher (LICAP, University of Leeds).  
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6.8 Concluding remarks  
This study has for the first time identified the intracellular signalling cascade that is 
triggered by CD40 ligation and results in extensive apoptosis in CRC carcinoma cells 
summarised schematically in figure 6.1. It has identified a TRAF3-Nox-ROS-ASK1-MKK-
p38/JNK pathway (that activates caspase-10 and caspase-9) as being the driving force that 
triggers both a TRAIL-associated extrinsic as well as the intrinsic apoptotic pathways. Thus 
in CRC cells CD40 demonstrates ability to induce apoptosis by pathway cross talk which 
permits strikingly rapid apoptosis. These findings have not only provided novel observations 
on the mechanisms of apoptosis triggered by the TNSRF member CD40 and also reinforced 
the importance of the quality of CD40 signal in determining functional outcome, but they have 
also raised interesting hypotheses for further biological studies. Equally importantly, the 
findings have also assisted in the formulation of a novel therapeutic avenue that may exploit 
CD40 for anticancer therapy. 
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Figure 6. 1 Fintracellular signalling triggered by CD40 ligation in CRC  
Intracellular signalling triggered by CD40 ligation and results in extensive apoptosis in CRC carcinoma 
cells. It has identified a TRAF3-Nox-ROS-ASK1-MKK-p38/JNK pathway (that activates caspase-10 
and caspase-9) as being the driving force that triggers both a TRAIL-associated extrinsic as well as 
the intrinsic apoptotic pathways. Thus, in CRC cells CD40 demonstrates the ability to induce apoptosis 
by pathway cross talk which permits strikingly rapid apoptosis.  
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Appendix I  
List of Suppliers 
Supplier Webpage/Address 
Alpha labs www.alphalabs.co.uk  
                Autogen Bioclear UK Ltd Holly Ditch Farm, Mile Elm, 
BD Biosciences www.bdbiosciences.com/eu  
BDH Supplied by VWR 
Bio-Rad Laboratories Ltd www.bio-rad.com  
Biosera www.biosera.com  
Calbiochem Supplied by Merck 
Cambridge Bioscience www.bioscience.co.uk  
Clontech (Takara Bio Inc) www.clontech.com  
ENZO www.enzolifesciences.com  
Falcon Supplied by VWR 
Fisher Scientific UK Ltd www.fisher.co.uk  
Gompels healthcare www.gompels.co.uk  
Greiner Bio-one Ltd www.greinerbioone.com/en/england/start/ 
Insight Biotechnology Ltd www.insightbio.com  
Invitrogen Ltd www.invitrogen .com 
Invivogen www.invivogen.com  
Jencons-PLS Supplied by VWR International 
Li-Cor Biosciences UK Ltd www.licor.com  
Merck www.merck.co.uk  
Microsoft Corporation www.microsoft.com  
Millipore www.merckmillipore.co.uk  
Molecular Probes Supplied by Invitrogen 
Nalgene Europe Ltd Supplied by Fisher Scientific 
New England Biolabs (UK) www.neb.uk.com  
Pierce Supplied by Thermo Scientific 
Promega UK Ltd www.promega.com  
Qiagen Ltd www.qiagen.com  
Roche Diagnostics Ltd www.roche.co.uk/portal/uk/diagnostics  
Santa Cruz Biotechnology Supplied by Insight Biotechnology Ltd 
Sigma-Aldrich Company www.sigmaaldrich.com  
Starstedt Ltd www.sarstedt.com  
Statebourne Cryogenics www.statebourne.com  
Sterilin Ltd Supplied by Fisher 
Tebu-bio www.tebu-bio.co.uk  
ThermoFisher Scientific www.fisher.com  
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Appendix II 
Reagents  
1- Phosphaste Buffer Saline (PBS) (Invitrogen 14200-67) 
Compound Concentration 
137mM Sodium Chloride NaCl 
2.7mM Potassium Chloride KCl 
3.2mM Disodium hydrogen phosphate Na2HPO4 
147mM Potassium hydrogen phosphate KH2PO4 
pH 7.2 dissolved in autoclaved dH2O. Prepared from 10X solution 
 
2- 2x SDS lysis buffer: 
Amount(volume or mass) Material 
10 ml (2% W/V) Glycerol (Sigma) 
1 gram (2% W/V) SDS 
6.25 ml   (Stock 1M Tris-HCl 
0.42g /200mM  Sodium fluoride (NaF)(Sigma) 
0.446g Sodium pyrophosphate tetrabasic 
2mM  Sodium Orthovandate 
Up to total volume of 50ml Deionised water 
Chemicals used in preparation of SDS sample buffer. To dissolve all chemicals, use 
magnetic heat block to and magnetic flea then store at -20C in 2.5ml or aliquots.  
 
3- Standards: Cat# PN23208 
Standards Concentrations µg/ml BSA/ volume 
bovine serum albumin (BSA) 125, 250, 500, 750, 1000, 1500, 2000/ 
3.5ml each 
Diluted in 0.9% saline and preserved with 0.05% sodium azide 
 
 
4- Tris Buffered Saline (TBS) 
Volume  or Weight Chemical 
1.21g Tris (Hydroxy methyl amino methan) 
8.18g Sodium hydrochloride (NaCl) (Sigma) 
Made up to 1 L by deionised water              pH 7.4   
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5-  TBS-Tween 
Volume  or Weight Chemical 
1.21g Tris (Hydroxy methyl amino methane) 
8.18g Sodium hydrochloride (NaCl) (Sigma) 
Made up to 1 L by deionised water, and pH was adjusted (pH 7.4) then 1ml of 
Tween-20 was added.  
   
6- Transfer Buffer  
Volume  or Weight Chemicals 
1.45g Tris( 12mM) 
7.2g Glycine(96mM) 
200ml Methanol (20%) 
Make up to 1 litter by deionised water (*made fresh on day of use*) 
     
7- The CellTiter 96® Cell proliferation assay 
Volume   Chemicals 
100ml CellTiter 96 
 
Cell Proliferation Assay 5,000 assays  
CellTiter 96® AQueous One Solution  
G3581 
Ready to use / 20µl/well- store the reagent at -20C for long term storage or for short up 
to 6 week at 4C protected from the light  
  (www.promega.com)  
8- Caspase 3/7 activity reagents 
Components Volume Store 
components 
Caspase 3/7 substrate 270 µl -20 ºC 
AFC, Fluorescence reference standard 20µl (in 10mM DMSO) -20 ºC 
Ac-DEVD-CHO a Known caspase 3/7 
inhibitor 5 mM DMSO solution 15 µl -20 ºC 
Assay buffer 30ml 4 ºC 
DTT 1ml -20 ºC 
Lysis buffer 20ml 4 ºC 
 The chemical compound used in the measurement of caspase 3/7 activity. 
(www.anaspec,com)   
9-  CytoTox-GloTM Cytotoxicity reagents  
Component  Bottle/Size  Storge Cat # 
Assay Buffer  5 x10ml  
-20 ºC 
 
G9291 AAF-GloTM substrate(Alanyle alanyl-phenylal alanyl-amino luciferin  5 bottles 
Digitonin  175 µl 
  (www.promega.com)  
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Appendix III  
The concentrations of protein for all lysates; (3T3-CD40, 3T3-neo, and SW480-
CD40) are shown in the Table. 
 3T3Neo 3T3CD40L SW480-CD40 
µg/ml 8010.849 6871.365 4819.18 
µg/µl 8.01 6.87 4.82 
Volume with20µg 2.50 2.91 4.15 
dH2O 10.50 10.09 8.85 
Sample volume 13 13 13 
Reducing Agent 2 2 2 
LDS Sample buffer 5 5 5 
Total (µl) 20 20 20 
Protein concentration in different cell lysates. The table also indicates the amount of other 
reagents added to the lysates preparation for western blotting. 
 
 
Standard curve (4-parameter-fit to measure protein concentration in different cell 
lines (3T3-CD40L, 3T3-Neo, and SW480-CD40).  
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Appendix IV  
Caspase 3/7 activity with different concentration of staurosporine  
HCT116/3T3-CD40L HCT116/3T3-Neo HCT116/staurosporine(5) HCT116/staurosporine(2.5) HCT116/staurosporine (1) HCT116/3T3-Neo 
16571 6779 17471 16210 12994 6446 
16422 6862 17222 15534 12400 6709 
16433 6680 18643 16065 12118 6506 
17233 6344 17123 16141 12215 6314 
16664.75 6666.25 17614.75 15987.5 12431.75 6493.75 
284.125 161.125 514.125 226.75 281.125 113.75 
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